BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167-185. [PMID: 22436845 DOI: 10.1016/j.jhep.2012.02.010] [Cited by in Crossref: 2167] [Cited by in F6Publishing: 2020] [Article Influence: 240.8] [Reference Citation Analysis]
Number Citing Articles
1 Saitta C, Musolino C, Marabello G, Martino D, Leonardi MS, Pollicino T, Altavilla G, Raimondo G. Risk of occult hepatitis B virus infection reactivation in patients with solid tumours undergoing chemotherapy. Dig Liver Dis. 2013;45:683-686. [PMID: 23490344 DOI: 10.1016/j.dld.2013.01.022] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
2 Park JH, Ahn SJ, Cho HJ, Kim SS, Cheong JY, Cho SW. Clinical course of partial virological responders under prolonged entecavir monotherapy in patients with chronic hepatitis B. J Med Virol. 2016;88:252-259. [PMID: 26178822 DOI: 10.1002/jmv.24330] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
3 Li W, Shen X, Fu B, Guo C, Liu Y, Ye Y, Sun R, Li J, Tian Z, Wei H. KIR3DS1/HLA-B Bw4-80Ile Genotype Is Correlated with the IFN-α Therapy Response in hepatitis B e antigen-Positive Chronic Hepatitis B. Front Immunol 2017;8:1285. [PMID: 29075265 DOI: 10.3389/fimmu.2017.01285] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
4 Andriamandimby SF, Olive MM, Shimakawa Y, Rakotomanana F, Razanajatovo IM, Andrianinarivomanana TM, Ravalohery JP, Andriamamonjy S, Rogier C, Héraud JM. Prevalence of chronic hepatitis B virus infection and infrastructure for its diagnosis in Madagascar: implication for the WHO's elimination strategy. BMC Public Health 2017;17:636. [PMID: 28778194 DOI: 10.1186/s12889-017-4630-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
5 Ning Q, Han M, Sun Y, Jiang J, Tan D, Hou J, Tang H, Sheng J, Zhao M. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial). J Hepatol 2014;61:777-84. [PMID: 24915612 DOI: 10.1016/j.jhep.2014.05.044] [Cited by in Crossref: 136] [Cited by in F6Publishing: 111] [Article Influence: 19.4] [Reference Citation Analysis]
6 Berraondo P, Di Scala M, Korolowicz K, Thampi LM, Otano I, Suarez L, Fioravanti J, Aranda F, Ardaiz N, Yang J. Liver-directed gene therapy of chronic hepadnavirus infection using interferon alpha tethered to apolipoprotein A-I. J Hepatol. 2015;63:329-336. [PMID: 25772035 DOI: 10.1016/j.jhep.2015.02.048] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
7 Lin CL, Kao JH. Risk stratification for hepatitis B virus related hepatocellular carcinoma. J Gastroenterol Hepatol. 2013;28:10-17. [PMID: 23094699 DOI: 10.1111/jgh.12010] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 7.1] [Reference Citation Analysis]
8 Brunetto MR, Cavallone D, Oliveri F, Moriconi F, Colombatto P, Coco B, Ciccorossi P, Rastelli C, Romagnoli V, Cherubini B, Teilum MW, Blondal T, Bonino F. A serum microRNA signature is associated with the immune control of chronic hepatitis B virus infection. PLoS One. 2014;9:e110782. [PMID: 25350115 DOI: 10.1371/journal.pone.0110782] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
9 Pereira CV, Tovo CV, Grossmann TK, Mirenda H, Dal-Pupo BB, Almeida PR, Mattos AA. Efficacy of entecavir and tenofovir in chronic hepatitis B under treatment in the public health system in southern Brazil. Mem Inst Oswaldo Cruz 2016;111:252-7. [PMID: 27074254 DOI: 10.1590/0074-02760150390] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
10 Gao S, Fan Y, Zhao J, Sun F, Han J, Zhao Z, Wang K. A model to predict antiviral treatment in HBeAg negative chronic hepatitis B with alanine aminotransferase ≤2 upper limit of normal. Liver Int 2014;34:e229-37. [DOI: 10.1111/liv.12344] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
11 Wang Q, Li H, Ding D, Peng M, Ren H, Hu P. Upgrade Combination Response Is Limited by Prolonged Nucelos(t)ide Analogue Therapy in HBeAg-positive Chronic Hepatitis B: A Real-life Study. J Clin Transl Hepatol 2018;6:11-7. [PMID: 29577027 DOI: 10.14218/JCTH.2017.00020] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Kumar R, Pérez-Del-Pulgar S, Testoni B, Lebossé F, Zoulim F. Clinical relevance of the study of hepatitis B virus covalently closed circular DNA. Liver Int 2016;36 Suppl 1:72-7. [PMID: 26725901 DOI: 10.1111/liv.13001] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 5.4] [Reference Citation Analysis]
13 Alavian SM, Imanieh MH, Imanieh MH. Predictive Factors in the Incidence of Cirrhosis in Chronic Hepatitis B Virus Infections. Hepat Mon. 2016;16:e34790. [PMID: 27330536 DOI: 10.5812/hepatmon.34790] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
14 Azmi AN, Tan SS, Mohamed R. Practical approach in hepatitis B e antigen-negative individuals to identify treatment candidates. World J Gastroenterol 2014;20:12045-55. [PMID: 25232242 DOI: 10.3748/wjg.v20.i34.12045] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
15 Striki A, Manolakopoulos S, Deutsch M, Kourikou A, Kontos G, Kranidioti H, Hadziyannis E, Papatheodoridis G. Hepatitis B s antigen kinetics during treatment with nucleos(t)ides analogues in patients with hepatitis B e antigen-negative chronic hepatitis B. Liver Int. 2017;37:1642-1650. [PMID: 28345181 DOI: 10.1111/liv.13432] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
16 Wang X, Liu X, Dang Z, Yu L, Jiang Y, Wang X, Yang Z. Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis. Gut Liver. 2019;. [PMID: 31158948 DOI: 10.5009/gnl18546.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Wobser H, Paur T, Schnoy E, Hartl J, Kirchner GI. Suitability of the simplified autoimmune hepatitis score for the diagnosis of autoimmune hepatitis in a German cohort. United European Gastroenterol J 2018;6:247-54. [PMID: 29511554 DOI: 10.1177/2050640617711632] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
18 Desalegn H, Aberra H, Berhe N, Mekasha B, Stene-Johansen K, Krarup H, Pereira AP, Gundersen SG, Johannessen A. Treatment of chronic hepatitis B in sub-Saharan Africa: 1-year results of a pilot program in Ethiopia. BMC Med 2018;16:234. [PMID: 30554571 DOI: 10.1186/s12916-018-1229-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
19 Yang J, Yan D, Guo R, Chen J, Li Y, Fan J, Fu X, Yao X, Diao H, Li L. Predictive value of serum ALT and T-cell receptor beta variable chain for HBeAg seroconversion in chronic hepatitis B patients during tenofovir treatment. Medicine (Baltimore). 2017;96:e6242. [PMID: 28272219 DOI: 10.1097/md.0000000000006242] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Shimakawa Y, Njie R, Ndow G, Vray M, Mbaye PS, Bonnard P, Sombié R, Nana J, Leroy V, Bottero J, Ingiliz P, Post G, Sanneh B, Baldeh I, Suso P, Ceesay A, Jeng A, Njai HF, Nayagam S, D'Alessandro U, Chemin I, Mendy M, Thursz M, Lemoine M. Development of a simple score based on HBeAg and ALT for selecting patients for HBV treatment in Africa. J Hepatol 2018;69:776-84. [PMID: 30104154 DOI: 10.1016/j.jhep.2018.05.024] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 10.7] [Reference Citation Analysis]
21 Bian DD, Zhou HY, Liu S, Liu M, Duan C, Zhang JY, Jiang YY, Wang T, Chen Y, Wang Z, Zheng SJ, Duan ZP. Current treatment status and barriers for patients with chronic HCV infection in mainland China: A national multicenter cross-sectional survey in 56 hospitals. Medicine (Baltimore) 2017;96:e7885. [PMID: 28834904 DOI: 10.1097/MD.0000000000007885] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
22 Solay AH, Acar A, Eser F, Kuşcu F, Tütüncü EE, Kul G, Şentürk GÇ, Gürbüz Y. Reactivation rates in patients using biological agents, with resolved HBV infection or isolated anti-HBc IgG positivity. Turk J Gastroenterol 2018;29:561-5. [PMID: 30260778 DOI: 10.5152/tjg.2018.18032] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
23 Society for Maternal-Fetal Medicine (SMFM). Dionne-Odom J, Tita AT, Silverman NS. #38: Hepatitis B in pregnancy screening, treatment, and prevention of vertical transmission. Am J Obstet Gynecol. 2016;214:6-14. [PMID: 26454123 DOI: 10.1016/j.ajog.2015.09.100] [Cited by in Crossref: 93] [Cited by in F6Publishing: 68] [Article Influence: 15.5] [Reference Citation Analysis]
24 Aragri M, Alteri C, Battisti A, Di Carlo D, Minichini C, Sagnelli C, Bellocchi MC, Pisaturo MA, Starace M, Armenia D, Carioti L, Pollicita M, Salpini R, Sagnelli E, Perno CF, Coppola N, Svicher V. Multiple Hepatitis B Virus (HBV) Quasispecies and Immune-Escape Mutations Are Present in HBV Surface Antigen and Reverse Transcriptase of Patients With Acute Hepatitis B. J Infect Dis. 2016;213:1897-1905. [PMID: 26908731 DOI: 10.1093/infdis/jiw049] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 6.4] [Reference Citation Analysis]
25 Cassinotto C, Lapuyade B, Mouries A, Hiriart J, Vergniol J, Gaye D, Castain C, Le Bail B, Chermak F, Foucher J, Laurent F, Montaudon M, De Ledinghen V. Non-invasive assessment of liver fibrosis with impulse elastography: Comparison of Supersonic Shear Imaging with ARFI and FibroScan®. Journal of Hepatology 2014;61:550-7. [DOI: 10.1016/j.jhep.2014.04.044] [Cited by in Crossref: 214] [Cited by in F6Publishing: 165] [Article Influence: 30.6] [Reference Citation Analysis]
26 Wu S, Luo W, Wu Y, Chen H, Peng J. HBsAg quantification predicts off-treatment response to interferon in chronic hepatitis B patients: a retrospective study of 250 cases. BMC Gastroenterol. 2020;20:121. [PMID: 32316928 DOI: 10.1186/s12876-020-01263-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
27 Tseng T, Liu C, Yang H, Chen C, Yang W, Tsai C, Kuo SF, Verbree FC, Su T, Wang C, Liu C, Chen P, Chen D, Kao J. Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers. Gut 2015;64:292-302. [DOI: 10.1136/gutjnl-2014-306977] [Cited by in Crossref: 73] [Cited by in F6Publishing: 66] [Article Influence: 10.4] [Reference Citation Analysis]
28 Brinck-Jensen NS, Erichsen P, Tarp B, Lindberg J, Kristensen LH, Erlandsen M, Petersen E, Leutscher PD; InfCare Hepatitis DK group. Clinical findings in a multi-ethnic adult hepatitis B virus patient population in Denmark with emphasis on genotypic characteristics. Scand J Gastroenterol 2015;50:1032-8. [PMID: 25861877 DOI: 10.3109/00365521.2014.974202] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
29 Zheng YB, Gu YR, Zhang M, Wang K, Huang ZL, Lin CS, Gao ZL. Health care workers in Pearl River Delta Area of China are not vaccinated adequately against hepatitis B: a retrospective cohort study. BMC Infect Dis 2015;15:542. [PMID: 26590815 DOI: 10.1186/s12879-015-1278-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
30 Boglione L, D'avolio A, Cariti G, Milia MG, Simiele M, De Nicolò A, Ghisetti V, Di Perri G. Sequential therapy with entecavir and PEG-INF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes. J Viral Hepat 2013;20:e11-9. [DOI: 10.1111/jvh.12018] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
31 Lee JM, Seo YS, Kim TH, Ahn JM, Yim SY, Kim SU, Jung YK, Kim JH, An H, Yim HJ, Yeon JE, Lee HS, Byun KS, Um SH, Kim CD, Ryu HS. The LAW index as an accurate indicator of the initiation of antiviral treatment in patients with chronic hepatitis B. J Gastroenterol Hepatol 2017;32:208-14. [PMID: 27194632 DOI: 10.1111/jgh.13447] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
32 Kondylis P, Schlicksup CJ, Katen SP, Lee LS, Zlotnick A, Jacobson SC. Evolution of Intermediates during Capsid Assembly of Hepatitis B Virus with Phenylpropenamide-Based Antivirals. ACS Infect Dis 2019;5:769-77. [PMID: 30616343 DOI: 10.1021/acsinfecdis.8b00290] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
33 Chen CY, Huang SY, Cheng A, Chou WC, Yao M, Tang JL, Tsay W, Sheng WH, Tien HF. High Risk of Hepatitis B Reactivation among Patients with Acute Myeloid Leukemia. PLoS One. 2015;10:e0126037. [PMID: 25973905 DOI: 10.1371/journal.pone.0126037] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
34 Zeng DW, Dong J, Liu YR, Jiang JJ, Zhu YY. Noninvasive models for assessment of liver fibrosis in patients with chronic hepatitis B virus infection. World J Gastroenterol 2016;22:6663-72. [PMID: 27547009 DOI: 10.3748/wjg.v22.i29.6663] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
35 Huang R, Yang CC, Liu Y, Xia J, Su R, Xiong YL, Wang GY, Sun ZH, Yan XM, Lu S, Wu C. Association of serum gamma-glutamyl transferase with treatment outcome in chronic hepatitis B patients. World J Gastroenterol 2015;21:9957-65. [PMID: 26379400 DOI: 10.3748/wjg.v21.i34.9957] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
36 Wiegand S, Jaroszewicz J, Potthoff A, Höner zu Siederdissen C, Maasoumy B, Deterding K, Manns M, Wedemeyer H, Cornberg M. Dominance of hepatitis C virus (HCV) is associated with lower quantitative hepatitis B surface antigen and higher serum interferon-γ-induced protein 10 levels in HBV/HCV-coinfected patients. Clinical Microbiology and Infection 2015;21:710.e1-9. [DOI: 10.1016/j.cmi.2015.03.003] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 5.7] [Reference Citation Analysis]
37 Wu JQ, Song YP, Su LP, Zhang MZ, Li W, Hu Y, Zhang XH, Gao YH, Niu ZX, Feng R, Wang W, Peng JW, Li XL, Ouyang XN, Wu CP, Zhang WJ, Zeng Y, Xiao Z, Liang YM, Zhuang YZ, Wang JS, Sun ZM, Bai H, Cui TJ, Feng JF. Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China: A Prospective, Multicenter, Noninterventional Study. Chin Med J (Engl) 2018;131:1767-75. [PMID: 30058572 DOI: 10.4103/0366-6999.237401] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
38 Chang C, Tsai C, Yan S. Hepatitis B reactivation in patients receiving targeted therapies. Hematology 2017;22:592-8. [DOI: 10.1080/10245332.2017.1321882] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
39 Restellini S, Chazouillères O, Frossard JL. Hepatic manifestations of inflammatory bowel diseases. Liver Int 2017;37:475-89. [PMID: 27712010 DOI: 10.1111/liv.13265] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 4.2] [Reference Citation Analysis]
40 Lee HW, Kang W, Kim BK, Kim SU, Park JY, Kim DY, Ahn SH, Park YN, Han KH. Red cell volume distribution width-to-platelet ratio in assessment of liver fibrosis in patients with chronic hepatitis B. Liver Int. 2016;36:24-30. [PMID: 25966326 DOI: 10.1111/liv.12868] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
41 Yu G, Chi X, Wu R, Wang X, Gao X, Kong F, Feng X, Gao Y, Huang X, Jin J, Qi Y, Tu Z, Sun B, Zhong J, Pan Y, Niu J. Replication Inhibition of Hepatitis B Virus and Hepatitis C Virus in Co-Infected Patients in Chinese Population. PLoS One 2015;10:e0139015. [PMID: 26422607 DOI: 10.1371/journal.pone.0139015] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
42 Stevens K, Palmo T, Wangchuk T, Solomon S, Dierberg K, Hoffmann CJ. Hepatitis B prevalence and treatment needs among Tibetan refugees residing in India. J Med Virol 2016;88:1357-63. [PMID: 26822932 DOI: 10.1002/jmv.24488] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
43 Pan XB, Lu YQ, Lin SZ, Ye J, Wu N, Lou YY, Ni L, Han JC, Zheng XQ, Wei L. An Assessment of Upper Limits of Normal for ALT and the Impact on Evaluating Natural Course of Chronic Hepatitis B Virus Infection in Chinese Children. Am J Gastroenterol 2018;113:1660-8. [PMID: 30353056 DOI: 10.1038/s41395-018-0248-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
44 Larsson SB, Eilard A, Malmström S, Hannoun C, Dhillon AP, Norkrans G, Lindh M. HBsAg quantification for identification of liver disease in chronic hepatitis B virus carriers. Liver Int 2014;34:e238-45. [DOI: 10.1111/liv.12345] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
45 Lian M, Zhang J, Zhao L, Chen X, Peng Y, Wang Q, Chen S, Ma X. Interleukin-35 Regulates Immune Microenvironment of Autoimmune Hepatitis Through Inducing the Expansion of Myeloid-Derived Suppressor Cells. Front Immunol 2019;10:2577. [PMID: 31787974 DOI: 10.3389/fimmu.2019.02577] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
46 Cho Y, Lee DH, Chung KH, Jin E, Lee J, Cho EJ, Yu SJ, Kim JW, Jeong SH, Yoon J, Lee H, Kim CY, Kim YJ. The Efficacy of Adefovir Plus Entecavir Combination Therapy in Patients with Chronic Hepatitis B Refractory to Both Lamivudine and Adefovir. Dig Dis Sci 2013;58:1363-70. [DOI: 10.1007/s10620-012-2480-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
47 Chen J, Zhao SS, Liu XX, Huang ZB, Huang Y. Comparison of the Efficacy of Tenofovir Versus Tenofovir plus Entecavir in the Treatment of Chronic Hepatitis B in Patients With Poor Efficacy of Entecavir: A Systematic Review and Meta-analysis. Clin Ther 2017;39:1870-80. [PMID: 28797777 DOI: 10.1016/j.clinthera.2017.07.015] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
48 Ji SS, Jiang HD, Jiang JC, Li J, Lin ST, Chen B, Xu SH. Applicability of liver stiffness measurement based nomograms to the assessments of hepatitis B related significant fibrosis and cirrhosis. Clin Chim Acta 2019;489:75-82. [PMID: 30471249 DOI: 10.1016/j.cca.2018.11.029] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
49 Di Bisceglie AM, Lombardero M, Teckman J, Roberts L, Janssen HL, Belle SH, Hoofnagle JH; Hepatitis B Research Network (HBRN). Determination of hepatitis B phenotype using biochemical and serological markers. J Viral Hepat. 2017;24:320-329. [PMID: 27917600 DOI: 10.1111/jvh.12643] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
50 Ruggeri M, Basile M, Coretti S, Drago C, Cicchetti A. Economic Analysis and Budget Impact of Tenofovir and Entecavir in the First-Line Treatment of Hepatitis B Virus in Italy. Appl Health Econ Health Policy 2017;15:479-90. [DOI: 10.1007/s40258-017-0311-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
51 García-bengoechea M, Hernández-lópez C, Crespo J, Gea F. Prácticas de cribado del virus de la hepatitis B previo a las terapias de riesgo de reactivación vírica en diferentes especialidades médicas. Proyecto HEBRA. Medicina Clínica 2012;139:498-501. [DOI: 10.1016/j.medcli.2012.06.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
52 Yu HC, Lin KH, Hsu PI, Tsay FW, Wang HM, Tsai TJ, Lai KH. Real-world application of the roadmap model in chronic hepatitis B patients with telbivudine therapy. Clin Ther. 2013;35:1386-1399. [PMID: 24054706 DOI: 10.1016/j.clinthera.2013.07.329] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
53 Ma ZJ, Li Q, Wang JB, Zhao YL, Zhong YW, Bai YF, Wang RL, Li JY, Yang HY, Zeng LN, Pu SB, Liu FF, Xiao DK, Xia XH, Xiao XH. Combining Oxymatrine or Matrine with Lamivudine Increased Its Antireplication Effect against the Hepatitis B Virus In Vitro. Evid Based Complement Alternat Med 2013;2013:186573. [PMID: 23401707 DOI: 10.1155/2013/186573] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
54 Luk A, Jiang Q, Glavini K, Triyatni M, Zhao N, Racek T, Zhu Y, Grippo JF. A Single and Multiple Ascending Dose Study of Toll-Like Receptor 7 Agonist (RO7020531) in Chinese Healthy Volunteers. Clin Transl Sci. 2020;13:985-993. [PMID: 32268000 DOI: 10.1111/cts.12791] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
55 Braun P, Delgado R, Drago M, Fanti D, Fleury H, Izopet J, Lombardi A, Marcos M, Sauné K, O'Shea S, Pérez-Rivilla A, Ramble J, Trimoulet P, Vila J, Whittaker D, Artus A, Rhodes D. A European multicientre study on the comparison of HBV viral loads between VERIS HBV assay and Roche COBAS® TAQMAN® HBV test, Abbott RealTime HBV assay, Siemens VERSANT HBV assay, and Qiagen artus HBV RG kit. J Clin Virol 2017;95:76-83. [PMID: 28892764 DOI: 10.1016/j.jcv.2017.08.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
56 Xie F, Yan L, Lu J, Zheng T, Shi C, Ying J, Shen R, Yang J. Effects of nucleoside analogue on patients with chronic hepatitis B-associated liver failure: meta-analysis. PLoS One. 2013;8:e54773. [PMID: 23382964 DOI: 10.1371/journal.pone.0054773] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
57 Sun YY, Fan YC, Wang N, Xia HH, Xiao XY, Wang K. Increased A20 mRNA Level in Peripheral Blood Mononuclear Cells is Associated With Immune Phases of Patients With Chronic Hepatitis B. Medicine (Baltimore) 2015;94:e2428. [PMID: 26717404 DOI: 10.1097/MD.0000000000002428] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Sporea I, Bota S, Gradinaru-taşcău O, Şirli R, Popescu A, Jurchiş A. Which are the cut-off values of 2D-Shear Wave Elastography (2D-SWE) liver stiffness measurements predicting different stages of liver fibrosis, considering Transient Elastography (TE) as the reference method? European Journal of Radiology 2014;83:e118-22. [DOI: 10.1016/j.ejrad.2013.12.011] [Cited by in Crossref: 54] [Cited by in F6Publishing: 43] [Article Influence: 7.7] [Reference Citation Analysis]
59 Barone M, Notarnicola A, Lopalco G, Viggiani MT, Sebastiani F, Covelli M, Iannone F, Avolio AW, Di Leo A, Cantarini L. Safety of long-term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection. Hepatology. 2015;62:40-46. [PMID: 25613809 DOI: 10.1002/hep.27716] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 9.2] [Reference Citation Analysis]
60 Indolfi G, Nesi A, Resti M. Treatment of chronic hepatitis B and C in children. Future Virology 2012;7:955-72. [DOI: 10.2217/fvl.12.94] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
61 Boyd A, Maylin S, Moh R, Mahjoub N, Gabillard D, Eholié SP, Danel C, Anglaret X, Zoulim F, Girard P, Delaugerre C, Lacombefor the Anrs Varbva study K. Hepatitis B surface antigen quantification as a predictor of seroclearance during treatment in HIV-hepatitis B virus coinfected patients from Sub-Saharan Africa: Seroclearance during treatment. Journal of Gastroenterology and Hepatology 2016;31:634-44. [DOI: 10.1111/jgh.13156] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
62 Vlachogiannakos J, Papatheodoridis GV. HBV: Do I treat my immunotolerant patients? Liver Int. 2016;36 Suppl 1:93-99. [PMID: 26725904 DOI: 10.1111/liv.12996] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
63 Hou JL, Jia JD, Wei L, Zhao W, Wang YM, Cheng M, Tang X, Tan DM, Ren H, Tang H, Cohen D, Llamoso C. Efficacy and safety of entecavir treatment in a heterogeneous CHB population from a ‘real-world’ clinical practice setting in China. J Viral Hepat 2013;20:811-20. [PMID: 23876210 DOI: 10.1111/jvh.12115] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
64 Yu R, Dan Y, Xiang X, Zhou Y, Kuang X, Yang G, Tang Y, Liu M, Kong W, Tan W, Deng G. Stability of Chronic Hepatitis-Related Parameters in Serum Samples After Long-Term Storage. Biopreserv Biobank 2017;15:211-9. [PMID: 27960069 DOI: 10.1089/bio.2016.0043] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
65 Lu K, Wang HP, Chen YS. Outcomes of kidney transplantation recipients with hepatitis in the antiviral therapy era: a single-center experience. Transplant Proc. 2014;46:460-463. [PMID: 24655988 DOI: 10.1016/j.transproceed.2013.11.041] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
66 Lemoine M, Nayagam S, Thursz M. Viral hepatitis in resource-limited countries and access to antiviral therapies: current and future challenges. Future Virol. 2013;8:371-380. [PMID: 23662157 DOI: 10.2217/fvl.13.11] [Cited by in Crossref: 77] [Cited by in F6Publishing: 60] [Article Influence: 9.6] [Reference Citation Analysis]
67 Zhao XY, Li J, Wang JH, Habib S, Wei W, Sun SJ, Strobel HW, Jia JD. Vitamin D serum level is associated with Child-Pugh score and metabolic enzyme imbalances, but not viral load in chronic hepatitis B patients. Medicine (Baltimore). 2016;95:e3926. [PMID: 27399065 DOI: 10.1097/md.0000000000003926] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
68 Wang M, Gong Q, Zhang J, Chen L, Zhang Z, Lu L, Yu D, Han Y, Zhang D, Chen P, Zhang X, Yuan Z, Huang J, Zhang X. Characterization of gene expression profiles in HBV-related liver fibrosis patients and identification of ITGBL1 as a key regulator of fibrogenesis. Sci Rep 2017;7:43446. [PMID: 28262670 DOI: 10.1038/srep43446] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 7.8] [Reference Citation Analysis]
69 Kim HJ, Cho JY, Kim YJ, Gwak GY, Paik YH, Choi MS, Koh KC, Paik SW, Yoo BC, Lee JH. Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients. Korean J Intern Med 2015;30:32-41. [PMID: 25589833 DOI: 10.3904/kjim.2015.30.1.32] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
70 Song LW, Liu PG, Liu CJ, Zhang TY, Cheng XD, Wu HL, Yang HC, Hao XK, Yuan Q, Zhang J, Kao JH, Chen DS, Chen PJ, Xia NS. Quantitative hepatitis B core antibody levels in the natural history of hepatitis B virus infection. Clin Microbiol Infect 2015;21:197-203. [PMID: 25658546 DOI: 10.1016/j.cmi.2014.10.002] [Cited by in Crossref: 62] [Cited by in F6Publishing: 56] [Article Influence: 8.9] [Reference Citation Analysis]
71 Loggi E, Vitale G, Conti F, Bernardi M, Andreone P. Chronic hepatitis B: Are we close to a cure? Dig Liver Dis. 2015;47:836-841. [PMID: 26138799 DOI: 10.1016/j.dld.2015.05.019] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
72 Lee HW, Chang HY, Yang SY, Kim HJ. Viral evolutionary changes during tenofovir treatment in a chronic hepatitis B patient with sequential nucleos(t)ide therapy. J Clin Virol. 2014;60:313-316. [PMID: 24836314 DOI: 10.1016/j.jcv.2014.03.018] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
73 Choi J, Lim Y. Nucleos(t)ide Therapy and Long-Term Outcomes. In: Kao J, Chen D, editors. Hepatitis B Virus and Liver Disease. Singapore: Springer; 2018. pp. 193-217. [DOI: 10.1007/978-981-10-4843-2_11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
74 He J, Zhou D, Tong G, Xing Y, Chen Y, Zhang X, Zhan B, Gao H, Zhou X, Xiong Y, Liu X, Peng L, Qiu M, Zheng Y. Efficacy and safety of a chinese herbal formula (invigorating kidney and strengthening spleen) in chronic hepatitis B virus carrier: results from a multicenter, randomized, double-blind, and placebo-controlled trial. Evid Based Complement Alternat Med. 2013;2013:961926. [PMID: 23935692 DOI: 10.1155/2013/961926] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
75 Vlachogiannakos J, Papatheodoridis G. Hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy. World J Gastroenterol. 2013;19:8822-8830. [PMID: 24379605 DOI: 10.3748/wjg.v19.i47.8822] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.1] [Reference Citation Analysis]
76 Kania D, Ottomani L, Meda N, Peries M, Dujols P, Bolloré K, Rénier W, Viljoen J, Ducos J, Van de Perre P. Performance of two real-time PCR assays for hepatitis B virus DNA detection and quantitation. J Virol Methods. 2014;201:24-30. [PMID: 24560781 DOI: 10.1016/j.jviromet.2014.01.015] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
77 Hong MZ, Huang WQ, Min F, Xu JC, Lin Z, Fang KN, Pan JS. Enhanced HBsAg synthesis correlates with increased severity of fibrosis in chronic hepatitis B patients. PLoS One 2014;9:e87344. [PMID: 24498079 DOI: 10.1371/journal.pone.0087344] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
78 Chen Y, Liaw Y. Pharmacotherapeutic options for hepatitis B. Expert Opinion on Pharmacotherapy 2016;17:355-67. [DOI: 10.1517/14656566.2016.1118056] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
79 Ben Selma W, Alibi S, Smach MA, Saad A, Boukadida J. IL-18 variant increases risk of enhanced HBV DNA replication in chronic hepatitis. Immunology Letters 2020;228:70-5. [DOI: 10.1016/j.imlet.2020.10.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
80 Chen L, Bao D, Gu L, Gu Y, Zhou L, Gao Z, Huang Y. Co-infection with hepatitis B virus among tuberculosis patients is associated with poor outcomes during anti-tuberculosis treatment. BMC Infect Dis 2018;18:295. [PMID: 29970037 DOI: 10.1186/s12879-018-3192-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
81 Li Q, Lu C, Li W, Huang Y, Chen L. Evaluation of eLIFT for Non-invasive Assessment of Liver fibrosis and Cirrhosis in Patients with Chronic Hepatitis B Virus Infection. Sci Rep 2017;7:5429. [PMID: 28710435 DOI: 10.1038/s41598-017-05718-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
82 Bechini A, Falla A, Ahmad A, Veldhuijzen I, Boccalini S, Porchia B, Levi M. Identification of hepatitis B and C screening and patient management guidelines and availability of training for chronic viral hepatitis among health professionals in six European countries: results of a semi-quantitative survey. BMC Infect Dis 2015;15:353. [PMID: 26286525 DOI: 10.1186/s12879-015-1104-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
83 Chen X, Xiang K, Zhang H, Kong X, Huang C, Liu Y, Lou J, Gao Z, Yan H. Occult HBV infection in patients with autoimmune hepatitis: A virological and clinical study. Journal of Microbiology, Immunology and Infection 2020;53:946-54. [DOI: 10.1016/j.jmii.2019.04.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
84 Wahle RC, Perez RM, Pereira PF, Oliveira EM, Emori CT, Uehara SN, Silva IS, Silva AE, Ferraz ML. Hepatitis B virus reactivation after treatment for hepatitis C in hemodialysis patients with HBV/HCV coinfection. Braz J Infect Dis 2015;19:533-7. [PMID: 25997784 DOI: 10.1016/j.bjid.2015.04.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
85 Gonen C, Gunduz F, Doganay L, Enc FY, Yegin EG, Ahishali E, Erdem E, Sokmen M, Tuncer I, Ozdogan O. High treatment modification rates with lamivudine therapy in HBV-infected patients with low baseline viremia and early virological response: A multicenter study. J Dig Dis 2015;16:286-92. [PMID: 25708813 DOI: 10.1111/1751-2980.12237] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
86 Su TH, Kao JH, Liu CJ. Molecular mechanism and treatment of viral hepatitis-related liver fibrosis. Int J Mol Sci. 2014;15:10578-10604. [PMID: 24927147 DOI: 10.3390/ijms150610578] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 6.3] [Reference Citation Analysis]
87 Zeng Y, Yang B, Wu Y, Chen J, Shang H, Chen X, Su M, Wu S, Lin J, Ou Q. Clinical significance of periodic detection of hepatitis B virus YVDD mutation by ultrasensitive real-time amplification refractory mutation system quantitative PCR during lamivudine treatment in patients with chronic hepatitis B. J Med Microbiol 2015;64:237-42. [PMID: 25596114 DOI: 10.1099/jmm.0.000022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
88 Huang M, Zhong J, Lu C, Deng F, Li L, Nong Y, Liang L, Qin H, Deng Y. Genotypic Resistance Remains A Concern In Chronic Hepatitis B Patients With High Viral Load After Lamivudine And Adefovir Combination Therapy. Pharmgenomics Pers Med 2019;12:297-303. [PMID: 31695474 DOI: 10.2147/PGPM.S224256] [Reference Citation Analysis]
89 Kozielewicz D, Zaleśna A, Dybowska D. Can pegylated interferon α 2a cause development of thyroid disorders in patients with chronic hepatitis B? Expert Opinion on Drug Safety 2014;13:1009-14. [DOI: 10.1517/14740338.2014.921156] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
90 Ramírez-Soto MC, Bracho MA, González-Candelas F, Huichi-Atamari M. Genotypes and subgenotypes of hepatitis B virus circulating in an endemic area in Peru. Arch Virol 2018;163:183-9. [PMID: 28948365 DOI: 10.1007/s00705-017-3557-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
91 Mantzoukis K, Rodríguez-Perálvarez M, Buzzetti E, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS. Pharmacological interventions for acute hepatitis B infection: an attempted network meta-analysis. Cochrane Database Syst Rev 2017;3:CD011645. [PMID: 28321877 DOI: 10.1002/14651858.CD011645.pub2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
92 Walker TY, Smith EA, Fenlon N, Lazaroff JE, Dusek C, Fineis P, Crowley SA, Benson R, Veselsky SL, Murphy TV. Characteristics of Pregnant Women With Hepatitis B Virus Infection in 5 US Public Health Jurisdictions, 2008-2012. Public Health Rep 2016;131:685-94. [PMID: 28123209 DOI: 10.1177/0033354916663183] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
93 Welker MW, Zeuzem S. Pre- and Post-Transplant Antiviral Therapy (HBV, HCV). Visc Med 2016;32:105-9. [PMID: 27413727 DOI: 10.1159/000445152] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
94 Wu YS, Zhang WW, Ling XM, Yang L, Huang SB, Wang XC, Wu H, Cai WP, Wang M, Wang H, Liu YF, He HL, Wei FL, Wu ZY, Zhang FJ. Efficacy and Safety of Tenofovir and Lamivudine in Combination with Efavirenz in Patients Co-infected with Human Immunodeficiency Virus and Hepatitis B Virus in China. Chin Med J (Engl) 2016;129:304-8. [PMID: 26831232 DOI: 10.4103/0366-6999.174509] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
95 Pang X, Zhang L, Liu N, Liu B, Chen Z, Li H, Chen M, Peng M, Ren H, Hu P. Combination of pegylated interferon-alpha and nucleos(t)ide analogue treatment enhances the activity of natural killer cells in nucleos(t)ide analogue experienced chronic hepatitis B patients. Clin Exp Immunol 2020;202:80-92. [PMID: 32638357 DOI: 10.1111/cei.13486] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
96 Wang JY. Antiviral therapy for hepatitis B virus-related decompensated cirrhosis. J Dig Dis. 2012;13:555-557. [PMID: 23107441 DOI: 10.1111/j.1751-2980.2012.00630.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
97 Lampertico P. Oral antiviral therapy for HBeAg negative chronic hepatitis B: better stop or continue? Gut 2015;64:526-8. [DOI: 10.1136/gutjnl-2014-307596] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
98 Lin TC, Hashemi N, Kim SC, Yang YK, Yoshida K, Tedeschi S, Desai R, Solomon DH. Practice Pattern of Hepatitis B Testing in Rheumatoid Arthritis Patients: A Cross-National Comparison Between the US and Taiwan. Arthritis Care Res (Hoboken) 2018;70:30-8. [PMID: 28320050 DOI: 10.1002/acr.23241] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
99 Buzzetti E, Lombardi R, De Luca L, Tsochatzis EA. Noninvasive Assessment of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. Int J Endocrinol 2015;2015:343828. [PMID: 26064107 DOI: 10.1155/2015/343828] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
100 Battaglia Y, Cojocaru E, Forcellini S, Russo L, Russo D. Tenofovir and kidney transplantation: case report. Clin Nephrol Case Stud. 2016;4:18-23. [PMID: 29043137 DOI: 10.5414/cncs108929] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
101 Wang X, Liu X, Dang Z, Yu L, Jiang Y, Wang X, Yan Z. Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis. Gut Liver 2020;14:232-47. [PMID: 31158948 DOI: 10.5009/gnl18546] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 15.0] [Reference Citation Analysis]
102 Pollack HJ, Kwon SC, Wang SH, Wyatt LC, Trinh-Shevrin C. Chronic hepatitis B and liver cancer risks among Asian immigrants in New York City: Results from a large, community-based screening, evaluation, and treatment program. Cancer Epidemiol Biomarkers Prev. 2014;23:2229-2239. [PMID: 25368398 DOI: 10.1158/1055-9965.epi-14-0491] [Cited by in Crossref: 28] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
103 Chan WK, Tan S, Mohamed R. Stopping Therapy in HBeAg Negative Disease. Curr Hepatitis Rep 2013;12:105-11. [DOI: 10.1007/s11901-013-0167-5] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
104 Wen WH, Chen HL, Shih TT, Wu JF, Ni YH, Lee CN, Zhao LL, Lai MW, Mu SC, Tung YC, Hsu HY, Chang MH; Taiwan Study Group for the Prevention of Mother-to-Infant Transmission of HBV (PreMIT study)(‡). Long-term growth and bone development in children of HBV-infected mothers with and without fetal exposure to tenofovir disoproxil fumarate. J Hepatol 2020;72:1082-7. [PMID: 32044401 DOI: 10.1016/j.jhep.2020.01.021] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
105 Chan HL, Chan CK, Hui AJ, Chan S, Poordad F, Chang TT, Mathurin P, Flaherty JF, Lin L, Corsa A, Gaggar A, Subramanian GM, McHutchison JG, Lau G, Lee S, Gane EJ. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA. Gastroenterology. 2014;146:1240-1248. [PMID: 24462735 DOI: 10.1053/j.gastro.2014.01.044] [Cited by in Crossref: 101] [Cited by in F6Publishing: 90] [Article Influence: 14.4] [Reference Citation Analysis]
106 Xiang KH, Michailidis E, Ding H, Peng YQ, Su MZ, Li Y, Liu XE, Dao Thi VL, Wu XF, Schneider WM. Effects of amino acid substitutions in hepatitis B virus surface protein on virion secretion, antigenicity, HBsAg and viral DNA. J Hepatol. 2017;66:288-296. [PMID: 27650283 DOI: 10.1016/j.jhep.2016.09.005] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 7.4] [Reference Citation Analysis]
107 Chuang WL, Jia J, Chan HLY, Han KH, Tanwandee T, Tan D, Chen X, Gane E, Piratvisuth T, Chen L, Xie Q, Sung JJ, Messinger D, Wat C, Bakalos G, Liaw YF. Responses are durable for up to 5 years after completion of peginterferon alfa-2a treatment in hepatitis B e antigen-positive patients. Aliment Pharmacol Ther 2018;47:1306-16. [PMID: 29520872 DOI: 10.1111/apt.14595] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
108 Lee J, Sinn DH, Kim JH, Gwak GY, Kim HS, Jung SH, Paik YH, Choi MS, Lee JH, Koh KC, Yoo BC, Paik SW. Hepatocellular Carcinoma Risk of Compensated Cirrhosis Patients with Elevated HBV DNA Levels according to Serum Aminotransferase Levels. J Korean Med Sci 2015;30:1618-24. [PMID: 26539006 DOI: 10.3346/jkms.2015.30.11.1618] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
109 Kelling M, Sokol L, Dalia S. Hepatitis B Reactivation in the Treatment of Non-Hodgkin Lymphoma. Cancer Control 2018;25:1073274818767879. [PMID: 29606020 DOI: 10.1177/1073274818767879] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
110 Tan NK, Carrington D, Pope CF. Verification of the Roche cobas® 6800 PCR 200 µl and 500 µl protocols for the quantification of HIV-1 RNA, HBV DNA and HCV RNA and evaluation with COBAS® Ampliprep/COBAS® TaqMan® assays. Journal of Medical Microbiology 2018;67:1711-7. [DOI: 10.1099/jmm.0.000838] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
111 Wei L, Jia JD, Weng XH, Dou XG, Jiang JJ, Tang H, Ning Q, Dai QQ, Li RQ, Liu J. Treating chronic hepatitis B virus: Chinese physicians' awareness of the 2010 guidelines. World J Hepatol 2016;8:762-9. [PMID: 27366303 DOI: 10.4254/wjh.v8.i18.762] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
112 Zhang HY, Liu LG, Ye CY, Chen CH, Hang SX, Zhu Z, Shen HY, Huang ZY, Chen WY, Xue Y. Evolution of drug-resistant mutations in HBV genomes in patients with treatment failure during the past seven years (2010-2016). Virus Genes. 2018;54:41-47. [PMID: 29119303 DOI: 10.1007/s11262-017-1518-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
113 Zhang YQ, Guo JS. Antiviral therapies for hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol. 2015;21:3860-3866. [PMID: 25852270 DOI: 10.3748/wjg.v21.i13.3860] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
114 Butler EK, Gersch J, McNamara A, Luk KC, Holzmayer V, de Medina M, Schiff E, Kuhns M, Cloherty GA. Hepatitis B Virus Serum DNA andRNA Levels in Nucleos(t)ide Analog-Treated or Untreated Patients During Chronic and Acute Infection. Hepatology. 2018;68:2106-2117. [PMID: 29734472 DOI: 10.1002/hep.30082] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 19.3] [Reference Citation Analysis]
115 Cho H, Cho Y, Cho EJ, Lee JH, Yu SJ, Oh KH, Lee K, Mustika S, Yoon JH, Kim YJ. Tenofovir-associated nephrotoxicity in patients with chronic hepatitis B: two cases. Clin Mol Hepatol 2016;22:286-91. [PMID: 27377911 DOI: 10.3350/cmh.2015.0066] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
116 Hu ZX, Ye YN, Wu WG, Liang XJ, Wu QW, Zhang A, Zheng XR, Gao ZL, Peng L, Xie C. Real-Life State of Anti-Hepatitis B Virus Drug Choice in Child-Bearing Age Male Patients and Effect on Fertility and Fetal Safety. Can J Gastroenterol Hepatol 2019;2019:9703907. [PMID: 31058113 DOI: 10.1155/2019/9703907] [Reference Citation Analysis]
117 Keith P, Wetter D, Wilson J, Lehman J. Evidence-based guidelines for laboratory screening for infectious diseases before initiation of systemic immunosuppressive agents in patients with autoimmune bullous dermatoses. Br J Dermatol 2014;171:1307-17. [DOI: 10.1111/bjd.13355] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
118 Höner Zu Siederdissen C, Cornberg M. Management of HBV and HBV/HDV-Associated Liver Cirrhosis. Visc Med 2016;32:86-94. [PMID: 27413725 DOI: 10.1159/000445518] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
119 Lee KS, Kweon YO, Um SH, Kim BH, Lim YS, Paik SW, Heo J, Lee HJ, Kim DJ, Kim TH, Lee YS, Byun KS, Kim D, Lee MS, Yu K, Suh DJ. Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B. Clin Mol Hepatol 2017;23:331-9. [PMID: 28946736 DOI: 10.3350/cmh.2016.0040] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
120 AlMutairi N, Abouzaid HA. Safety of biologic agents for psoriasis in patients with viral hepatitis. J Dermatolog Treat 2018;29:553-6. [PMID: 29345515 DOI: 10.1080/09546634.2018.1430301] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
121 Runge JH, Bohte AE, Verheij J, Terpstra V, Nederveen AJ, van Nieuwkerk KM, de Knegt RJ, Baak BC, Jansen PL, Sinkus R, Stoker J. Comparison of interobserver agreement of magnetic resonance elastography with histopathological staging of liver fibrosis. Abdom Imaging. 2014;39:283-290. [PMID: 24366108 DOI: 10.1007/s00261-013-0063-z] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 5.1] [Reference Citation Analysis]
122 Chan HC, Wong VW, Wong GL, Tang W, Wu JC, Ng SC. Prevalence of hepatitis B and clinical outcomes in inflammatory bowel disease patients in a viral-endemic region. BMC Gastroenterol. 2016;16:100. [PMID: 27549153 DOI: 10.1186/s12876-016-0516-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
123 Baran B. Nucleos(t)ide analogs in the prevention of hepatitis B virus related hepatocellular carcinoma. World J Hepatol 2015;7:1742-54. [PMID: 26167247 DOI: 10.4254/wjh.v7.i13.1742] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
124 Hsu CW, Liang KH, Lin CL, Wang TH, Yeh CT. Platelet counts modulate the quantitative relationship between hepatitis B viral DNA and surface antigen concentrations: a cross-sectional study of hematological, histological and viral factors. BMC Infect Dis 2017;17:9. [PMID: 28056849 DOI: 10.1186/s12879-016-2121-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
125 Krastev Z, Petrova D, Kotzev I, Celen MK, Mendelson M, Chandra R, Pandey P, Hamed K. Telbivudine vs tenofovir in hepatitis B e antigen-negative chronic hepatitis B patients: OPTIMA roadmap study. World J Hepatol 2016;8:1402-13. [PMID: 27917266 DOI: 10.4254/wjh.v8.i32.1402] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
126 Riveiro-Barciela M, Buti M. [Hepatitis B virus infection in pregnancy and the immunosuppressed patient]. Gastroenterol Hepatol 2015;38:31-9. [PMID: 25066320 DOI: 10.1016/j.gastrohep.2014.05.011] [Reference Citation Analysis]
127 Croagh CM, Lubel JS. Natural history of chronic hepatitis B: phases in a complex relationship. World J Gastroenterol 2014;20:10395-404. [PMID: 25132755 DOI: 10.3748/wjg.v20.i30.10395] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 42] [Article Influence: 7.5] [Reference Citation Analysis]
128 Parsa SF, Vafajoo A, Rostami A, Salarian R, Rabiee M, Rabiee N, Rabiee G, Tahriri M, Yadegari A, Vashaee D, Tayebi L, Hamblin MR. Early diagnosis of disease using microbead array technology: A review. Anal Chim Acta 2018;1032:1-17. [PMID: 30143206 DOI: 10.1016/j.aca.2018.05.011] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
129 Wang Q, Klenerman P, Semmo N. Significance of anti-HBc alone serological status in clinical practice. The Lancet Gastroenterology & Hepatology 2017;2:123-34. [DOI: 10.1016/s2468-1253(16)30076-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 3] [Article Influence: 5.3] [Reference Citation Analysis]
130 Xu Y, Wang X, Liu Z, Zhou C, Qi W, Jiao J, Yu F, Guo H, Zhao P, Wang J. Addition of nucleoside analogues to peg-IFNα-2a enhances virological response in chronic hepatitis B patients without early response to peg-IFNα-2a: a randomized controlled trial. BMC Gastroenterol 2017;17:102. [PMID: 28854883 DOI: 10.1186/s12876-017-0657-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
131 Shi Y, Guo Q, Xia F, Dzyubak B, Glaser KJ, Li Q, Li J, Ehman RL. MR elastography for the assessment of hepatic fibrosis in patients with chronic hepatitis B infection: does histologic necroinflammation influence the measurement of hepatic stiffness? Radiology. 2014;273:88-98. [PMID: 24893048 DOI: 10.1148/radiol.14132] [Reference Citation Analysis]
132 Bang SJ, Kim BG, Shin JW, Ju HU, Park BR, Kim MH, Kim CJ, Park JH, Jeong ID, Jung SW. Clinical course of patients with insufficient viral suppression during entecavir therapy in genotype C chronic hepatitis B. Dig Liver Dis. 2013;45:600-605. [PMID: 23333665 DOI: 10.1016/j.dld.2012.12.013] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
133 Arora A, Anand AC, Kumar A, Singh SP, Aggarwal R, Dhiman RK, Aggarwal S, Alam S, Bhaumik P, Dixit VK, Goel A, Goswami B, Kumar A, Kumar M, Madan K, Murugan N, Nagral A, Puri AS, Rao PN, Saraf N, Saraswat VA, Sehgal S, Sharma P, Shenoy KT, Wadhawan M; Members of the INASL taskforce on Hepatitis B. INASL Guidelines on Management of Hepatitis B Virus Infection in Patients receiving Chemotherapy, Biologicals, Immunosupressants, or Corticosteroids. J Clin Exp Hepatol 2018;8:403-31. [PMID: 30568345 DOI: 10.1016/j.jceh.2018.06.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
134 Spradling PR, Bulkow L, Teshale EH, Negus S, Homan C, Simons B, McMahon BJ. Prevalence and causes of elevated serum aminotransferase levels in a population-based cohort of persons with chronic hepatitis B virus infection. J Hepatol. 2014;61:785-791. [PMID: 24911461 DOI: 10.1016/j.jhep.2014.05.045] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
135 Wong GL, Chan HL, Yu Z, Chan HY, Tse CH, Wong VW. Liver fibrosis progression is uncommon in patients with inactive chronic hepatitis B: a prospective cohort study with paired transient elastography examination. J Gastroenterol Hepatol. 2013;28:1842-1848. [PMID: 23829381 DOI: 10.1111/jgh.12327] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
136 Sellier PO, Maylin S, Berçot B, Chopin D, Lopes A, Simoneau G, Evans J, Delcey V, Bénifla JL, Simon F, Bergmann JF. Prospective interventional study of tenofovir in pregnancy to prevent vertical transmission of hepatitis B in highly viremic women. Eur J Gastroenterol Hepatol 2017;29:259-63. [PMID: 27879486 DOI: 10.1097/MEG.0000000000000793] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
137 Castera L. Hepatitis B: are non-invasive markers of liver fibrosis reliable? Liver Int. 2014;34 Suppl 1:91-96. [PMID: 24373084 DOI: 10.1111/liv.12393] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
138 Cheng XD, Song LW, Fang LL, Yang L, Wu Y, Ge SX, Yuan Q, Zhang J, Xia NS, Hao XK. Comparison of three luminescent immunoassays for hepatitis B virus surface antigen quantification during the natural history of chronic hepatitis B virus infection. Clin Vaccine Immunol 2014;21:1521-7. [PMID: 25209557 DOI: 10.1128/CVI.00529-14] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
139 Yang YJ, Shim JH, Kim KM, Lim YS, Lee HC. Assessment of current criteria for primary nonresponse in chronic hepatitis B patients receiving entecavir therapy. Hepatology. 2014;59:1303-1310. [PMID: 24170683 DOI: 10.1002/hep.26910] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
140 Ko YL, Sun CS, Chung KM, Lin YM, Feng IC, Sheu MJ, Koay LB, Lin CY, Ho CH, Kuo HT. Manifestations of perihepatic lymph nodes in acute flare of chronic hepatitis B: association with HBeAg status and with HBeAg seroconversion. PLoS One. 2015;10:e0117590. [PMID: 25689069 DOI: 10.1371/journal.pone.0117590] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
141 Yurlov KI, Masalova OV, Kisteneva LB, Khlopova IN, Samokhvalov EI, Malinovskaya VV, Parfyonov VV, Shuvalov AN, Kushch AA. Human Herpesviruses Increase the Severity of Hepatitis. Biology (Basel) 2021;10:483. [PMID: 34072365 DOI: 10.3390/biology10060483] [Reference Citation Analysis]
142 Ma G, Lou B, Lv F, Zhao D, Zhang Z, Chen Y. HBcrAg and pg RNA and the therapeutic effect in HBeAg-positive patients receiving anti-viral therapy, baseline serum HBV-RNA is a powerful predictor of response. J Viral Hepat 2020;27:837-46. [PMID: 32277539 DOI: 10.1111/jvh.13299] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
143 Karajibani M, Hasanjani Roushan MR, Bayani M, Javanian M, Masrour-Roudsari J. Spontaneous relapse in patients with inactive chronic hepatitis B virus infection. Caspian J Intern Med 2018;9:393-6. [PMID: 30510655 DOI: 10.22088/cjim.9.4.393] [Reference Citation Analysis]
144 He D, Tao S, Guo S, Li M, Wu J, Huang H, Guo X, Yan G, Zhu P, Wang Y. Interaction of TLR-IFN and HLA polymorphisms on susceptibility of chronic HBV infection in Southwest Han Chinese. Liver Int 2015;35:1941-9. [PMID: 25469587 DOI: 10.1111/liv.12756] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
145 Paulsen D, Weber O, Ruebsamen-Schaeff H, Tennant BC, Menne S. AIC649 Induces a Bi-Phasic Treatment Response in the Woodchuck Model of Chronic Hepatitis B. PLoS One. 2015;10:e0144383. [PMID: 26656974 DOI: 10.1371/journal.pone.0144383] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
146 Liou IW, Nguyen MH. The Cascade of Care in Chronic Hepatitis B. Curr Hepatology Rep 2016;15:209-19. [DOI: 10.1007/s11901-016-0316-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.2] [Reference Citation Analysis]
147 Fan R, Sun J, Yuan Q, Xie Q, Bai X, Ning Q, Cheng J, Yu Y, Niu J, Shi G, Wang H, Tan D, Wan M, Chen S, Xu M, Chen X, Tang H, Sheng J, Lu F, Jia J, Zhuang H, Xia N, Hou J;  Chronic Hepatitis B Study Consortium. Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues. Gut. 2016;65:313-320. [PMID: 25586058 DOI: 10.1136/gutjnl-2014-308546] [Cited by in Crossref: 72] [Cited by in F6Publishing: 70] [Article Influence: 12.0] [Reference Citation Analysis]
148 Shi A, Zhang X, Xiao F, Zhu L, Yan W, Han M, Luo X, Chen T, Ning Q. CD56 bright natural killer cells induce HBsAg reduction via cytolysis and cccDNA decay in long-term entecavir-treated patients switching to peginterferon alfa-2a. J Viral Hepat 2018;25:1352-62. [DOI: 10.1111/jvh.12946] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
149 Kumada H, Koike K, Suyama K, Ito H, Itoh H, Sugiura W. Efficacy and safety of tenofovir disoproxil fumarate rescue therapy for chronic hepatitis B patients who failed other nucleos(t)ide analogs: Efficacy of tenofovir for drug-resistant HBV. Hepatol Res 2017;47:1032-41. [DOI: 10.1111/hepr.12842] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
150 Tsai WL, Sun WC, Cheng JS. Chronic Hepatitis B with Spontaneous Severe Acute Exacerbation. Int J Mol Sci. 2015;16:28126-28145. [PMID: 26703566 DOI: 10.3390/ijms161226087] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
151 Kalafateli M, Zisimopoulos K, Vourli G, Rigamonti C, Goulis J, Manesis E, Manolakopoulos S, Tsochatzis E, Georgiou A, Diamantopoulou G, Thomopoulos K, Gogos C, Touloumi G, Akriviadis E, Lambropoulou-karatza C, Triantos C. Prognostic Models for Survival in Patients with Stable Cirrhosis: A Multicenter Cohort Study. Dig Dis Sci 2017;62:1363-72. [DOI: 10.1007/s10620-017-4504-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
152 Lee TY, Hsu YC, Tseng HC, Yu SH, Lin JT, Wu MS, Wu CY. Association of Daily Aspirin Therapy With Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B. JAMA Intern Med 2019;179:633-40. [PMID: 30882847 DOI: 10.1001/jamainternmed.2018.8342] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 47.0] [Reference Citation Analysis]
153 Samadi Kochaksaraei G, Castillo E, Osman M, Simmonds K, Scott AN, Oshiomogho JI, Lee SS, Myers RP, Martin SR, Coffin CS. Clinical course of 161 untreated and tenofovir-treated chronic hepatitis B pregnant patients in a low hepatitis B virus endemic region. J Viral Hepat. 2016;23:15-22. [PMID: 26192022 DOI: 10.1111/jvh.12436] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 5.8] [Reference Citation Analysis]
154 Jeon HJ, Jung SW, Park NH, Yang Y, Noh JH, Ahn JS, Kim HR, Lee JH, Shin JW. Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir. Clin Mol Hepatol 2017;23:230-8. [PMID: 28669175 DOI: 10.3350/cmh.2017.0003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
155 Papatheodoridis GV. Hepatitis B virus treatment: Which patients can have treatment deferred? Clin Liver Dis (Hoboken). 2013;2:15-17. [PMID: 30992813 DOI: 10.1002/cld.160] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
156 Aljumah AA, Bin Selayem NA, Al-Howti SY, Dafallah M, AlGhamdi H, Mokhtar H, Albekairy AM, Sanai FM. Clinical and virological outcomes of entecavir therapy in patients with chronic hepatitis B: A real life experience. J Infect Chemother 2019;25:12-6. [PMID: 30366861 DOI: 10.1016/j.jiac.2018.09.014] [Reference Citation Analysis]
157 Coffin CS, Lee SS. New paradigms in hepatitis B management: only diamonds are forever. Br Med Bull 2015;116:79-91. [PMID: 26377741 DOI: 10.1093/bmb/ldv039] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
158 Rajbhandari R, Chung RT. Treatment of Hepatitis B: A Concise Review. Clin Transl Gastroenterol 2016;7:e190. [PMID: 27628420 DOI: 10.1038/ctg.2016.46] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
159 Wang X, Chi X, Wu R, Xu H, Gao X, Yu L, Liu L, Zhang M, Tan Y, Niu J, Jin Q. Serum HBV RNA correlated with intrahepatic cccDNA more strongly than other HBV markers during peg-interferon treatment. Virol J 2021;18:4. [PMID: 33407619 DOI: 10.1186/s12985-020-01471-2] [Reference Citation Analysis]
160 Law ST, Lee MK, Lee AS, Tung Y, Li KK. Comparison of clinical efficacy and renal safety of telbivudine and entecavir in chronic hepatitis B patients receiving cytotoxic chemotherapy. J Dig Dis 2016;17:325-33. [PMID: 27085094 DOI: 10.1111/1751-2980.12349] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
161 Yan T, He Y, Li Y, Wang J, Chen T, Yang Y, Liu J, Jin L, Zhang Y, Yi R, Zhao Y. With Cytometric Bead Assay, the Interleukin-10/HBV DNA Ratio Is an Early Predictor for Response to Interferon-α Treatment in Chronic Hepatitis B. Journal of Interferon & Cytokine Research 2015;35:779-84. [DOI: 10.1089/jir.2015.0004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
162 Kim JH, Kim MN, Han K, Kim SU. Clinical application of transient elastography in patients with chronic viral hepatitis receiving antiviral treatment. Liver Int 2015;35:1103-15. [DOI: 10.1111/liv.12628] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 6.1] [Reference Citation Analysis]
163 Zheng W, Zhou Z, Wong C, Pei X, Zhuang S, Li Q, Chen M, Li A, Zhang F. Evaluation of liver parenchyma stiffness in patients with liver tumours: optimal strategy for shear wave elastography. Eur Radiol 2019;29:1479-88. [DOI: 10.1007/s00330-018-5676-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
164 Li GJ, Yu YQ, Chen SL, Fan P, Shao LY, Chen JZ, Li CS, Yi B, Chen WC, Xie SY. Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment. Antimicrob Agents Chemother. 2015;59:4121-4128. [PMID: 25941216 DOI: 10.1128/AAC.00249-15] [Cited by in Crossref: 37] [Cited by in F6Publishing: 8] [Article Influence: 6.2] [Reference Citation Analysis]
165 European Association for Study of Liver. Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63:237-264. [PMID: 25911335 DOI: 10.1016/j.jhep.2015.04.006] [Cited by in Crossref: 918] [Cited by in F6Publishing: 738] [Article Influence: 153.0] [Reference Citation Analysis]
166 Sonneveld MJ, Hansen BE, Piratvisuth T, Jia JD, Zeuzem S, Gane E, Liaw YF, Xie Q, Heathcote EJ, Chan HL, Janssen HL. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology 2013;58:872-80. [PMID: 23553752 DOI: 10.1002/hep.26436] [Cited by in Crossref: 154] [Cited by in F6Publishing: 135] [Article Influence: 19.3] [Reference Citation Analysis]
167 Murdaca G, Negrini S, Magnani O, Penza E, Pellecchio M, Gulli R, Mandich P, Puppo F. Update upon efficacy and safety of etanercept for the treatment of spondyloarthritis and juvenile idiopathic arthritis. Modern Rheumatology 2018;28:417-31. [DOI: 10.1080/14397595.2017.1366006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
168 Ma X, Yang Y, Tu H, Gao J, Tan YT, Zheng JL, Bray F, Xiang YB. Risk prediction models for hepatocellular carcinoma in different populations. Chin J Cancer Res. 2016;28:150-160. [PMID: 27199512 DOI: 10.21147/j.issn.1000-9604.2016.02.02] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
169 Wong GL, Chan HL, Yu Z, Wong CK, Leung C, Ho PP, Chan CY, Chung VC, Chan ZC, Tse YK, Chim AM, Lau TK, Chan HY, Tse CH, Wong VW. Noninvasive assessments of liver fibrosis with transient elastography and Hui index predict survival in patients with chronic hepatitis B. J Gastroenterol Hepatol 2015;30:582-90. [PMID: 25252074 DOI: 10.1111/jgh.12779] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
170 Chen X, Wen H, Zhang X, Dong C, Lin H, Guo Y, Shan L, Yao S, Yang M, Le X, Liu Y. Development of a Simple Noninvasive Model to Predict Significant Fibrosis in Patients with Chronic Hepatitis B: Combination of Ultrasound Elastography, Serum Biomarkers, and Individual Characteristics. Clin Transl Gastroenterol. 2017;8:e84. [PMID: 28383564 DOI: 10.1038/ctg.2017.11] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
171 Rodríguez M, Pascasio JM, Fraga E, Fuentes J, Prieto M, Sánchez-Antolín G, Calleja JL, Molina E, García-Buey ML, Blanco MÁ, Salmerón J, Bonet ML, Pons JA, González JM, Casado MÁ, Jorquera F; TENOSIMP-B Research Group. Tenofovir vs lamivudine plus adefovir in chronic hepatitis B: TENOSIMP-B study. World J Gastroenterol 2017;23:7459-69. [PMID: 29151700 DOI: 10.3748/wjg.v23.i41.7459] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
172 Jaroszewicz J, Reiberger T, Meyer-Olson D, Mauss S, Vogel M, Ingiliz P, Payer BA, Stoll M, Manns MP, Schmidt RE, Flisiak R, Wedemeyer H, Peck-Radosavljevic M, Rockstroh J, Cornberg M. Hepatitis B surface antigen concentrations in patients with HIV/HBV co-infection. PLoS One 2012;7:e43143. [PMID: 22905219 DOI: 10.1371/journal.pone.0043143] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
173 Papatheodoridis G, Vlachogiannakos I, Cholongitas E, Wursthorn K, Thomadakis C, Touloumi G, Petersen J. Discontinuation of oral antivirals in chronic hepatitis B: A systematic review. Hepatology 2016;63:1481-92. [PMID: 27100145 DOI: 10.1002/hep.28438] [Cited by in Crossref: 133] [Cited by in F6Publishing: 117] [Article Influence: 26.6] [Reference Citation Analysis]
174 Zhang W, Zhang D, Dou X, Xie Q, Jiang J, Chen X, Ren H. Consensus on Pegylated Interferon Alpha in Treatment of Chronic Hepatitis B. J Clin Transl Hepatol 2018;6:1-10. [PMID: 29577026 DOI: 10.14218/JCTH.2017.00073] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
175 Piaserico S, Dapavo P, Conti A, Gisondi P, Russo FP. Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature. J Eur Acad Dermatol Venereol. 2017;31:1853-1859. [PMID: 28146345 DOI: 10.1111/jdv.14146] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
176 Pinter M, Trauner M, Peck-Radosavljevic M, Sieghart W. Cancer and liver cirrhosis: implications on prognosis and management. ESMO Open. 2016;1:e000042. [PMID: 27843598 DOI: 10.1136/esmoopen-2016-000042] [Cited by in Crossref: 108] [Cited by in F6Publishing: 83] [Article Influence: 21.6] [Reference Citation Analysis]
177 Liu J, Chen T, Zhao Y. Telbivudine therapy for gravidas with chronic hepatitis B infection and patients at risk of renal impairment. J Viral Hepat 2017;24 Suppl 1:6-11. [PMID: 29082653 DOI: 10.1111/jvh.12787] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
178 Mealing S, Ghement I, Hawkins N, Scott DA, Lescrauwaet B, Watt M, Thursz M, Lampertico P, Mantovani L, Morais E, Bregman B, Cucherat M. The importance of baseline viral load when assessing relative efficacy in treatment-naïve HBeAg-positive chronic hepatitis B: a systematic review and network meta-analysis. Syst Rev 2014;3:21. [PMID: 24602249 DOI: 10.1186/2046-4053-3-21] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
179 Saccà F, Pane C, De Rosa A, Matarazzo M, Brescia Morra V. Lamivudine and fingolimod co-administration in two patients with multiple sclerosis and occult hepatitis B virus infection. Neurol Sci 2017;38:501-2. [DOI: 10.1007/s10072-016-2726-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
180 Londoño MC, Lens S, Mariño Z, Bonacci M, Ariza X, Broquetas T, Pla A, Bartres C, Adriani MV, Rodríguez-Tajes S, Costa J, Carrión JA, Pérez-Del-Pulgar S, Forns X. Hepatitis B reactivation in patients with chronic hepatitis C undergoing anti-viral therapy with an interferon-free regimen. Aliment Pharmacol Ther 2017;45:1156-61. [PMID: 28206681 DOI: 10.1111/apt.13985] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 9.5] [Reference Citation Analysis]
181 Shi H, Xiao G, Liao M, Zheng L, Jie Y, Lin G, Chong Y. Inappropriate cessation of nucleos(t)ide analog associated with reduced liver transplant-free survival in patients with HBV-related acute on chronic liver failure. Biomed Pharmacother 2021;134:111118. [PMID: 33341047 DOI: 10.1016/j.biopha.2020.111118] [Reference Citation Analysis]
182 Ahn SH, Park YK, Park ES, Kim JH, Kim DH, Lim KH, Jang MS, Choe WH, Ko SY, Sung IK. The impact of the hepatitis B virus polymerase rtA181T mutation on replication and drug resistance is potentially affected by overlapping changes in surface gene. J Virol. 2014;88:6805-6818. [PMID: 24696492 DOI: 10.1128/jvi.00635-14] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
183 Cornberg M, Wong VW, Locarnini S, Brunetto M, Janssen HLA, Chan HL. The role of quantitative hepatitis B surface antigen revisited. J Hepatol. 2017;66:398-411. [PMID: 27575311 DOI: 10.1016/j.jhep.2016.08.009] [Cited by in Crossref: 157] [Cited by in F6Publishing: 135] [Article Influence: 31.4] [Reference Citation Analysis]
184 Gutiérrez García ML, Alonso Lopez S, Martín Rios MD, Sanmartin Fenollera P, Agudo Fernandez S, Fernández Rodriguez CM. Reactivación del virus de la hepatitis B en pacientes tratados con rituximab: incidencia y factores de riesgo. Gastroenterología y Hepatología 2015;38:1-6. [DOI: 10.1016/j.gastrohep.2014.05.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
185 Zhao Z, Qin Z, Zhou L, Xiang L, You J, Cao R, Wang H, Wang B, Li M. The impact of IFNL3 genotype on interferon treatment outcome in patients chronically infected with hepatitis B virus: A meta-analysis. Microb Pathog 2019;134:103598. [PMID: 31201901 DOI: 10.1016/j.micpath.2019.103598] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
186 Wong GL. Prediction of fibrosis progression in chronic viral hepatitis. Clin Mol Hepatol 2014;20:228-36. [PMID: 25320725 DOI: 10.3350/cmh.2014.20.3.228] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.1] [Reference Citation Analysis]
187 Papatheodoridis GV, Chan HL, Hansen BE, Janssen HL, Lampertico P. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. J Hepatol. 2015;62:956-967. [PMID: 25595883 DOI: 10.1016/j.jhep.2015.01.002] [Cited by in Crossref: 247] [Cited by in F6Publishing: 232] [Article Influence: 41.2] [Reference Citation Analysis]
188 Pan HY, Pan HY, Song WY, Zheng W, Tong YX, Yang DH, Dai YN, Chen MJ, Wang MS, Huang YC, Zhang JJ, Huang HJ. Long-term outcome of telbivudine versus entecavir in treating higher viral load chronic hepatitis B patients without cirrhosis. J Viral Hepat 2017;24 Suppl 1:29-35. [PMID: 29082652 DOI: 10.1111/jvh.12794] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
189 Gane EJ, Deray G, Liaw YF, Lim SG, Lai CL, Rasenack J, Wang Y, Papatheodoridis G, Di Bisceglie A, Buti M. Telbivudine improves renal function in patients with chronic hepatitis B. Gastroenterology. 2014;146:138-146.e5. [PMID: 24067879 DOI: 10.1053/j.gastro.2013.09.031] [Cited by in Crossref: 86] [Cited by in F6Publishing: 77] [Article Influence: 10.8] [Reference Citation Analysis]
190 Wang Y, Xu X, Ran M, Guo X, Zhou L, Wang X, Wang B, Zhang J. The Enlargement of Abdominal Lymph Nodes Is a Characteristic of Autoimmune Liver Disease. Mediators Inflamm 2020;2020:3631625. [PMID: 32273828 DOI: 10.1155/2020/3631625] [Reference Citation Analysis]
191 Jia JD, Hou JL, Yin YK, Tan DM, Xu D, Niu JQ, Zhou XQ, Wang YM, Zhu LM, Chen CW, He YW, Ren H, Wan MB, Wu SM, Wang QH, Wei L, Bao W, Dong Y, Trylesinski A. Two-year results of a randomized, phase III comparative trial of telbivudine versus lamivudine in Chinese patients. Hepatol Int 2014;8:72-82. [PMID: 26202408 DOI: 10.1007/s12072-013-9488-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
192 Sato A, Ishii T, Sano F, Yamada T, Takahashi H, Matsumoto N. Severe de novo Hepatitis B Recovered from Late-Onset Liver Insufficiency with Prolonged Ascites and Hypoalbuminemia due to Hepatitis B Virus Genotype Bj with Precore Mutation. Case Rep Gastroenterol 2016;10:553-9. [PMID: 27920641 DOI: 10.1159/000450543] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
193 Meng C, Belino C, Pereira L, Pinho A, Sampaio S, Tavares I, Bustorff M, Sarmento A, Pestana M. Reactivation of Hepatitis B virus in kidney transplant recipients with previous clinically resolved infection: A single-center experience. Nefrologia (Engl Ed) 2018;38:545-50. [PMID: 29709320 DOI: 10.1016/j.nefro.2018.02.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
194 Cheng X, Guan W, Sun S, Li B, Li H, Kang F, Kang J, Yang D, Nassal M, Sun D. Stable Human Hepatoma Cell Lines for Efficient Regulated Expression of Nucleoside/Nucleotide Analog Resistant and Vaccine Escape Hepatitis B Virus Variants and Woolly Monkey Hepatitis B Virus. PLoS One 2015;10:e0145746. [PMID: 26699621 DOI: 10.1371/journal.pone.0145746] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
195 Tooyama M, Tamori A, Nakano A, Hai H, Thuy le TT, Enomoto M, Kawada N. A pregnant woman with acute hepatitis B in whom vertical transmission was prevented by tenofovir disoproxil fumarate. Clin J Gastroenterol 2013;6:173-6. [PMID: 26181458 DOI: 10.1007/s12328-013-0370-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
196 Liu CJ, Chuang WL, Sheen IS, Wang HY, Chen CY, Tseng KC, Chang TT, Massetto B, Yang JC, Yun C, Knox SJ, Osinusi A, Camus G, Jiang D, Brainard DM, McHutchison JG, Hu TH, Hsu YC, Lo GH, Chu CJ, Chen JJ, Peng CY, Chien RN, Chen PJ. Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV. Gastroenterology 2018;154:989-97. [PMID: 29174546 DOI: 10.1053/j.gastro.2017.11.011] [Cited by in Crossref: 70] [Cited by in F6Publishing: 59] [Article Influence: 17.5] [Reference Citation Analysis]
197 Zoulim F, Białkowska-Warzecha J, Diculescu MM, Goldis AE, Heyne R, Mach T, Marcellin P, Petersen J, Simon K, Bendahmane S, Klauck I, Wasiak W, Janssen HL. Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure. Hepatol Int 2016;10:779-88. [PMID: 27206517 DOI: 10.1007/s12072-016-9737-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
198 Xu J, Song L, Li N, Wang S, Zeng Z, Si C, Li J, Mao Q, Zhang D, Tang H, Sheng J, Chen X, Ning Q, Shi G, Xie Q, Yuan Q, Yu Y, Xia N. Baseline hepatitis B core antibody predicts treatment response in chronic hepatitis B patients receiving long-term entecavir. J Viral Hepat 2017;24:148-54. [DOI: 10.1111/jvh.12626] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
199 Dunkelberg JC, Berkley EM, Thiel KW, Leslie KK. Hepatitis B and C in pregnancy: a review and recommendations for care. J Perinatol. 2014;34:882-891. [PMID: 25233195 DOI: 10.1038/jp.2014.167] [Cited by in Crossref: 58] [Cited by in F6Publishing: 46] [Article Influence: 8.3] [Reference Citation Analysis]
200 Polis S, Zablotska-Manos I, Zekry A, Maher L. Adherence to Hepatitis B Antiviral Therapy: A Qualitative Study. Gastroenterol Nurs 2017;40:239-46. [PMID: 28570424 DOI: 10.1097/SGA.0000000000000161] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
201 Qiu K, Liu B, Li S, Li H, Chen Z, Luo A, Peng M, Ren H, Hu P. Systematic review with meta-analysis: combination treatment of regimens based on pegylated interferon for chronic hepatitis B focusing on hepatitis B surface antigen clearance. Aliment Pharmacol Ther 2018;47:1340-8. [DOI: 10.1111/apt.14629] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 8.7] [Reference Citation Analysis]
202 Zhou B, Dong H, He Y, Sun J, Jin W, Xie Q, Fan R, Wang M, Li R, Chen Y, Xie S, Shen Y, Huang X, Wang S, Lu F, Jia J, Zhuang H, Locarnini S, Zhao GP, Jin L, Hou J. Composition and Interactions of Hepatitis B Virus Quasispecies Defined the Virological Response During Telbivudine Therapy. Sci Rep 2015;5:17123. [PMID: 26599443 DOI: 10.1038/srep17123] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
203 Crossan C, Tsochatzis EA, Longworth L, Gurusamy K, Papastergiou V, Thalassinos E, Mantzoukis K, Rodriguez-Peralvarez M, O'Brien J, Noel-Storr A, Papatheodoridis GV, Davidson B, Burroughs AK. Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis B in the UK: systematic review and economic evaluation. J Viral Hepat 2016;23:139-49. [PMID: 26444996 DOI: 10.1111/jvh.12469] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
204 Liu Z, Gao F, Shao Z, Xie H, Zhou L, Xu X, Zheng S. TFCP2 Genetic Polymorphism Is Associated with Predisposition to and Transplant Prognosis of Hepatocellular Carcinoma. Gastroenterol Res Pract 2017;2017:6353248. [PMID: 28348581 DOI: 10.1155/2017/6353248] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
205 Ye YA, Li XK, Zhou DQ, Chi XL, Li Q, Wang L, Lu BJ, Mao DW, Wu QK, Wang XB, Zhang MX, Xue JD, Li Y, Lu W, Guo JC, Jiang F, Zhang XW, Du HB, Yang XZ, Guo H, Gan DN, Li ZG. Chinese Herbal Medicine Combined with Entecavir for HBeAg Positive Chronic Hepatitis B: Study Protocol for a Multi-Center, Double-Blind Randomized-Controlled Trial. Chin J Integr Med 2018;24:653-60. [PMID: 30209792 DOI: 10.1007/s11655-018-3011-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
206 Chuaypen N, Posuwan N, Payungporn S, Tanaka Y, Shinkai N, Poovorawan Y, Tangkijvanich P. Serum hepatitis B core-related antigen as a treatment predictor of pegylated interferon in patients with HBeAg-positive chronic hepatitis B. Liver Int 2016;36:827-36. [DOI: 10.1111/liv.13046] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 6.4] [Reference Citation Analysis]
207 Fukuda W, Hanyu T, Katayama M, Mizuki S, Okada A, Miyata M, Handa Y, Hayashi M, Koyama Y, Arii K, Kitaori T, Hagiyama H, Urushidani Y, Yamasaki T, Ikeno Y, Suzuki T, Omoto A, Sugitani T, Morita S, Inokuma S. Risk stratification and clinical course of hepatitis B virus reactivation in rheumatoid arthritis patients with resolved infection: final report of a multicenter prospective observational study at Japanese Red Cross Hospital. Arthritis Res Ther 2019;21:255. [PMID: 31779676 DOI: 10.1186/s13075-019-2053-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
208 Tacke F, Kroy DC. Treatment for hepatitis B in patients with drug resistance. Ann Transl Med 2016;4:334. [PMID: 27761438 DOI: 10.21037/atm.2016.09.19] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
209 Buti M, Riveiro-Barciela M, Esteban R. Tenofovir Alafenamide Fumarate: A New Tenofovir Prodrug for the Treatment of Chronic Hepatitis B Infection. J Infect Dis. 2017;216:S792-S796. [PMID: 29156043 DOI: 10.1093/infdis/jix135] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
210 Lee J, Sinn DH, Paik SW. The Author's Response: Anti-Viral Therapy for Compensated Liver Cirrhosis Patients with Normal Alanine Aminotransferase. J Korean Med Sci 2016;31:825-6. [PMID: 27134510 DOI: 10.3346/jkms.2016.31.5.825] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
211 Lin D, Yang HI, Nguyen N, Hoang J, Kim Y, Vu V, Le A, Chaung K, Nguyen V, Trinh H, Li J, Zhang J, Hsing A, Chen CJ, Nguyen MH. Reduction of chronic hepatitis B-related hepatocellular carcinoma with anti-viral therapy, including low risk patients. Aliment Pharmacol Ther. 2016;44:846-855. [PMID: 27549411 DOI: 10.1111/apt.13774] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 6.2] [Reference Citation Analysis]
212 Lampertico P, Chan HL, Janssen HL, Strasser SI, Schindler R, Berg T. Review article: long-term safety of nucleoside and nucleotide analogues in HBV-monoinfected patients. Aliment Pharmacol Ther. 2016;44:16-34. [PMID: 27198929 DOI: 10.1111/apt.13659] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 11.4] [Reference Citation Analysis]
213 Caviglia GP, Abate ML, Noviello D, Olivero A, Rosso C, Troshina G, Ciancio A, Rizzetto M, Saracco GM, Smedile A. Hepatitis B core-related antigen kinetics in chronic hepatitis B virus genotype D-infected patients treated with nucleos(t)ide analogues or pegylated-interferon-α: HBcrAg kinetics in CHB therapy. Hepatol Res 2017;47:747-54. [DOI: 10.1111/hepr.12811] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
214 Tujios SR, Lee WM. Update in the management of chronic hepatitis B. Curr Opin Gastroenterol 2013;29:250-6. [PMID: 23519135 DOI: 10.1097/MOG.0b013e32835ff1e9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
215 Liang X, Cheng J, Sun Y, Chen X, Li T, Wang H, Jiang J, Chen X, Long H, Tang H, Yu Y, Sheng J, Chen S, Niu J, Ren H, Shi J, Dou X, Wan M, Jiang J, Xie Q, Shi G, Ning Q, Chen C, Tan D, Ma H, Sun J, Jia J, Zhuang H, Hou J. Randomized, three-arm study to optimize lamivudine efficacy in hepatitis B e antigen-positive chronic hepatitis B patients. J Gastroenterol Hepatol 2015;30:748-55. [PMID: 25352300 DOI: 10.1111/jgh.12835] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
216 Strasser SI. Managing hepatitis B to prevent liver cancer: recent advances. Expert Rev Gastroenterol Hepatol 2014;8:409-15. [PMID: 24580046 DOI: 10.1586/17474124.2014.893823] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
217 Xu Y, Nie ZW. Telbivudine and adefovir dipivoxil combination therapy improves renal function in patients with chronic hepatitis B: A STROBE-compliant article. Medicine (Baltimore) 2018;97:e13430. [PMID: 30508954 DOI: 10.1097/MD.0000000000013430] [Reference Citation Analysis]
218 Petit PR, Borentain P, Aherfi S, Gérolami R, Colson P. Hepatitis Delta recurrence post-liver transplantation in absence of detectable hepatitis B surface antigen and hepatitis B virus DNA in peripheral blood. Clinics and Research in Hepatology and Gastroenterology 2020;44:e41-4. [DOI: 10.1016/j.clinre.2019.11.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
219 Pan X, Zhang K, Yang X, Liang J, Sun H, Li X, Zou Y, Xu Q, An G, Li G. Relapse rate and associated-factor of recurrence after stopping NUCs therapy with different prolonged consolidation therapy in HBeAg positive CHB patients. PLoS One. 2013;8:e68568. [PMID: 23844222 DOI: 10.1371/journal.pone.0068568] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
220 Chen L, Cheng C, Chen B, Zhao Y, Zhang J, Wang B. Cumulative incidence and risk factors of creatine kinase elevation associated with telbivudine. Eur J Clin Pharmacol 2016;72:235-41. [PMID: 26566799 DOI: 10.1007/s00228-015-1978-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
221 Wang A, Wu S, Tao Z, Li X, Lv K, Ma C, Li Y, Li L, Liu M. Design, Synthesis, and Anti-HBV Activity of New Bis(l-amino acid) Ester Tenofovir Prodrugs. ACS Med Chem Lett 2019;10:991-5. [PMID: 31223460 DOI: 10.1021/acsmedchemlett.9b00184] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
222 Zhong JH. Nucleos(t)ide analogue therapy for HBV-related HCC after hepatic resection: clinical benefits and unanswered questions. Tumour Biol. 2014;35:12779-12784. [PMID: 25431264 DOI: 10.1007/s13277-014-2881-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
223 Stalke P, Rybicka M, Wróblewska A, Dreczewski M, Stracewska E, Smiatacz T, Bielawski KP. An initial assessment of correlations between host- and virus-related factors affecting analogues antiviral therapy in HBV chronically infected patients. Med Sci Monit 2014;20:321-8. [PMID: 24569300 DOI: 10.12659/MSM.889788] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
224 Han Q, Yang C, Li N, Li F, Sang J, Lv Y, Zhao W, Li C, Liu Z. Association of genetic variation in B-cell activating factor with chronic hepatitis B virus infection. Immunol Lett 2017;188:53-8. [PMID: 28627389 DOI: 10.1016/j.imlet.2017.06.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
225 Loustaud-Ratti V, Jacques J, Debette-Gratien M, Carrier P. Hepatitis B and elders: An underestimated issue. Hepatol Res. 2016;46:22-28. [PMID: 25651806 DOI: 10.1111/hepr.12499] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
226 Zhang C, Ke W, Gao Y, Zhou S, Liu L, Ye X, Yao Z, Yang Y. Cost-effectiveness analysis of antiviral therapies for hepatitis B e antigen-positive chronic hepatitis B patients in China. Clin Drug Investig 2015;35:197-209. [PMID: 25672930 DOI: 10.1007/s40261-015-0273-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
227 Yang C, Li N, Wang Y, Zhang P, Zhu Q, Li F, Han Q, Lv Y, Yu L, Wei P, Liu Z. Serum levels of B-cell activating factor in chronic hepatitis B virus infection: association with clinical diseases. J Interferon Cytokine Res 2014;34:787-94. [PMID: 24811691 DOI: 10.1089/jir.2014.0032] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
228 Chien RN, Kao JH, Peng CY, Chen CH, Liu CJ, Huang YH, Hu TH, Yang HI, Lu SN, Ni YH, Chuang WL, Lee CM, Wu JC, Chen PJ, Liaw YF. Taiwan consensus statement on the management of chronic hepatitis B. J Formos Med Assoc. 2019;118:7-38. [PMID: 30527436 DOI: 10.1016/j.jfma.2018.11.008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 7.7] [Reference Citation Analysis]
229 Jung KS, Kim SU, Song K, Park JY, Kim DY, Ahn SH, Kim BK, Han KH. Validation of hepatitis B virus-related hepatocellular carcinoma prediction models in the era of antiviral therapy. Hepatology. 2015;62:1757-1766. [PMID: 26249025 DOI: 10.1002/hep.28115] [Cited by in Crossref: 65] [Cited by in F6Publishing: 60] [Article Influence: 10.8] [Reference Citation Analysis]
230 Hwang JP, Lok AS. Management of patients with hepatitis B who require immunosuppressive therapy. Nat Rev Gastroenterol Hepatol 2014;11:209-19. [PMID: 24247262 DOI: 10.1038/nrgastro.2013.216] [Cited by in Crossref: 155] [Cited by in F6Publishing: 131] [Article Influence: 19.4] [Reference Citation Analysis]
231 Boglione L, De Nicolò A, Cusato J, Bonifacio G, Cariti G, Di Perri G, D'Avolio A. Entecavir plasma concentrations are inversely related to HBV-DNA decrease in a cohort of treatment-naïve patients with chronic hepatitis B. Int J Antimicrob Agents 2016;48:324-7. [PMID: 27444118 DOI: 10.1016/j.ijantimicag.2016.05.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
232 Boni C, Lampertico P, Talamona L, Giuberti T, Invernizzi F, Barili V, Fisicaro P, Rossi M, Cavallo MC, Vecchi A. Natural killer cell phenotype modulation and natural killer/T-cell interplay in nucleos(t)ide analogue-treated hepatitis e antigen-negative patients with chronic hepatitis B. Hepatology. 2015;62:1697-1709. [PMID: 26361374 DOI: 10.1002/hep.28155] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 9.0] [Reference Citation Analysis]
233 Yuan BH, Li RH, Yuan WP, Xiang BD, Zheng MH, Yang T, Zhong JH, Li LQ. Perioperative entecavir for patients with HBV-related hepatocellular carcinoma and low levels of viral DNA: analysis using propensity score matching. Oncotarget 2017;8:51810-6. [PMID: 28881690 DOI: 10.18632/oncotarget.15395] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
234 Liao B, Wang Z, Lin S, Xu Y, Yi J, Xu M, Huang Z, Zhou Y, Zhang F, Hou J. Significant fibrosis is not rare in Chinese chronic hepatitis B patients with persistent normal ALT. PLoS One 2013;8:e78672. [PMID: 24205292 DOI: 10.1371/journal.pone.0078672] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
235 Phillips S, Mistry S, Riva A, Cooksley H, Hadzhiolova-Lebeau T, Plavova S, Katzarov K, Simonova M, Zeuzem S, Woffendin C, Chen PJ, Peng CY, Chang TT, Lueth S, De Knegt R, Choi MS, Wedemeyer H, Dao M, Kim CW, Chu HC, Wind-Rotolo M, Williams R, Cooney E, Chokshi S. Peg-Interferon Lambda Treatment Induces Robust Innate and Adaptive Immunity in Chronic Hepatitis B Patients. Front Immunol 2017;8:621. [PMID: 28611778 DOI: 10.3389/fimmu.2017.00621] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
236 Luo A, Jiang X, Ren H. Entecavir-based combination therapies for chronic hepatitis B: A meta-analysis. Medicine (Baltimore) 2018;97:e13596. [PMID: 30572464 DOI: 10.1097/MD.0000000000013596] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
237 Wong GL, Chan HL, Yu Z, Chan H, Tse C, Wong VW. Liver fibrosis progression in chronic hepatitis B patients positive for hepatitis B e antigen: A prospective cohort study with paired transient elastography examination: Fibrosis progression in hepatitis B. J Gastroenterol Hepatol 2013;28:1762-9. [DOI: 10.1111/jgh.12312] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
238 Coste M, De Sèze M, Diallo A, Carrieri MP, Marcellin F, Boyer S; ANRS 12356 AmBASS Study Group. Burden and impacts of chronic hepatitis B infection in rural Senegal: study protocol of a cross-sectional survey in the area of Niakhar (AmBASS ANRS 12356). BMJ Open 2019;9:e030211. [PMID: 31320358 DOI: 10.1136/bmjopen-2019-030211] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
239 Tsukune Y, Sasaki M, Odajima T, Isoda A, Matsumoto M, Koike M, Tamura H, Moriya K, Ito S, Asahi M, Imai Y, Tanaka J, Handa H, Koiso H, Tanosaki S, Hua J, Hagihara M, Yahata Y, Suzuki S, Watanabe S, Sugimori H, Komatsu N. Incidence and clinical background of hepatitis B virus reactivation in multiple myeloma in novel agents' era. Ann Hematol 2016;95:1465-72. [PMID: 27358178 DOI: 10.1007/s00277-016-2742-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
240 Konysbekova A. Chronic viral hepatitis D - the current state of a problem. J CLIN MED KAZ 2017;1:11-4. [DOI: 10.23950/1812-2892-jcmk-00388] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
241 Flemming JA, Terrault NA. Tenofovir vs Entecavir for Hepatocellular Carcinoma Prevention in Patients With Chronic Hepatitis B: One of These Things Is Not Like the Other. JAMA Oncol 2019;5:17-8. [PMID: 30267036 DOI: 10.1001/jamaoncol.2018.4039] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
242 Volpes R, Burra P, Germani G, Manini MA, Caccamo L, Strignano P, Rizza G, Tamè M, Pinna AD, Calise F, Migliaccio C, Carrai P, De Simone P, Valentini MF, Lupo LG, Cordone G, Picciotto FP, Nicolucci A. Switch from intravenous or intramuscular to subcutaneous hepatitis B immunoglobulin: effect on quality of life after liver transplantation. Health Qual Life Outcomes 2020;18:99. [PMID: 32276633 DOI: 10.1186/s12955-020-01349-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
243 Nard FD, Todoerti M, Grosso V, Monti S, Breda S, Rossi S, Montecucco C, Caporali R. Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs. World J Hepatol 2015;7:344-61. [PMID: 25848463 DOI: 10.4254/wjh.v7.i3.344] [Cited by in Crossref: 46] [Cited by in F6Publishing: 36] [Article Influence: 7.7] [Reference Citation Analysis]
244 Qiao J, Yu J, Yang H, Wei H. PCR-based in vitro synthesis of hepatitis C virus NS3 protease for rapid phenotypic resistance testing of protease inhibitors. J Clin Microbiol 2014;52:1139-45. [PMID: 24452171 DOI: 10.1128/JCM.03257-13] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
245 Gill US, Kennedy PTF. The impact of currently licensed therapies on viral and immune responses in chronic hepatitis B: Considerations for future novel therapeutics. J Viral Hepat 2018. [DOI: 10.1111/jvh.13040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
246 Lin CC, Bair MJ, Chen CJ, Lee KH, Chen MJ, Liu CY, Chang CW, Hu KC, Liou TC, Lin SC, Wang HY, Chu CH, Shih SC, Wang TE. Off-treatment efficacy of 3-year nucleos(t)ide analogues in chronic hepatitis B patients. Kaohsiung J Med Sci 2016;32:10-5. [PMID: 26853169 DOI: 10.1016/j.kjms.2015.11.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
247 Fouquet A, Jambon AC, Canva V, Bocket-Mouton L, Gottrand F, Subtil D. [Hepatitis B and pregnancy. Part 1. Thirteen practical issues in antenatal period]. J Gynecol Obstet Biol Reprod (Paris) 2016;45:531-9. [PMID: 26964700 DOI: 10.1016/j.jgyn.2016.02.004] [Reference Citation Analysis]
248 Gatselis NK, Vakrakou AG, Zachou K, Androutsakos T, Azariadis K, Hatzis G, Manoussakis MN, Dalekos GN. Decreased serum DNase1-activity in patients with autoimmune liver diseases. Autoimmunity 2017;50:125-32. [DOI: 10.1080/08916934.2017.1279610] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
249 Howell J, Ladep NG, Nayagam S, Lemoine M, Garside DA, Crossey MME, Okeke E, Njie R, Ka MM, Taal M, Thursz MR, Taylor-Robinson SD. PROLIFICA: a story of West African clinical and research collaborations to target hepatitis B-related hepatocellular carcinoma in West Africa. QJM 2016;109:373-5. [PMID: 26106184 DOI: 10.1093/qjmed/hcv118] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
250 Falla AM, Veldhuijzen IK, Ahmad AA, Levi M, Hendrik Richardus J. Limited access to hepatitis B/C treatment among vulnerable risk populations: an expert survey in six European countries. Eur J Public Health 2017;27:302-6. [PMID: 27542982 DOI: 10.1093/eurpub/ckw100] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
251 Wong GL, Chan HL, Choi PC, Chan AW, Yu Z, Lai JW, Chan HY, Wong VW. Non-invasive algorithm of enhanced liver fibrosis and liver stiffness measurement with transient elastography for advanced liver fibrosis in chronic hepatitis B. Aliment Pharmacol Ther. 2014;39:197-208. [PMID: 24261924 DOI: 10.1111/apt.12559] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 5.5] [Reference Citation Analysis]
252 Hadziyannis SJ, Vassilopoulos D, Sevastianos V, Hadziyannis E. Can Nucleos(t)ide Analogue (NA) Therapy Ever be Stopped in HBeAg-Negative Chronic Hepatitis B? Curr Hepatology Rep 2014;13:256-63. [DOI: 10.1007/s11901-014-0236-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
253 Yao M, Wang L, Leung PSC, Li Y, Liu S, Wang L, Guo X, Zhou G, Yan Y, Guan G, Chen X, Bowlus CL, Liu T, Jia J, Gershwin ME, Ma X, Zhao J, Lu F. The Clinical Significance of GP73 in Immunologically Mediated Chronic Liver Diseases: Experimental Data and Literature Review. Clin Rev Allergy Immunol. 2018;54:282-294. [PMID: 29256057 DOI: 10.1007/s12016-017-8655-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
254 Huang YW, Chayama K, Kao JH, Yang SS. Detectability and clinical significance of serum hepatitis B virus ribonucleic acid. Hepatobiliary Surg Nutr 2015;4:197-202. [PMID: 26151059 DOI: 10.3978/j.issn.2304-3881.2014.11.08] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
255 Chang ML, Jeng WJ, Liaw YF. Clinical events after cessation of lamivudine therapy in patients recovered from hepatitis B flare with hepatic decompensation. Clin Gastroenterol Hepatol 2015;13:979-86. [PMID: 25445774 DOI: 10.1016/j.cgh.2014.10.023] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
256 Kim J, Biondi MJ, Feld JJ, Chan WC. Clinical Validation of Quantum Dot Barcode Diagnostic Technology. ACS Nano 2016;10:4742-53. [PMID: 27035744 DOI: 10.1021/acsnano.6b01254] [Cited by in Crossref: 76] [Cited by in F6Publishing: 62] [Article Influence: 15.2] [Reference Citation Analysis]
257 Cai Q, Chen K, Chen J, Wu S, Geng Q, Huang H, Lin T, Jiang W, Xia Z, Duan H, Rao H, Yao M, Hu L. The Effect of Prophylactic Lamivudine plus Adefovir Therapy Compared with Lamivudine Alone in Preventing Hepatitis B Reactivation in Lymphoma Patients with High Baseline HBV DNA during Chemotherapy. PLoS One 2016;11:e0164210. [PMID: 27711135 DOI: 10.1371/journal.pone.0164210] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
258 Truong J, Shadbolt B, Ooi M, Chitturi S, Kaye G, Farrell GC, Teoh NC. Week 4 viral load predicts long-term suppression of hepatitis B virus DNA during antiviral therapy: improving hepatitis B treatment in the real world. Intern Med J 2017;47:50-6. [PMID: 27571991 DOI: 10.1111/imj.13244] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
259 Junus K, Aguilar M, Patel P, Irwin D, Yee S, Liu B, Bhuket T, Wong RJ. Improvements in hepatitis B virus screening before rituximab therapy: A community-based, safety-net hospital experience. Cancer 2017;123:650-6. [PMID: 27696389 DOI: 10.1002/cncr.30381] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
260 Gong WF, Zhong JH, Lu SD, Wang XB, Zhang QM, Ma L, Zhang ZM, Xiang BD, Li LQ. Effects of antiviral therapy on post-hepatectomy HBV reactivation and liver function in HBV DNA-negative patients with HBV-related hepatocellular carcinoma. Oncotarget 2017;8:15047-56. [PMID: 28122361 DOI: 10.18632/oncotarget.14789] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
261 Fasano M, Maggi P, Leone A, Volpe A, Fiore JR, Angarano G, Santantonio TA. Long-term efficacy and safety of switching from lamivudine+adefovir to tenofovir disoproxil fumarate in virologically suppressed patients. Dig Liver Dis 2017;49:530-4. [PMID: 28179096 DOI: 10.1016/j.dld.2017.01.140] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
262 Tan G, Song H, Xu F, Cheng G. When Hepatitis B Virus Meets Interferons. Front Microbiol 2018;9:1611. [PMID: 30072974 DOI: 10.3389/fmicb.2018.01611] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 9.3] [Reference Citation Analysis]
263 Hu B, Wang R, Fu J, Su M, Du M, Liu Y, Li H, Wang H, Lu F, Jiang J. Integration of hepatitis B virus S gene impacts on hepatitis B surface antigen levels in patients with antiviral therapy. J Gastroenterol Hepatol 2018;33:1389-96. [PMID: 29266382 DOI: 10.1111/jgh.14075] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
264 Sauerbruch T, Trebicka J. Future therapy of portal hypertension in liver cirrhosis - a guess. F1000Prime Rep. 2014;6:95. [PMID: 25374673 DOI: 10.12703/P6-95] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 1.9] [Reference Citation Analysis]
265 Koga H, Kai K, Aishima S, Kawaguchi A, Yamaji K, Ide T, Ueda J, Noshiro H. Occult hepatitis B virus infection and surgical outcomes in non-B, non-C patients with curative resection for hepatocellular carcinoma. World J Hepatol 2017;9:1286-95. [PMID: 29290910 DOI: 10.4254/wjh.v9.i35.1286] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
266 Shouval D. Focus. Journal of Hepatology 2013;58:641-2. [DOI: 10.1016/j.jhep.2013.01.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
267 Liu J, Ren W, Ai H, Dun G, Ji Y, Zhang Y, Wan Q, Lin S. Acoustic Structure Quantification Versus Point Shear Wave Speed Measurement for the Assessment of Liver Fibrosis in Viral Hepatitis B. Ultrasound Med Biol 2018;44:1177-86. [PMID: 29609809 DOI: 10.1016/j.ultrasmedbio.2018.02.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
268 Peng CY, Chien RN, Liaw YF. Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. J Hepatol. 2012;57:442-450. [PMID: 22504333 DOI: 10.1016/j.jhep.2012.02.033] [Cited by in Crossref: 119] [Cited by in F6Publishing: 108] [Article Influence: 13.2] [Reference Citation Analysis]
269 Su T, Yang H, Tseng T, Liou J, Liu C, Chen C, Chen P, Chen D, Liu C, Kao J. Distinct Relapse Rates and Risk Predictors After Discontinuing Tenofovir and Entecavir Therapy. The Journal of Infectious Diseases 2018;217:1193-201. [DOI: 10.1093/infdis/jix690] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 11.3] [Reference Citation Analysis]
270 Marcellin P, Ahn SH, Ma X, Caruntu FA, Tak WY, Elkashab M, Chuang WL, Lim SG, Tabak F, Mehta R, Petersen J, Foster GR, Lou L, Martins EB, Dinh P, Lin L, Corsa A, Charuworn P, Subramanian GM, Reiser H, Reesink HW, Fung S, Strasser SI, Trinh H, Buti M, Gaeta GB, Hui AJ, Papatheodoridis G, Flisiak R, Chan HL; Study 149 Investigators. Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B. Gastroenterology 2016;150:134-144.e10. [PMID: 26453773 DOI: 10.1053/j.gastro.2015.09.043] [Cited by in Crossref: 190] [Cited by in F6Publishing: 161] [Article Influence: 31.7] [Reference Citation Analysis]
271 Brook G, Brockmeyer N, van de Laar T, Schellberg S, Winter AJ. 2017 European guideline for the screening, prevention and initial management of hepatitis B and C infections in sexual health settings. Int J STD AIDS 2018;29:949-67. [PMID: 29716442 DOI: 10.1177/0956462418767576] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
272 Chen J, Zhang DH, Xu CR, Zhu MY, Yang ZT, Gong QM, Yu DM, Zhang XX. Quantitative hepatitis B surface antigen combined with hepatitis B e antigen as sustained virological response predictors during extended therapy with Peginterferon alfa-2a for hepatitis B e antigen-positive chronic hepatitis B. J Clin Virol 2015;72:88-94. [PMID: 26476325 DOI: 10.1016/j.jcv.2015.09.012] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
273 Chien RN, Peng CY, Kao JH, Hu TH, Lin CC, Hu CT, Chen CY, Hsieh TY, Lin HC, Chuang WL; Taiwan NA-Registry Group. Higher adherence with 3-year entecavir treatment than lamivudine or telbivudine in treatment-naïve Taiwanese patients with chronic hepatitis B. J Gastroenterol Hepatol 2014;29:185-92. [PMID: 24354995 DOI: 10.1111/jgh.12416] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
274 He Y, Yin J, Xu H. Efficacy and Safety of Pegylated Interferon for the Treatment of Chronic Hepatitis B in Children and Adolescents: A Systematic Review and Meta-analysis. Pediatr Infect Dis J 2020;39:1121-6. [PMID: 32858647 DOI: 10.1097/INF.0000000000002876] [Reference Citation Analysis]
275 Wang J, Xia J, Zhang R, Yan X, Yang Y, Zhao X, Chang H, Wang G, Chen G, Liu Y, Chen Y, Jia B, Zhang Z, Ding W, Huang R, Wu C. A novel index using routine clinical parameters for predicting significant liver inflammation in chronic hepatitis B. J Viral Hepat 2018;25:1151-60. [PMID: 29741221 DOI: 10.1111/jvh.12925] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
276 Pivert A, Servant-Delmas A, Lunel-Fabiani F, Le Guillou-Guillemette H, Laperche S, Ducancelle A. Correlation between the promoter basal core and precore mutations and HBsAg quantification in French blood donors infected with hepatitis B virus. J Med Virol 2015;87:529-35. [PMID: 25170961 DOI: 10.1002/jmv.24064] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
277 Huang H, Rückborn M, Le-Trilling VTK, Zhu D, Yang S, Zhou W, Yang X, Feng X, Lu Y, Lu M, Dittmer U, Yang D, Trilling M, Liu J. Prophylactic and therapeutic HBV vaccination by an HBs-expressing cytomegalovirus vector lacking an interferon antagonist in mice. Eur J Immunol 2021;51:393-407. [PMID: 33029793 DOI: 10.1002/eji.202048780] [Reference Citation Analysis]
278 Lee IC, Lin CH, Huang YH, Huo TI, Su CW, Hou MC, Huang HC, Lee KC, Chan CC, Lin MW. IL28B polymorphism correlates with active hepatitis in patients with HBeAg-negative chronic hepatitis B. PLoS One. 2013;8:e58071. [PMID: 23469142 DOI: 10.1371/journal.pone.0058071] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
279 Komatsu H, Inui A, Yoshio S, Fujisawa T. Pharmacotherapy options for managing hepatitis B in children. Expert Opin Pharmacother 2021;22:449-67. [PMID: 33090882 DOI: 10.1080/14656566.2020.1841165] [Reference Citation Analysis]
280 Koukoulioti E, Brodzinski A, Mihm U, Sarrazin C, Jung M, Schott E, Fülöp B, Schlosser B, Berg T, van Bömmel F. Risk factors for resistance development against lamivudine during long-term treatment of chronic hepatitis B virus infections. European Journal of Gastroenterology & Hepatology 2019;31:845-52. [DOI: 10.1097/meg.0000000000001351] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
281 Song ZL, Cui YJ, Zheng WP, Teng DH, Zheng H. Diagnostic and therapeutic progress of multi-drug resistance with anti-HBV nucleos(t)ide analogues. World J Gastroenterol 2012;18:7149-57. [PMID: 23326119 DOI: 10.3748/wjg.v18.i48.7149] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
282 Hsu CW, Chen YC, Chang ML, Lin CC, Lin SM, Chen WT, Chu YD, Yeh CT. Durability of Telbivudine-Associated Improvement of Renal Function Following Withdrawal or Switching of Antivirals in Chronic Hepatitis B Patients. Open Forum Infect Dis 2018;5:ofx271. [PMID: 29362723 DOI: 10.1093/ofid/ofx271] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
283 Lin CL, Kao JH. Hepatitis B viral factors and treatment responses in chronic hepatitis B. J Formos Med Assoc. 2013;112:302-311. [PMID: 23787007 DOI: 10.1016/j.jfma.2013.02.001] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
284 Stättermayer AF, Ferenci P. Effect of IL28B genotype on hepatitis B and C virus infection. Curr Opin Virol 2015;14:50-5. [PMID: 26284971 DOI: 10.1016/j.coviro.2015.07.011] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
285 Huang D, Sansas B, Jiang JH, Gong QM, Jin GD, Calais V, Yu DM, Zhu MY, Wei D, Zhang DH, Inchauspé G, Zhang XX, Zhu R. Recognition of Core- and Polymerase-derived immunogenic peptides included in novel therapeutic vaccine by T cells from Chinese chronic hepatitis B patients. J Viral Hepat 2017;24 Suppl 1:66-74. [PMID: 29082648 DOI: 10.1111/jvh.12791] [Reference Citation Analysis]
286 Tsai MC, Chen CH, Tseng PL, Hung CH, Chiu KW, Wang JH, Lu SN, Lee CM, Chang KC, Yen YH, Lin MT, Chou YP, Hu TH. Comparison of renal safety and efficacy of telbivudine, entecavir and tenofovir treatment in chronic hepatitis B patients: real world experience. Clin Microbiol Infect 2016; 22: 95.e1-95. e7. [PMID: 26055419 DOI: 10.1016/j.cmi.2015.05.035] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 5.5] [Reference Citation Analysis]
287 Hulstaert F, Schwierz C, Nevens F, Thiry N, Gamil M, Colle I, Van de Sande S, Horsmans Y. SHOULD CHRONIC HEPATITIS B BE TREATED AS EARLY AS POSSIBLE? Int J Technol Assess Health Care 2013;29:35-41. [DOI: 10.1017/s0266462312000736] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
288 Mu D, Yan L, Tang H, Liao Y. A sensitive and accurate quantification method for the detection of hepatitis B virus covalently closed circular DNA by the application of a droplet digital polymerase chain reaction amplification system. Biotechnol Lett 2015;37:2063-73. [DOI: 10.1007/s10529-015-1890-5] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 6.0] [Reference Citation Analysis]
289 Mo YQ, Liang AQ, Ma JD, Chen LF, Zheng DH, Schumacher HR, Dai L. Discontinuation of antiviral prophylaxis correlates with high prevalence of hepatitis B virus (HBV) reactivation in rheumatoid arthritis patients with HBV carrier state: a real-world clinical practice. BMC Musculoskelet Disord. 2014;15:449. [PMID: 25532827 DOI: 10.1186/1471-2474-15-449] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
290 Toy M. Cost-effectiveness of viral hepatitis B & C treatment. Best Pract Res Clin Gastroenterol 2013;27:973-85. [PMID: 24182615 DOI: 10.1016/j.bpg.2013.08.020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
291 Xi ZF, Xia Q. Recent advances in prevention of hepatitis B recurrence after liver transplantation. World J Gastroenterol 2015;21:829-35. [PMID: 25624716 DOI: 10.3748/wjg.v21.i3.829] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
292 Wong GL, Wen WH, Pan CQ. Hepatitis B-management of acute infection and active inflammation in pregnancy-a hepatologist's perspective. Best Pract Res Clin Obstet Gynaecol 2020;68:54-65. [PMID: 32340799 DOI: 10.1016/j.bpobgyn.2020.03.014] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
293 Kim V, Abreu RM, Nakagawa DM, Baldassare RM, Carrilho FJ, Ono SK. Pegylated interferon alfa for chronic hepatitis B: systematic review and meta-analysis. J Viral Hepat. 2016;23:154-169. [PMID: 25967226 DOI: 10.1111/jvh.12418] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
294 Joshita S, Ichikawa Y, Umemura T, Usami Y, Sugiura A, Shibata S, Yamazaki T, Fujimori N, Komatsu M, Matsumoto A, Igarashi K, Ota M, Tanaka E. Serum autotaxin is a useful liver fibrosis marker in patients with chronic hepatitis B virus infection. Hepatol Res 2018;48:275-85. [PMID: 29114991 DOI: 10.1111/hepr.12997] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
295 Chen G, Wang C, Lau G. Treatment of chronic hepatitis B infection-2017. Liver Int 2017;37:59-66. [DOI: 10.1111/liv.13309] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
296 Chong CC, Wong GL, Lai PB. Impact of antiviral therapy on post-hepatectomy outcome for hepatitis B-related hepatocellular carcinoma. World J Gastroenterol 2014;20:6006-12. [PMID: 24876723 DOI: 10.3748/wjg.v20.i20.6006] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
297 Broquetas T, Garcia-Retortillo M, Micó M, Canillas L, Puigvehí M, Cañete N, Coll S, Viu A, Hernandez JJ, Bessa X, Carrión JA. Hepatitis B surface antigen and hepatitis B core-related antigen kinetics after adding pegylated-interferon to nucleos(t)ids analogues in hepatitis B e antigen-negative patients. World J Hepatol 2020;12:1076-88. [PMID: 33312431 DOI: 10.4254/wjh.v12.i11.1076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
298 Hofstraat SHI, Falla AM, Duffell EF, Hahné SJM, Amato-Gauci AJ, Veldhuijzen IK, Tavoschi L. Current prevalence of chronic hepatitis B and C virus infection in the general population, blood donors and pregnant women in the EU/EEA: a systematic review. Epidemiol Infect 2017;145:2873-85. [PMID: 28891457 DOI: 10.1017/S0950268817001947] [Cited by in Crossref: 50] [Cited by in F6Publishing: 30] [Article Influence: 12.5] [Reference Citation Analysis]
299 Bota S, Paternostro R, Etschmaier A, Schwarzer R, Salzl P, Mandorfer M, Kienbacher C, Ferlitsch M, Reiberger T, Trauner M, Peck-Radosavljevic M, Ferlitsch A. Performance of 2-D shear wave elastography in liver fibrosis assessment compared with serologic tests and transient elastography in clinical routine. Ultrasound Med Biol. 2015;41:2340-2349. [PMID: 26004669 DOI: 10.1016/j.ultrasmedbio.2015.04.013] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
300 Cho EJ, Lee JH, Cho Y, Lee YB, Yoo JJ, Lee M, Lee DH, Yu SJ, Kim YJ, Yoon JH, Lee HS. Comparison of the Efficacy of Entecavir and Tenofovir in Nucleos(T)ide Analogue-Experienced Chronic Hepatitis B Patients. PLoS One 2015;10:e0130392. [PMID: 26121361 DOI: 10.1371/journal.pone.0130392] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
301 Jiang JN, Huang ZL, He LX, Huang YH, Su MH, Xie R, Liang YX, Fu WD, Huang XH, Guo WW. Residual amount of HBV DNA in serum is related to relapse in chronic hepatitis B patients after cessation of nucleos(t)ide analogs. J Clin Gastroenterol. 2015;49:323-328. [PMID: 25014234 DOI: 10.1097/mcg.0000000000000170] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
302 Huang KW, Tam KW, Luo JC, Kuan YC. Efficacy and Safety of Lamivudine Versus Entecavir for Treating Chronic Hepatitis B Virus-related Acute Exacerbation and Acute-on-Chronic Liver Failure: A Systematic Review and Meta-Analysis. J Clin Gastroenterol 2017;51:539-47. [PMID: 28067752 DOI: 10.1097/MCG.0000000000000675] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
303 Fragkou PC, Moschopoulos CD, Karofylakis E, Kelesidis T, Tsiodras S. Update in Viral Infections in the Intensive Care Unit. Front Med (Lausanne) 2021;8:575580. [PMID: 33708775 DOI: 10.3389/fmed.2021.575580] [Reference Citation Analysis]
304 Cao WH, Li MH, Pan CQ, Lu Y, Zhang L, Ran CP, Wu SL, Hua WH, Liu SA, Shen G, Chang M, Liu RY, Hao HX, Hu LP, Xie Y. Quantitation of Plasmacytoid Dendritic Cells in Chronic Hepatitis B Patients with HBeAg Positivity During PEG-IFN and Entecavir Therapy. J Interferon Cytokine Res 2018;38:197-205. [PMID: 29791282 DOI: 10.1089/jir.2018.0014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
305 Marcuccilli F, Chevaliez S, Muller T, Colagrossi L, Abbondanza G, Beyser K, Wlassow M, Ortonne V, Perno CF, Ciotti M. Multicenter Evaluation of the Cepheid Xpert® HBV Viral Load Test. Diagnostics (Basel) 2021;11:297. [PMID: 33673365 DOI: 10.3390/diagnostics11020297] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
306 Fouad R, Musa S, Sabry D, Salama A, Alem SA, Atef M, Zayed N. Analysis of clinical and virologic features in Hepatitis B e Antigen (HbeAg)-negative and HbeAg-positive Egyptian chronic hepatitis B patients. Afr Health Sci 2020;20:649-55. [PMID: 33163026 DOI: 10.4314/ahs.v20i2.13] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
307 Singh MP, Galhotra S, Saigal K, Kumar A, Ratho RK. Quantitative nucleic acid amplification methods and their implications in clinical virology. Int J Appl Basic Med Res 2017;7:3-9. [PMID: 28251100 DOI: 10.4103/2229-516X.198498] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
308 Maylin S, Boyd A, Martinot-peignoux M, Delaugerre C, Bagnard G, Lapalus M, Zoulim F, Lavocat F, Marcellin P, Simon F, Girard P, Lacombe K. Quantification of hepatitis B e antigen between Elecsys HBeAg and Architect HBeAg assays among patients infected with hepatitis B virus. Journal of Clinical Virology 2013;56:306-11. [DOI: 10.1016/j.jcv.2012.12.022] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
309 Li W, Jia L, Zhao X, Wu X, Tang H. Efficacy and safety of tenofovir in preventing mother-to-infant transmission of hepatitis B virus: a meta-analysis based on 6 studies from China and 3 studies from other countries. BMC Gastroenterol 2018;18:121. [PMID: 30071845 DOI: 10.1186/s12876-018-0847-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 4.3] [Reference Citation Analysis]
310 Maklad S, Reyad EM, William EA, Abouzeid A. Efficacy and Safety of Entecavir 0. 5 mg in Treating Naive Chronic Hepatitis B Virus Patients in Egypt: Five Years of Real Life Experience. Gastroenterology Res 2018;11:138-44. [PMID: 29707081 DOI: 10.14740/gr965w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
311 Bang KB, Kim HJ. Management of antiviral drug resistance in chronic hepatitis B. World J Gastroenterol. 2014;20:11641-11649. [PMID: 25206270 DOI: 10.3748/wjg.v20.i33.11641] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
312 Kwon JH, Jang JW, Choi JY, Park CH, Yoo SH, Bae SH, Yoon SK. Should lamivudine monotherapy be stopped or continued in patients infected with hepatitis B with favorable responses after more than 5 years of treatment? J Med Virol. 2013;85:34-42. [PMID: 23154874 DOI: 10.1002/jmv.23421] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
313 Boursier J, de Ledinghen V, Poynard T, Guéchot J, Carrat F, Leroy V, Wong GL, Friedrich-Rust M, Fraquelli M, Plebani M, Sebastiani G, Myers R, Angulo P, Bertrais S, Wendum D, Bricault I, Calès P; ARDENT group., AFEF. An extension of STARD statements for reporting diagnostic accuracy studies on liver fibrosis tests: the Liver-FibroSTARD standards. J Hepatol 2015;62:807-15. [PMID: 25450206 DOI: 10.1016/j.jhep.2014.10.042] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 5.6] [Reference Citation Analysis]
314 Zeng DW, Zhang JM, Liu YR, Dong J, Jiang JJ, Zhu YY. A Retrospective Study on the Significance of Liver Biopsy and Hepatitis B Surface Antigen in Chronic Hepatitis B Infection. Medicine (Baltimore). 2016;95:e2503. [PMID: 26937895 DOI: 10.1097/md.0000000000002503] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
315 Heidrich B, Yurdaydın C, Kabaçam G, Ratsch BA, Zachou K, Bremer B, Dalekos GN, Erhardt A, Tabak F, Yalcin K, Gürel S, Zeuzem S, Cornberg M, Bock CT, Manns MP, Wedemeyer H; HIDIT-1 Study Group. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. Hepatology 2014;60:87-97. [PMID: 24585488 DOI: 10.1002/hep.27102] [Cited by in Crossref: 149] [Cited by in F6Publishing: 116] [Article Influence: 21.3] [Reference Citation Analysis]
316 Zheng YX, Ma SJ, Lu MH. Diagnostic Estimation of Noninvasive Tests for Hepatic Fibrosis in Chronic Hepatitis B Patients Without a Gold Standard. Hepat Mon 2016;16:e31983. [PMID: 27148383 DOI: 10.5812/hepatmon.31983] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
317 Huang YH, Hsiao LT, Hong YC, Chiou TJ, Yu YB, Gau JP, Liu CY, Yang MH, Tzeng CH, Lee PC, Lin HC, Lee SD. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol. 2013;31:2765-2772. [PMID: 23775967 DOI: 10.1200/jco.2012.48.5938] [Cited by in Crossref: 221] [Cited by in F6Publishing: 83] [Article Influence: 27.6] [Reference Citation Analysis]
318 Enomoto M, Tamori A, Nishiguchi S, Kawada N. Combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B: simultaneous or sequential. J Gastroenterol. 2013;48:999-1005. [PMID: 23338486 DOI: 10.1007/s00535-012-0742-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
319 Shi H, Han Z, Liu J, Xue J, Zhang S, Zhu Z, Xia J, Huang M. Comparing Efficacy of Lamivudine, Adefovir Dipivoxil, Telbivudine, and Entecavir in Treating Nucleoside Analogues Naïve for HBeAg-Negative Hepatitis B with Medium Hepatitis B Virus (HBV) DNA Levels. Med Sci Monit 2017;23:5230-6. [PMID: 29095799 DOI: 10.12659/msm.903382] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
320 Hadziyannis SJ. Update on Hepatitis B Virus Infection: Focus on Treatment. J Clin Transl Hepatol 2014;2:285-91. [PMID: 26355326 DOI: 10.14218/JCTH.2014.00026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
321 Lampertico P. Oral antiviral therapy for hepatitis B: the case of besifovir, a new kid on the block with a long way to go. Gut 2014;63:869-70. [DOI: 10.1136/gutjnl-2013-305859] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
322 Broquetas T, Garcia-Retortillo M, Hernandez JJ, Puigvehí M, Cañete N, Coll S, Cabrero B, Giménez MD, Solà R, Carrión JA. Quantification of HBsAg to predict low levels and seroclearance in HBeAg-negative patients receiving nucleos(t)ide analogues. PLoS One 2017;12:e0188303. [PMID: 29190670 DOI: 10.1371/journal.pone.0188303] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
323 Thilakanathan C, Wark G, Maley M, Davison S, Lawler J, Lee A, Shackel N, Nguyen V, Jackson K, Glass A, Locarnini SA, Levy MT. Mother-to-child transmission of hepatitis B: Examining viral cut-offs, maternal HBsAg serology and infant testing. Liver Int 2018;38:1212-9. [PMID: 29532580 DOI: 10.1111/liv.13736] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
324 Houssou B, Massi RM, Camara M, Mifdal H, Nourichafi N, Zafad S, Oukkache B. [Reactivation of hepatitis B virus in a patient treated for non-Hodgkin B diffuse large cell lymphoma with rituximab: about a case]. Pan Afr Med J 2015;22:22. [PMID: 26664523 DOI: 10.11604/pamj.2015.22.22.7579] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
325 Cai SH, Lv FF, Zhang YH, Jiang YG, Peng J. Dynamic comparison between Daan real-time PCR and Cobas TaqMan for quantification of HBV DNA levels in patients with CHB. BMC Infect Dis. 2014;14:85. [PMID: 24528480 DOI: 10.1186/1471-2334-14-85] [Cited by in Crossref: 28] [Cited by in F6Publishing: 37] [Article Influence: 4.0] [Reference Citation Analysis]
326 Etzion O, Ghany MG. Screening for hepatitis B virus to prevent viral reactivation - who and when? Clinical Liver Disease. 2015;5:47-50. [PMID: 31040948 DOI: 10.1002/cld.458] [Cited by in Crossref: 4] [Article Influence: 0.7] [Reference Citation Analysis]
327 Mena Á, Pedreira JD, Castro Á, López S, Vázquez P, Poveda E. Metabolic syndrome association with fibrosis development in chronic hepatitis B virus inactive carriers. J Gastroenterol Hepatol. 2014;29:173-178. [PMID: 24219115 DOI: 10.1111/jgh.12432] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
328 Sobhonslidsuk A, Numthavaj P, Wanichanuwat J, Sophonsritsuk A, Petraksa S, Pugasub A, Jittorntam P, Kongsomgan A, Roytrakul S, Phakdeekitcharoen B. Reversal of Proximal Renal Tubular Dysfunction after Nucleotide Analogue Withdrawal in Chronic Hepatitis B. Biomed Res Int. 2017;2017:4327385. [PMID: 29214169 DOI: 10.1155/2017/4327385] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
329 Carey I, Bruce M, Horner M, Zen Y, D'Antiga L, Bansal S, Vergani D, Mieli-Vergani G. HBsAg plasma level kinetics: a new role for an old marker as a therapy response predictor in vertically infected children on combination therapy. J Viral Hepat 2015;22:441-52. [PMID: 25278170 DOI: 10.1111/jvh.12316] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
330 Ma G, Lou B, Lv F, Zhao D, Chen H, Ye X, Chen Y. HBcrAg, pg RNA and HBsAg dynamically supervise the seroconversion of HBsAg with anti-viral therapy: "Loss of HBsAg" maybe not a good end-point of anti-viral therapy. Clin Chim Acta 2020;501:264-9. [PMID: 31730814 DOI: 10.1016/j.cca.2019.10.049] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
331 Orkin C, Flanagan S, Wallis E, Ireland G, Dhairyawan R, Fox J, Nandwani R, O'Connell R, Lascar M, Bulman J, Reeves I, Palfreeman A, Foster GR, Ahmad K, Anderson J, Tong CY, Lattimore S. Incorporating HIV/hepatitis B virus/hepatitis C virus combined testing into routine blood tests in nine UK Emergency Departments: the "Going Viral" campaign. HIV Med 2016;17:222-30. [PMID: 26919291 DOI: 10.1111/hiv.12364] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 5.4] [Reference Citation Analysis]
332 Bahardoust M, Mokhtare M, Barati M, Bagheri-Hosseinabadi Z, Karimi Behnagh A, Keyvani H, Agah S. A randomized controlled trial of pegylated interferon-alpha with tenofovir disoproxil fumarate for hepatitis B e antigen-negative chronic hepatitis B: A 48-week follow-up study. J Infect Chemother 2020;26:1265-71. [PMID: 32762882 DOI: 10.1016/j.jiac.2020.07.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
333 Lim Y, Lee YS, Gwak G, Byun KS, Kim YJ, Choi J, An J, Lee HC, Yoo BC, Kwon SY. Monotherapy with tenofovir disoproxil fumarate for multiple drug-resistant chronic hepatitis B: 3-year trial. Hepatology 2017;66:772-83. [DOI: 10.1002/hep.29187] [Cited by in Crossref: 31] [Cited by in F6Publishing: 20] [Article Influence: 7.8] [Reference Citation Analysis]
334 White HA, Wiselka MJ, Wilson DJ. Antenatal hepatitis B in a large teaching NHS Trust - implications for future care. J Infect 2015;70:72-7. [PMID: 25135227 DOI: 10.1016/j.jinf.2014.07.028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
335 Yüksel E, Akbal E, Koçak E, Akyürek Ö, Köklü S, Ekiz F, Yılmaz B. The relationship between visfatin, liver inflammation, and acute phase reactants in chronic viral hepatitis B. Wien Klin Wochenschr 2016;128:658-62. [PMID: 25854905 DOI: 10.1007/s00508-015-0723-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
336 Shirvani-Dastgerdi E, Winer BY, Celià-Terrassa T, Kang Y, Tabernero D, Yagmur E, Rodríguez-Frías F, Gregori J, Luedde T, Trautwein C, Ploss A, Tacke F. Selection of the highly replicative and partially multidrug resistant rtS78T HBV polymerase mutation during TDF-ETV combination therapy. J Hepatol 2017;67:246-54. [PMID: 28392234 DOI: 10.1016/j.jhep.2017.03.027] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 9.3] [Reference Citation Analysis]
337 Banerjee P, Chakraborty A, Mondal RK, Khatun M, Datta S, Das K, Pandit P, Mukherjee S, Banerjee S, Ghosh S, Chakrabarti S, Chowdhury A, Datta S. HBV quasispecies composition in Lamivudine-failed chronic hepatitis B patients and its influence on virological response to Tenofovir-based rescue therapy. Sci Rep 2017;7:44742. [PMID: 28303969 DOI: 10.1038/srep44742] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
338 Lou C, Bai T, Bi LW, Gao YT, Du Z. Negative impact of hepatitis B surface seroclearance on prognosis of hepatitis B-related primary liver cancer. World J Clin Cases 2018;6:192-9. [PMID: 30148147 DOI: 10.12998/wjcc.v6.i8.192] [Reference Citation Analysis]
339 Mekky MA, Nasr AM, Saleh MA, Wasif NK, Khalaf M, Aboalam H, Haredy M. Virologic and histologic characterisation of dual hepatitis B and C co-infection in Egyptian patients. Arab J Gastroenterol 2013;14:143-7. [PMID: 24433642 DOI: 10.1016/j.ajg.2013.11.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
340 Pittman C, Plitt S, Birse T, Doucette K, Romanowski B, Cooper R, Houston S, Shafran S, Singh AE. Prevalence and correlates of HIV and hepatitis B virus coinfection in Northern Alberta. Can J Infect Dis Med Microbiol 2014;25:e8-e13. [PMID: 24634693 DOI: 10.1155/2014/971546] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
341 An P, Xu J, Yu Y, Winkler CA. Host and Viral Genetic Variation in HBV-Related Hepatocellular Carcinoma. Front Genet 2018;9:261. [PMID: 30073017 DOI: 10.3389/fgene.2018.00261] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 15.0] [Reference Citation Analysis]
342 Pattullo V. Prevention of Hepatitis B reactivation in the setting of immunosuppression. Clin Mol Hepatol. 2016;22:219-237. [PMID: 27291888 DOI: 10.3350/cmh.2016.0024] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 11.2] [Reference Citation Analysis]
343 Fujii H, Yamaguchi S, Kurai O, Miyano M, Ueda W, Oba H, Aoki T, Enomoto M, Kawada N, Okawa K. Putting "sticky notes" on the electronic medical record to promote intra-hospital referral of hepatitis B and C virus-positive patients to hepatology specialists: an exploratory study. BMC Infect Dis 2016;16:410. [PMID: 27519695 DOI: 10.1186/s12879-016-1765-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
344 Luedde T, Kaplowitz N, Schwabe RF. Cell death and cell death responses in liver disease: mechanisms and clinical relevance. Gastroenterology. 2014;147:765-783.e4. [PMID: 25046161 DOI: 10.1053/j.gastro.2014.07.018] [Cited by in Crossref: 365] [Cited by in F6Publishing: 332] [Article Influence: 52.1] [Reference Citation Analysis]
345 Stelma F, de Niet A, Tempelmans Plat-Sinnige MJ, Jansen L, Takkenberg RB, Reesink HW, Kootstra NA, van Leeuwen EM. Natural Killer Cell Characteristics in Patients With Chronic Hepatitis B Virus (HBV) Infection Are Associated With HBV Surface Antigen Clearance After Combination Treatment With Pegylated Interferon Alfa-2a and Adefovir. J Infect Dis. 2015;212:1042-1051. [PMID: 25791117 DOI: 10.1093/infdis/jiv180] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 5.7] [Reference Citation Analysis]
346 Stelma F, van der Ree MH, Jansen L, Peters MW, Janssen HLA, Zaaijer HL, Takkenberg RB, Reesink HW. HBsAg loss after peginterferon-nucleotide combination treatment in chronic hepatitis B patients: 5 years of follow-up. J Viral Hepat 2017;24:1107-13. [PMID: 28632898 DOI: 10.1111/jvh.12738] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
347 Lee CH, Kim IH, Moon JC, Seo SY, Kim SH, Kim SW, Lee SO, Lee ST, Kim DG, Yang JD, Yu HC. 3-Dimensional liver volume assessment in patients with hepatitis B virus-related liver cirrhosis during long-term oral nucleos(t)ide analogues therapy. World J Gastroenterol 2017;23:297-305. [PMID: 28127203 DOI: 10.3748/wjg.v23.i2.297] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
348 Sperl J, Frankova S, Spicak J, Viklicky O. Further evidence of the benefits associated with antiviral treatment in kidney allograft recipients with chronic hepatitis B virus infection. J Hepatol. 2013;58:833-835. [PMID: 23207145 DOI: 10.1016/j.jhep.2012.11.032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
349 Wu D, Ning Q. Toward a Cure for Hepatitis B Virus Infection: Combination Therapy Involving Viral Suppression and Immune Modulation and Long-term Outcome. J Infect Dis. 2017;216:S771-S777. [PMID: 29156046 DOI: 10.1093/infdis/jix355] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
350 Lee J, Park JY, Huh KH, Kim BS, Kim MS, Kim SI, Ahn SH, Kim YS. Rituximab and hepatitis B reactivation in HBsAg-negative/ anti-HBc-positive kidney transplant recipients. Nephrol Dial Transplant. 2017;32:722-729. [PMID: 28339910 DOI: 10.1093/ndt/gfw455] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
351 Cao J, Chi H, Yu T, Li Z, Hansen BE, Zhang X, Zhong C, Sun J, Hou J, Janssen HLA. Off-Treatment Hepatitis B Virus (HBV) DNA Levels and the Prediction of Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy in Patients With Chronic Hepatitis B: A Prospective Stop Study. J Infect Dis. 2017;215:581-589. [PMID: 28329347 DOI: 10.1093/infdis/jix025] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 8.5] [Reference Citation Analysis]
352 Fang X, Wu X, Li C, Zhou B, Chen X, Chen T, Yang F. Targeting selenium nanoparticles combined with baicalin to treat HBV-infected liver cancer. RSC Adv 2017;7:8178-85. [DOI: 10.1039/c6ra28229f] [Cited by in Crossref: 17] [Article Influence: 4.3] [Reference Citation Analysis]
353 Komatsu H, Inui A, Fujisawa T. Pediatric hepatitis B treatment. Ann Transl Med 2017;5:37. [PMID: 28251116 DOI: 10.21037/atm.2016.11.52] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
354 Caviglia GP, Abate ML, Petrini E, Gaia S, Rizzetto M, Smedile A. Highly sensitive alpha-fetoprotein, Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxyprothrombin for hepatocellular carcinoma detection: Highly sensitive HCC biomarkers. Hepatol Res 2016;46:E130-5. [DOI: 10.1111/hepr.12544] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
355 Lembo T, Saffioti F, Chiofalo B, Granese R, Filomia R, Grasso R, Triolo O, Raimondo G. Low prevalence of hepatitis B and hepatitis C virus serum markers in a cohort of pregnant women from Southern Italy. Dig Liver Dis. 2017;49:1368-1372. [PMID: 28818677 DOI: 10.1016/j.dld.2017.07.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
356 Mondelli MU, Oliviero B, Mele D, Mantovani S, Gazzabin C, Varchetta S. Natural killer cell functional dichotomy: a feature of chronic viral hepatitis? Front Immunol 2012;3:351. [PMID: 23420385 DOI: 10.3389/fimmu.2012.00351] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
357 Baltayiannis G, Karayiannis P. Treatment options beyond IFNα and NUCs for chronic HBV infection: expectations for tomorrow. J Viral Hepat 2014;21:753-61. [PMID: 25271858 DOI: 10.1111/jvh.12307] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
358 Segeral O, Dim B, Durier C, Prak S, Chhim K, Vong C, Pech S, Tiv S, Nem B, Hout K, Nouhin J, Chhun S, Borand L. Hepatitis B e Antigen (HBeAg) Rapid Test and Alanine Aminotransferase Level-Based Algorithm to Identify Pregnant Women at Risk of HBV Mother-to-Child Transmission: The ANRS 12345 TA PROHM Study. Clin Infect Dis 2020;71:e587-93. [PMID: 32188982 DOI: 10.1093/cid/ciaa282] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
359 Loglio A, Iavarone M, Viganò M, Orenti A, Facchetti F, Cortinovis I, Lunghi G, Ceriotti F, Occhipinti V, Rumi M, Sangiovanni A, Colombo M, Lampertico P. Minimal increases of serum alpha‐foetoprotein herald HCC detection in Caucasian HBV cirrhotic patients under long‐term oral therapy. Liver Int 2019;39:1964-74. [DOI: 10.1111/liv.14197] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
360 Wong GL, Chan HL, Chan HY, Tse CH, Chim AM, Lo AO, Wong VW. Serum interferon-inducible protein 10 levels predict hepatitis B s antigen seroclearance in patients with chronic hepatitis B. Aliment Pharmacol Ther 2016;43:145-53. [PMID: 26526395 DOI: 10.1111/apt.13447] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
361 Enomoto M, Morikawa H, Tamori A, Kawada N. Noninvasive assessment of liver fibrosis in patients with chronic hepatitis B. World J Gastroenterol. 2014;20:12031-12038. [PMID: 25232240 DOI: 10.3748/wjg.v20.i34.12031] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
362 Lai GM, Yan SL, Chang CS, Tsai CY. Hepatitis B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor. World J Gastroenterol. 2013;19:1318-1321. [PMID: 23483799 DOI: 10.3748/wjg.v19.i8.1318] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 48] [Article Influence: 6.1] [Reference Citation Analysis]
363 Bao S, Zheng J, Li N, Huang C, Chen M, Cheng Q, Li Q, Lu Q, Zhu M, Ling Q, Yu K, Chen S, Shi G. Role of interleukin-23 in monocyte-derived dendritic cells of HBV-related acute-on-chronic liver failure and its correlation with the severity of liver damage. Clin Res Hepatol Gastroenterol. 2017;41:147-155. [PMID: 28041935 DOI: 10.1016/j.clinre.2016.10.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
364 Pipili CL, Papatheodoridis GV, Cholongitas EC. Treatment of hepatitis B in patients with chronic kidney disease. Kidney Int. 2013;84:880-885. [PMID: 23783238 DOI: 10.1038/ki.2013.249] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
365 Li MR, Xi HL, Wang QH, Hou FQ, Huo N, Zhang XX, Li F, Xu XY. Kinetics and prediction of HBsAg loss during long-term therapy with nucleos(t)ide analogues of different potency in patients with chronic hepatitis B. PLoS One. 2014;9:e98476. [PMID: 24905586 DOI: 10.1371/journal.pone.0098476] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
366 Grossi O, Généreau T. Corticoïdes et… infections, dopage, chirurgie et sexualité. La Revue de Médecine Interne 2013;34:269-78. [DOI: 10.1016/j.revmed.2012.12.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
367 Masaki N, Shrestha PK, Nishimura S, Ito K, Sugiyama M, Mizokami M. Use of nucleoside analogs in patients with chronic hepatitis B in Nepal: A prospective cohort study in a single hospital. Hepatol Res 2015;45:1163-9. [PMID: 25581418 DOI: 10.1111/hepr.12482] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
368 Tong Y, Liu B, Liu H, Zheng H, Gu J, Liu H, Lin M, Ding Y, Song C, Li Y. New universal primers for genotyping and resistance detection of low HBV DNA levels. Medicine (Baltimore) 2016;95:e4618. [PMID: 27537600 DOI: 10.1097/MD.0000000000004618] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
369 Braun-Moscovici Y, Braun M, Saadi T, Markovits D, Nahir MA, Balbir-Gurman A. Safety of Corticosteroid Treatment in Rheumatologic Patients With Markers of Hepatitis B Viral Infection: Pilot Evaluation Study. J Clin Rheumatol 2016;22:364-8. [PMID: 27660934 DOI: 10.1097/RHU.0000000000000434] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
370 Song BC. Switch to tenofovir-based therapy or to continue adefovir-based therapy in CHB patients with suboptimal response to adefovir-based combination? Clin Mol Hepatol 2016;22:439-42. [PMID: 28081595 DOI: 10.3350/cmh.2016.0108] [Reference Citation Analysis]
371 Wang FY, Li B, Li Y, Liu H, Qu WD, Xu HW, Qi JN, Qin CY. Entecavir for Patients with Hepatitis B Decompensated Cirrhosis in China: a meta-analysis. Sci Rep. 2016;6:32722. [PMID: 27601086 DOI: 10.1038/srep32722] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
372 Etzion O, Novack V, Perl Y, Abel O, Schwartz D, Munteanu D, Abufreha N, Ben-Yaakov G, Maoz ED, Moshaklo A, Dizingf V, Fich A. Sci-B-VacTM Vs ENGERIX-B Vaccines for Hepatitis B Virus in Patients with Inflammatory Bowel Diseases: A Randomised Controlled Trial. J Crohns Colitis. 2016;10:905-912. [PMID: 26928962 DOI: 10.1093/ecco-jcc/jjw046] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
373 Hui VW, Yip TC, Wong VW, Tse YK, Chan HL, Lui GC, Wong GL. Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog. Clin Transl Gastroenterol 2021;12:e00324. [PMID: 33750746 DOI: 10.14309/ctg.0000000000000324] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
374 Wu I, Hu T, Hung C, Lu S, Wang J, Lee C, Chen C. Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective cohort study. Clinical Microbiology and Infection 2017;23:464-9. [DOI: 10.1016/j.cmi.2017.02.001] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
375 Liu W, Song H, Chen Q, Xu C, Zhang W, Liu Y, Wang B, Xu D, Lu M, Yang D, Zheng X. Multidrug resistance protein 4 is a critical protein associated with the antiviral efficacy of nucleos(t)ide analogues. Liver Int 2016;36:1284-94. [PMID: 26931636 DOI: 10.1111/liv.13104] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 2.4] [Reference Citation Analysis]
376 Masaki K, Suzuki F, Hara T, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kobayashi M, Kumada H. Long-term effects of peginterferon alfa-2a therapy in Japanese patients with chronic hepatitis B virus infection. Virol J 2015;12:225. [PMID: 26700861 DOI: 10.1186/s12985-015-0453-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
377 Zoulim F, Testoni B, Lebossé F. Kinetics of intrahepatic covalently closed circular DNA and serum hepatitis B surface antigen during antiviral therapy for chronic hepatitis B: lessons from experimental and clinical studies. Clin Gastroenterol Hepatol. 2013;11:1011-1013. [PMID: 23602824 DOI: 10.1016/j.cgh.2013.04.010] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
378 Khemichian S, Hsieh MJ, Zhang SR, Limurti J, Kim J, Fong TL. Nucleoside-Nucleotide Analog Combination Therapy Is Effective in Preventing Recurrent Hepatitis B After Liver Transplantation. Dig Dis Sci 2015;60:2807-12. [PMID: 25939541 DOI: 10.1007/s10620-015-3671-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
379 Wiens A, Lenzi L, Venson R, Correr CJ, Rotta I, Pedroso ML, Pontarolo R. Comparative efficacy of oral nucleoside or nucleotide analog monotherapy used in chronic hepatitis B: a mixed-treatment comparison meta-analysis. Pharmacotherapy. 2013;33:144-151. [PMID: 23359454 DOI: 10.1002/phar.1188] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
380 Kim YW, Kwon JH, Jang JW, Kim MJ, Oh BS, Chung KW, Park ES, Nam SW. Diagnostic usefulness of real-time elastography for liver fibrosis in chronic viral hepatitis B and C. Gastroenterol Res Pract 2014;2014:210407. [PMID: 25180031 DOI: 10.1155/2014/210407] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
381 Tourret J, Deray G, Isnard-Bagnis C. Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword? J Am Soc Nephrol. 2013;24:1519-1527. [PMID: 24052632 DOI: 10.1681/asn.2012080857] [Cited by in Crossref: 81] [Cited by in F6Publishing: 38] [Article Influence: 10.1] [Reference Citation Analysis]
382 Dong H, Ni L, Sheng G, Song H, Xu J, Ling Y. Risk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy: A meta-analysis. Journal of Clinical Virology 2013;57:209-14. [DOI: 10.1016/j.jcv.2013.03.010] [Cited by in Crossref: 72] [Cited by in F6Publishing: 67] [Article Influence: 9.0] [Reference Citation Analysis]
383 Zhu L, Kong J, Zheng Y, Song M, Cheng X, Zhang L, Patrick DL, Wang H. Development and initial validation of the chronic hepatitis B quality of life instrument (CHBQOL) among Chinese patients. Qual Life Res 2019;28:3071-81. [PMID: 31243621 DOI: 10.1007/s11136-019-02240-7] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
384 Liu Y, Jiang M, Xue J, Yan H, Liang X. Serum HBV RNA quantification: useful for monitoring natural history of chronic hepatitis B infection. BMC Gastroenterol 2019;19:53. [PMID: 30991954 DOI: 10.1186/s12876-019-0966-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
385 Zhang Q, Liao Y, Cai B, Li Y, Li L, Zhang J, An Y, Wang L. Incidence of natural resistance mutations in naïve chronic hepatitis B patients: A systematic review and meta-analysis: Hepatitis B virus natural mutation rate. J Gastroenterol Hepatol 2015;30:252-61. [DOI: 10.1111/jgh.12831] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
386 Lai CL, Wong D, Ip P, Kopaniszen M, Seto WK, Fung J, Huang FY, Lee B, Cullaro G, Chong CK, Wu R, Cheng C, Yuen J, Ngai V, Yuen MF. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B. J Hepatol. 2017;66:275-281. [PMID: 27639844 DOI: 10.1016/j.jhep.2016.08.022] [Cited by in Crossref: 87] [Cited by in F6Publishing: 74] [Article Influence: 17.4] [Reference Citation Analysis]
387 Habersetzer F, Moenne-Loccoz R, Meyer N, Schvoerer E, Simo-Noumbissie P, Dritsas S, Baumert TF, Doffoël M. Loss of hepatitis B surface antigen in a real-life clinical cohort of patients with chronic hepatitis B virus infection. Liver Int 2015;35:130-9. [PMID: 25145784 DOI: 10.1111/liv.12661] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
388 Ma T, Lee LY, Aw MM, Lee GH. Cost-effectiveness analysis of antiviral treatment for pregnant women with high viral load to prevent hepatitis B virus vertical transmission. Singapore Med J 2020;61:24-7. [PMID: 31388686 DOI: 10.11622/smedj.2019092] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
389 Kayaaslan B, Akinci E, Ari A, Tufan ZK, Alpat SN, Gunal O, Tosun S, Guner R, Tabak F. A long-term multicenter study: Entecavir versus Tenofovir in treatment of nucleos(t)ide analogue-naive chronic hepatitis B patients. Clin Res Hepatol Gastroenterol 2018;42:40-7. [PMID: 28757048 DOI: 10.1016/j.clinre.2017.06.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
390 Wirden M, Larrouy L, Mahjoub N, Todesco E, Damond F, Delagreverie H, Akhavan S, Charpentier C, Chaix M, Descamps D, Calvez V, Marcelin A. Multicenter comparison of the new Cobas 6800 system with Cobas Ampliprep/Cobas TaqMan and Abbott RealTime for the quantification of HIV, HBV and HCV viral load. Journal of Clinical Virology 2017;96:49-53. [DOI: 10.1016/j.jcv.2017.09.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
391 Zhang J, Du X, Zhou Z, Lv F, Yu Y. Spleen thickness can predict significant liver pathology in patients with chronic hepatitis B with persistently normal alanine aminotransferase or minimally raised alanine aminotransferase: a retrospective study. J Int Med Res 2019;47:122-32. [PMID: 30213226 DOI: 10.1177/0300060518796760] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
392 Pena M, Horga J, Zapater P. Variations of pharmacokinetics of drugs in patients with cirrhosis. Expert Review of Clinical Pharmacology 2015;9:441-58. [DOI: 10.1586/17512433.2016.1135733] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
393 Kim WR, Berg T, Asselah T, Flisiak R, Fung S, Gordon SC, Janssen HL, Lampertico P, Lau D, Bornstein JD, Schall RE, Dinh P, Yee LJ, Martins EB, Lim SG, Loomba R, Petersen J, Buti M, Marcellin P. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. J Hepatol. 2016;64:773-780. [PMID: 26626497 DOI: 10.1016/j.jhep.2015.11.012] [Cited by in Crossref: 143] [Cited by in F6Publishing: 129] [Article Influence: 23.8] [Reference Citation Analysis]
394 Chen HL, Cai JY, Song YP, Zha ML, Qin G. Vaginal delivery and HBV mother to child transmission risk after immunoprophylaxis: A systematic review and a meta-analysis. Midwifery 2019;74:116-25. [PMID: 30953967 DOI: 10.1016/j.midw.2019.03.024] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
395 Coppola N, Alessio L, Gualdieri L, Pisaturo M, Sagnelli C, Minichini C, Di Caprio G, Starace M, Onorato L, Signoriello G, Macera M, Angelillo IF, Pasquale G, Sagnelli E. Hepatitis B virus infection in undocumented immigrants and refugees in Southern Italy: demographic, virological, and clinical features. Infect Dis Poverty. 2017;6:33. [PMID: 28179020 DOI: 10.1186/s40249-016-0228-4] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 8.5] [Reference Citation Analysis]
396 Snast I, Atzmony L, Braun M, Hodak E, Pavlovsky L. Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature. Journal of the American Academy of Dermatology 2017;77:88-97.e5. [DOI: 10.1016/j.jaad.2017.01.037] [Cited by in Crossref: 44] [Cited by in F6Publishing: 33] [Article Influence: 11.0] [Reference Citation Analysis]
397 Bayliss J, Yuen L, Rosenberg G, Wong D, Littlejohn M, Jackson K, Gaggar A, Kitrinos KM, Subramanian GM, Marcellin P, Buti M, Janssen HLA, Gane E, Sozzi V, Colledge D, Hammond R, Edwards R, Locarnini S, Thompson A, Revill PA. Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B. Gut 2017;66:2013-23. [PMID: 27534671 DOI: 10.1136/gutjnl-2015-309300] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 6.6] [Reference Citation Analysis]
398 Jüngst C, Berg T, Cheng J, Green RM, Jia J, Mason AL, Lammert F. Intrahepatic cholestasis in common chronic liver diseases. Eur J Clin Invest. 2013;43:1069-1083. [PMID: 23927644 DOI: 10.1111/eci.12128] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
399 Lin TC, Yoshida K, Tedeschi SK, de Abreu MM, Hashemi N, Solomon DH. Risk of Hepatitis B Virus Reactivation in Patients With Inflammatory Arthritis Receiving Disease-Modifying Antirheumatic Drugs: A Systematic Review and Meta-Analysis. Arthritis Care Res (Hoboken). 2018;70:724-731. [PMID: 28834412 DOI: 10.1002/acr.23346] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
400 Westbrook RH, Dusheiko G, Williamson C. Pregnancy and liver disease. J Hepatol. 2016;64:933-945. [PMID: 26658682 DOI: 10.1016/j.jhep.2015.11.030] [Cited by in Crossref: 92] [Cited by in F6Publishing: 49] [Article Influence: 15.3] [Reference Citation Analysis]
401 Foaud H, Maklad S, Mahmoud F, El-karaksy H. Occult hepatitis B virus infection in children born to HBsAg-positive mothers after neonatal passive-active immunoprophylaxis. Infection 2015;43:307-14. [DOI: 10.1007/s15010-015-0733-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
402 Marzano A, Tucci A, Chialà C, Saracco GM, Fadda M, Debernardi Venon W. Liver stiffness-based model for portal hypertension and hepatocellular cancer risk in HBV responsive to antivirals. Minerva Gastroenterol Dietol 2019;65. [DOI: 10.23736/s1121-421x.18.02534-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
403 Lo AO, Wong VW, Wong GL, Chan HL, Dan Y. Cost Effectiveness of Response-Guided Therapy With Peginterferon in the Treatment of Chronic Hepatitis B. Clinical Gastroenterology and Hepatology 2015;13:377-385.e5. [DOI: 10.1016/j.cgh.2014.06.022] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
404 Hunyady B, Gervain J, Horváth G, Makara M, Pár A, Szalay F, Telegdy L, Tornai I. [Diagnosis, treatment, and follow-up of hepatitis C-virus related liver disease. Hungarian national consensus guideline]. Orv Hetil 2014;155 Suppl:3-24. [PMID: 24631886 DOI: 10.1556/OH.2013.29893] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
405 Peng H, Wei F, Liu J, Hu H, Ren H, Hu P. Response-guided therapy of regimens based on PEG-interferon for chronic hepatitis B using on-treatment hepatitis B surface antigen quantification: a meta-analysis. Hepatol Int 2015;9:543-57. [DOI: 10.1007/s12072-015-9644-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
406 Han M, Li Y, Wu W, Zhang Y, Yan W, Luo X, Ning Q. Altered expression of interferon-stimulated genes is strongly associated with therapeutic outcomes in hepatitis B virus infection. Antiviral Research 2017;147:75-85. [DOI: 10.1016/j.antiviral.2017.10.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
407 Soresi M, Giannitrapani L, Cervello M, Licata A, Montalto G. Non invasive tools for the diagnosis of liver cirrhosis. World J Gastroenterol. 2014;20:18131-18150. [PMID: 25561782 DOI: 10.3748/wjg.v20.i48.18131] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 38] [Article Influence: 7.2] [Reference Citation Analysis]
408 Jiang X, Zhang B, Zhao J, Xu Y, Han H, Su K, Tao J, Fan R, Zhao X, Li L, Li MD. Identification and characterization of SEC24D as a susceptibility gene for hepatitis B virus infection. Sci Rep 2019;9:13425. [PMID: 31530870 DOI: 10.1038/s41598-019-49777-8] [Reference Citation Analysis]
409 Sun WC, Hsu PI, Yu HC, Lin KH, Tsay FW, Wang HM, Tsai TJ, Chen WC, Lai KH, Cheng JS. The compliance of doctors with viral hepatitis B screening and antiviral prophylaxis in cancer patients receiving cytotoxic chemotherapy using a hospital-based screening reminder system. PLoS One. 2015;10:e0116978. [PMID: 25658926 DOI: 10.1371/journal.pone.0116978] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
410 Wong GL, Wong VW, Chan HL. Virus and Host Testing to Manage Chronic Hepatitis B. Clin Infect Dis 2016;62 Suppl 4:S298-305. [PMID: 27190319 DOI: 10.1093/cid/ciw024] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
411 Yang S, Xing H, Wang Q, Wang X, Liu S, Cheng J. De novo entecavir+adefovir dipivoxil+lamivudine triple-resistance mutations resulting from sequential therapy with adefovir dipivoxil, and lamivudine. Ann Clin Microbiol Antimicrob 2016;15:24. [PMID: 27079793 DOI: 10.1186/s12941-016-0138-0] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
412 Wiegand J, Wedemeyer H, Franke A, Rößler S, Zeuzem S, Teuber G, Wächtler M, Römmele U, Ruf B, Spengler U, Trautwein C, Bock CT, Fiedler GM, Thiery J, Manns MP, Brosteanu O, Tillmann HL; German Hep-Net Acute Hepatitis B (GAHB) Study Group. Treatment of severe, nonfulminant acute hepatitis B with lamivudine vs placebo: a prospective randomized double-blinded multicentre trial. J Viral Hepat 2014;21:744-50. [PMID: 24329913 DOI: 10.1111/jvh.12210] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
413 Appourchaux K, Dokmak S, Resche-Rigon M, Treton X, Lapalus M, Gattolliat CH, Porchet E, Martinot-Peignoux M, Boyer N, Vidaud M, Bedossa P, Marcellin P, Bièche I, Estrabaud E, Asselah T. MicroRNA-based diagnostic tools for advanced fibrosis and cirrhosis in patients with chronic hepatitis B and C. Sci Rep 2016;6:34935. [PMID: 27731343 DOI: 10.1038/srep34935] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
414 Fujii H, Nishimoto N, Yamaguchi S, Kurai O, Miyano M, Ueda W, Oba H, Aoki T, Kawada N, Okawa K. The Alcohol Use Disorders Identification Test for Consumption (AUDIT-C) is more useful than pre-existing laboratory tests for predicting hazardous drinking: a cross-sectional study. BMC Public Health 2016;16:379. [PMID: 27165437 DOI: 10.1186/s12889-016-3053-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 4.4] [Reference Citation Analysis]
415 Yoo JJ, Cho EJ, Cho YY, Lee M, Lee DH, Cho Y, Lee JH, Yu SJ, Yoon SS, Yoon JH. Efficacy of antiviral prophylaxis in HBsAg-negative, anti-HBc positive patients undergoing hematopoietic stem cell transplantation. Liver Int. 2015;35:2530-2536. [PMID: 26053357 DOI: 10.1111/liv.12882] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
416 Xie Q, Hu X, Zhang Y, Jiang X, Li X, Li J. Decreasing hepatitis B viral load is associated with a risk of significant liver fibrosis in hepatitis B e antigen positive chronic hepatitis B. J Med Virol. 2014;86:1828-1837. [PMID: 25145769 DOI: 10.1002/jmv.24000] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
417 Zhao M, Zou H, Chen Y, Duan Z. Mechanism and Antiviral Therapy in Preventing Mother-to-Child Transmission During Pregnancy with Hepatitis B Virus Infection. Hepat Mon 2019;19. [DOI: 10.5812/hepatmon.81903] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
418 Cao W, Li M, Zhang L, Lu Y, Wu S, Shen G, Chang M, Liu R, Gao Y, Hao H, Hu L, Yi W, Pan CQ, Xie Y. The Characteristics of Natural Killer Cells in Chronic Hepatitis B Patients Who Received PEGylated-Interferon versus Entecavir Therapy. Biomed Res Int 2021;2021:2178143. [PMID: 33575322 DOI: 10.1155/2021/2178143] [Reference Citation Analysis]
419 Milana M, Angelico M. The evolving scenario of HBV infection and disease: A never-ending story. Dig Liver Dis 2019;51:443-4. [PMID: 30470554 DOI: 10.1016/j.dld.2018.10.017] [Reference Citation Analysis]
420 Yapali S, Talaat N, Fontana RJ, Oberhelman K, Lok AS. Outcomes of patients with chronic hepatitis B who do not meet criteria for antiviral treatment at presentation. Clin Gastroenterol Hepatol. 2015;13:193-201.e1. [PMID: 25041863 DOI: 10.1016/j.cgh.2014.07.019] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
421 Wang ML, Chen EQ, Zhang DM, Du LY, Yan LB, Zhou TY, Lei XZ, Lei BJ, Lu JJ, Liao J, Tang H. Efficacy and safety of three adefovir-based combination therapies in HBeAg-positive chronic hepatitis B patients with suboptimal response to adefovir monotherapy. J Viral Hepat 2017;24 Suppl 1:21-8. [PMID: 29082645 DOI: 10.1111/jvh.12792] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
422 Yu W, Zhao C, Shen C, Wang Y, Lu H, Fan J. The efficacy and safety of Nucleos(t)ide analogues in patients with spontaneous acute exacerbation of chronic hepatitis B: a systematic review and meta-analysis. PLoS One 2013;8:e65952. [PMID: 23776577 DOI: 10.1371/journal.pone.0065952] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
423 Wang CC, Kao JH. How have the recent advances in antiviral therapy impacted the management of virus-related hepatocellular carcinoma? Expert Opin Pharmacother 2016;17:911-9. [PMID: 26831361 DOI: 10.1517/14656566.2016.1149165] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
424 Rigopoulou EI, Zachou K, Gatselis N, Koukoulis GK, Dalekos GN. Autoimmune hepatitis in patients with chronic HBV and HCV infections: patterns of clinical characteristics, disease progression and outcome. Annals of Hepatology 2014;13:127-35. [DOI: 10.1016/s1665-2681(19)30914-7] [Cited by in Crossref: 22] [Article Influence: 3.1] [Reference Citation Analysis]
425 Suh YS, Chun DI, Choi SW, Lee HW, Nho JH, Kwon SH, Cho JH, Won SH. Pathologic femoral fracture due to tenofovir-induced Fanconi syndrome in patient with chronic hepatitis B: A case report. Medicine (Baltimore) 2017;96:e8760. [PMID: 29145330 DOI: 10.1097/MD.0000000000008760] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
426 Jung KS, Kim SU. Clinical applications of transient elastography. Clin Mol Hepatol 2012;18:163-73. [PMID: 22893866 DOI: 10.3350/cmh.2012.18.2.163] [Cited by in Crossref: 61] [Cited by in F6Publishing: 57] [Article Influence: 6.8] [Reference Citation Analysis]
427 Ma H, Jia J. Why do I treat HBeAg-positive chronic hepatitis B patients with a nucleoside analogue. Liver Int. 2013;33 Suppl 1:133-136. [PMID: 23286857 DOI: 10.1111/liv.12065] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
428 Matsumoto A. Hepatitis B core-related antigen: a strong indicator for cessation of nucleos(t)ide analog therapy in patients with chronic hepatitis B. J Gastroenterol 2017;52:127-8. [DOI: 10.1007/s00535-016-1259-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
429 Lemoine M, Shimakawa Y, Njie R, Taal M, Ndow G, Chemin I, Ghosh S, Njai HF, Jeng A, Sow A. Acceptability and feasibility of a screen-and-treat programme for hepatitis B virus infection in The Gambia: the Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) study. Lancet Glob Health. 2016;4:e559-e567. [PMID: 27443781 DOI: 10.1016/s2214-109x(16)30130-9] [Cited by in Crossref: 88] [Cited by in F6Publishing: 46] [Article Influence: 29.3] [Reference Citation Analysis]
430 Winther TN, Heiberg IL, Bang-Berthelsen CH, Pociot F, Hogh B. Hepatitis B surface antigen quantity positively correlates with plasma levels of microRNAs differentially expressed in immunological phases of chronic hepatitis B in children. PLoS One 2013;8:e80384. [PMID: 24244683 DOI: 10.1371/journal.pone.0080384] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
431 You CR, Lee SW, Jang JW, Yoon SK. Update on hepatitis B virus infection. World J Gastroenterol. 2014;20:13293-13305. [PMID: 25309066 DOI: 10.3748/wjg.v20.i37.13293] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 38] [Article Influence: 8.0] [Reference Citation Analysis]
432 Viganò M, Mangia G, Lampertico P. HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues? Liver Int 2014;34 Suppl 1:120-6. [PMID: 24373088 DOI: 10.1111/liv.12401] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
433 Oh MJ, Lee HJ. Antiviral efficacy of entecavir versus entecavir plus adefovir for hepatitis B virus rtA181V/T mutants alone. Saudi J Gastroenterol 2016;22:37-42. [PMID: 26831605 DOI: 10.4103/1319-3767.173757] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
434 Cuneo A, Marchetti M, Barosi G, Billio A, Brugiatelli M, Ciolli S, Laurenti L, Mauro FR, Molica S, Montillo M, Zinzani P, Tura S. Appropriate use of bendamustine in first-line therapy of chronic lymphocytic leukemia. Recommendations from SIE, SIES, GITMO Group. Leukemia Research 2014;38:1269-77. [DOI: 10.1016/j.leukres.2014.06.017] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
435 de Niet A, Jansen L, Stelma F, Willemse SB, Kuiken SD, Weijer S, van Nieuwkerk CMJ, Zaaijer HL, Molenkamp R, Takkenberg RB, Koot M, Verheij J, Beuers U, Reesink HW. Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trial. The Lancet Gastroenterology & Hepatology 2017;2:576-84. [DOI: 10.1016/s2468-1253(17)30083-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 5] [Article Influence: 5.3] [Reference Citation Analysis]
436 Kim MN, Lee CK, Ahn SH, Lee S, Kim SU, Kim DY, Kim HS, Han KH, Chon CY, Park JY. Maintaining remission in lamivudine-resistant patients with a virological response to adefovir add-on lamivudine after stopping lamivudine therapy. Liver Int 2014;34:1543-9. [PMID: 24330475 DOI: 10.1111/liv.12437] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
437 Papatheodoridis G, Sypsa V, Kantzanou M, Nikolakopoulos I, Hatzakis A. Estimating the treatment cascade of chronic hepatitis B and C in Greece using a telephone survey. J Viral Hepat. 2015;22:409-415. [PMID: 25209157 DOI: 10.1111/jvh.12314] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
438 Ferrarese A, Zanetto A, Gambato M, Bortoluzzi I, Nadal E, Germani G, Senzolo M, Burra P, Russo FP. Liver transplantation for viral hepatitis in 2015. World J Gastroenterol 2016;22:1570-81. [PMID: 26819523 DOI: 10.3748/wjg.v22.i4.1570] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 19] [Article Influence: 5.8] [Reference Citation Analysis]
439 Lee HJ, Kim SJ, Kweon YO, Park SY, Heo J, Woo HY, Hwang JS, Chung WJ, Lee CH, Kim BS, Suh JI, Tak WY, Jang BK. Evaluating the efficacy of switching from lamivudine plus adefovir to tenofovir disoproxil fumarate monotherapy in lamivudine-resistant stable hepatitis B patients. PLoS One 2018;13:e0190581. [PMID: 29329305 DOI: 10.1371/journal.pone.0190581] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
440 De Clercq E, Li G. Approved Antiviral Drugs over the Past 50 Years. Clin Microbiol Rev. 2016;29:695-747. [PMID: 27281742 DOI: 10.1128/cmr.00102-15] [Cited by in Crossref: 592] [Cited by in F6Publishing: 259] [Article Influence: 118.4] [Reference Citation Analysis]
441 Choi SH, Yang KJ, Lee DS. Effects of Complementary Combination Therapy of Korean Red Ginseng and Antiviral Agents in Chronic Hepatitis B. J Altern Complement Med 2016;22:964-9. [PMID: 27603149 DOI: 10.1089/acm.2015.0206] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
442 Martinot-Peignoux M, Carvalho-Filho R, Lapalus M, Netto-Cardoso AC, Lada O, Batrla R, Krause F, Asselah T, Marcellin P. Hepatitis B surface antigen serum level is associated with fibrosis severity in treatment-naïve, e antigen-positive patients. J Hepatol. 2013;58:1089-1095. [PMID: 23369792 DOI: 10.1016/j.jhep.2013.01.028] [Cited by in Crossref: 77] [Cited by in F6Publishing: 70] [Article Influence: 9.6] [Reference Citation Analysis]
443 Gao S, Ji XF, Li F, Sun FK, Zhao J, Fan YC, Wang K. Aberrant DNA methylation of G-protein-coupled bile acid receptor Gpbar1 predicts prognosis of acute-on-chronic hepatitis B liver failure. J Viral Hepat 2015;22:112-9. [PMID: 24995843 DOI: 10.1111/jvh.12277] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
444 Chi H, Hansen BE, Guo S, Zhang NP, Qi X, Chen L, Guo Q, Arends P, Wang JY, Verhey E, de Knegt RJ, Xie Q, Janssen HLA. Pegylated Interferon Alfa-2b Add-on Treatment in Hepatitis B Virus Envelope Antigen-Positive Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogue: A Randomized, Controlled Trial (PEGON). J Infect Dis 2017;215:1085-93. [PMID: 28329061 DOI: 10.1093/infdis/jix024] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
445 Ridruejo E. Treatment of chronic hepatitis B in clinical practice with entecavir or tenofovir. World J Gastroenterol. 2014;20:7169-80. [PMID: 24966587 DOI: 10.3748/wjg.v20.i23.7169] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
446 Tan M, Bhadoria AS, Cui F, Tan A, Van Holten J, Easterbrook P, Ford N, Han Q, Lu Y, Bulterys M, Hutin Y. Estimating the proportion of people with chronic hepatitis B virus infection eligible for hepatitis B antiviral treatment worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2021;6:106-19. [PMID: 33197397 DOI: 10.1016/S2468-1253(20)30307-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 12.0] [Reference Citation Analysis]
447 Park JJ, Wong DK, Wahed AS, Lee WM, Feld JJ, Terrault N, Khalili M, Sterling RK, Kowdley KV, Bzowej N, Lau DT, Kim WR, Smith C, Carithers RL, Torrey KW, Keith JW, Levine DL, Traum D, Ho S, Valiga ME, Johnson GS, Doo E, Lok AS, Chang KM;  Hepatitis B Research Network. Hepatitis B Virus--Specific and Global T-Cell Dysfunction in Chronic Hepatitis B.. Gastroenterology. 2016;150:684-695.e5. [PMID: 26684441 DOI: 10.1053/j.gastro.2015.11.050] [Cited by in Crossref: 98] [Cited by in F6Publishing: 95] [Article Influence: 16.3] [Reference Citation Analysis]
448 Yang S, Chen G, Li Y, Li G, Liang Y, Zhou F, Zhou S, Yang Y, Jia W, Gao Y, Chen Y. The trend of direct medical costs and associated factors in patients with chronic hepatitis B in Guangzhou, China: an eight-year retrospective cohort study. BMC Med Inform Decis Mak 2021;21:71. [PMID: 34330262 DOI: 10.1186/s12911-021-01429-6] [Reference Citation Analysis]
449 Maier M, Liebert UG, Wittekind C, Kaiser T, Berg T, Wiegand J. Clinical Relevance of Minimal Residual Viremia during Long-Term Therapy with Nucleos(t)ide Analogues in Patients with Chronic Hepatitis B. PLoS One. 2013;8:e67481. [PMID: 23826307 DOI: 10.1371/journal.pone.0067481] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
450 Tsai MC, Chen CH, Hung CH, Lee CM, Chiu KW, Wang JH, Lu SN, Tseng PL, Chang KC, Yen YH. A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B: a match-control study. Clin Microbiol Infect. 2014;20:O90-O100. [PMID: 23659493 DOI: 10.1111/1469-0691.12220] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
451 Cornberg M, Höner Zu Siederdissen C. HBsAg seroclearance with NUCs: rare but important. Gut 2014;63:1208-9. [PMID: 24398879 DOI: 10.1136/gutjnl-2013-306221] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.9] [Reference Citation Analysis]
452 Kim BG, Park NH, Lee SB, Lee H, Lee BU, Park JH, Jung SW, Jeong ID, Bang S, Shin JW. Mortality, liver transplantation and hepatic complications in patients with treatment-naïve chronic hepatitis B treated with entecavir vs tenofovir. J Viral Hepat 2018;25:1565-75. [DOI: 10.1111/jvh.12971] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 12.7] [Reference Citation Analysis]
453 Jia W, Song LW, Fang YQ, Wu XF, Liu DY, Xu C, Wang XM, Wang W, Lv DX, Li J, Deng YQ, Wang Y, Huo N, Yu M, Xi HL, Liu D, Zhou YX, Wang GQ, Xia NS, Zhang MX. Antibody to hepatitis B core antigen levels in the natural history of chronic hepatitis B: a prospective observational study. Medicine (Baltimore) 2014;93:e322. [PMID: 25546679 DOI: 10.1097/MD.0000000000000322] [Cited by in Crossref: 32] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
454 Locarnini S, Hatzakis A, Chen DS, Lok A. Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs. J Hepatol. 2015;62:S76-S86. [PMID: 25920093 DOI: 10.1016/j.jhep.2015.01.018] [Cited by in Crossref: 120] [Cited by in F6Publishing: 112] [Article Influence: 24.0] [Reference Citation Analysis]
455 Yeh C, Liang K, Chang M, Hsu C, Chen Y, Lin C, Lin W, Lai M. Phenotypic and Genotypic Shifts in Hepatitis B Virus in Treatment-Naive Patients, Taiwan, 2008–2012. Emerg Infect Dis 2017;23:820-1. [DOI: 10.3201/10.3201/eid2305.161894] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
456 Javaid A, Poongkunran M, Allard FD, Kyaw W, Maung HH, Lau D. Subtle presentation of active primary biliary cirrhosis in chronic hepatitis B: a case report. Gastroenterol Rep (Oxf). 2016; Epub ahead of print. [PMID: 26893441 DOI: 10.1093/gastro/gov064] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
457 Lewandowska M, Piekarska A. New directions in hepatitis B therapy research. Clin Exp Hepatol 2017;3:119-26. [PMID: 29062901 DOI: 10.5114/ceh.2017.68831] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
458 Lin TF, Hsu PI, Lin KH, Tsay FW, Tsai TJ, Chen YH, Yu HC. Factors Related to Significant Improvement of Estimated Glomerular Filtration Rates in Chronic Hepatitis B Patients Receiving Telbivudine Therapy. Gastroenterol Res Pract 2017;2017:4192169. [PMID: 28757867 DOI: 10.1155/2017/4192169] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
459 Liu Y, Li L, Liu J, She WM, Shi JM, Li J, Wang JY, Jiang W. Activated hepatic stellate cells directly induce pathogenic Th17 cells in chronic hepatitis B virus infection. Exp Cell Res. 2017;359:129-137. [PMID: 28780305 DOI: 10.1016/j.yexcr.2017.08.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
460 Causse X, Cadranel JF, Potier P, Hanslik B, Denis J, Renou C, Delasalle P; Club de Réflexion des Cabinets et Groupes d’Hépato-Gastroentérologie (CREGG)., Association Nationale des hépato-Gastroentérologues des Hôpitaux généraux de France (ANGH). Hepatogastroenterologists' knowledge of inactive carriers and immunotolerant hepatitis B virus patients in France: results of a practice survey. Eur J Gastroenterol Hepatol 2015;27:544-9. [PMID: 25822863 DOI: 10.1097/MEG.0000000000000306] [Reference Citation Analysis]
461 Paik N, Sinn DH, Lee JH, Oh IS, Kim JH, Kang W, Gwak G, Paik Y, Choi MS, Lee JH, Koh KC, Paik SW. Non-invasive tests for liver disease severity and the hepatocellular carcinoma risk in chronic hepatitis B patients with low-level viremia. Liver Int 2018;38:68-75. [DOI: 10.1111/liv.13489] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 5.8] [Reference Citation Analysis]
462 Pita I, Horta-vale AM, Cardoso H, Macedo G. Hepatitis B inactive carriers: An overlooked population? GE Portuguese Journal of Gastroenterology 2014;21:241-9. [DOI: 10.1016/j.jpge.2014.08.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.9] [Reference Citation Analysis]
463 Bohte AE, de Niet A, Jansen L, Bipat S, Nederveen AJ, Verheij J, Terpstra V, Sinkus R, van Nieuwkerk KMJ, de Knegt RJ, Baak BC, Jansen PLM, Reesink HW, Stoker J. Non-invasive evaluation of liver fibrosis: a comparison of ultrasound-based transient elastography and MR elastography in patients with viral hepatitis B and C. Eur Radiol 2014;24:638-48. [DOI: 10.1007/s00330-013-3046-0] [Cited by in Crossref: 77] [Cited by in F6Publishing: 63] [Article Influence: 9.6] [Reference Citation Analysis]
464 Kim MN, Park JY, Ahn SH, Kim BK, Kim SU, Kim DY, Han KH. Durability of the virological response after lamivudine discontinuation in lamivudine-resistant patients with a complete virological response after lamivudine and adefovir combination therapy. J Med Virol 2017;89:85-90. [PMID: 27357598 DOI: 10.1002/jmv.24616] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
465 Xu HZ, Liu YP, Guleng B, Ren JL. Hepatitis B Virus-Related Hepatocellular Carcinoma: Pathogenic Mechanisms and Novel Therapeutic Interventions. Gastrointest Tumors. 2014;1:135-145. [PMID: 26676160 DOI: 10.1159/000365307] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
466 Lin J, Wu JF, Zhang Q, Zhang HW, Cao GW. Virus-related liver cirrhosis: molecular basis and therapeutic options. World J Gastroenterol 2014;20:6457-69. [PMID: 24914367 DOI: 10.3748/wjg.v20.i21.6457] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
467 Korean Liver Cancer Association., National Cancer Center. 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Gut Liver 2019;13:227-99. [PMID: 31060120 DOI: 10.5009/gnl19024] [Cited by in Crossref: 90] [Cited by in F6Publishing: 78] [Article Influence: 90.0] [Reference Citation Analysis]
468 Zhuang Y, Li X, Li X, Xu H, Ye H, Sun D, Liu X, Ren G. Association of KIR Genotypes and Haplotypes in HBeAg-positive Chronic Hepatitis B Patients Treated with Entecavir. Immunol Invest 2019;48:333-44. [PMID: 30325691 DOI: 10.1080/08820139.2018.1529791] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
469 Wirth S, Zhang H, Hardikar W, Schwarz KB, Sokal E, Yang W, Fan H, Morozov V, Mao Q, Deng H, Huang Y, Yang L, Frey N, Nasmyth-Miller C, Pavlovic V, Wat C. Efficacy and Safety of Peginterferon Alfa-2a (40KD) in Children With Chronic Hepatitis B: The PEG-B-ACTIVE Study. Hepatology. 2018;68:1681-1694. [PMID: 29689122 DOI: 10.1002/hep.30050] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
470 Guarino M, Picardi M, Vitiello A, Pugliese N, Rea M, Cossiga V, Pane F, Caporaso N, Morisco F. Viral Outcome in Patients with Occult HBV Infection or HCV-Ab Positivity Treated for Lymphoma. Annals of Hepatology 2017;16:198-206. [DOI: 10.5604/16652681.1231579] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
471 Horváth G. New drugs for the treatment of chronic hepatitis B and interdisciplinary aspects of chronic hepatitis B virus infection. Orvosi Hetilap 2013;154:1142-50. [DOI: 10.1556/oh.2013.29625] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
472 Wen Y, Peng S, Fu L, Fu X, Wu D, Liu B, Tan D, Ouyang Y. Serum levels of miRNA in patients with hepatitis B virus-associated acute-on-chronic liver failure. Hepatobiliary & Pancreatic Diseases International 2018;17:126-32. [DOI: 10.1016/j.hbpd.2018.03.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
473 Ridruejo E, Marciano S, Galdame O, Reggiardo MV, Muñoz AE, Adrover R, Cocozzella D, Fernandez N, Estepo C, Mendizabal M, Romero GA, Levi D, Schroder T, Paz S, Fainboim H, Mandó OG, Gadano AC, Silva MO. Efficacy and safety of long term entecavir in chronic hepatitis B treatment naïve patients in clinical practice. Annals of Hepatology 2014;13:327-36. [DOI: 10.1016/s1665-2681(19)30861-0] [Cited by in Crossref: 9] [Article Influence: 1.3] [Reference Citation Analysis]
474 Drazilova S, Janicko M, Kristian P, Schreter I, Kucinsky B, Kozlej M, Hockickova I, Jarcuska P. Lower Viral Response to Pegylated Interferon Alpha 2a Treatment of Chronic Hepatitis B in Roma People in Eastern Slovakia. Gastroenterol Res Pract 2016;2016:8682494. [PMID: 26858755 DOI: 10.1155/2016/8682494] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
475 Ramière C, Roche L, Scholtès C, Iwaz J, Saison J, Ecochard R, André P. Evolution of the incidence of hepatitis B virus infection and immunization rates in a large French cohort born between 1960 and 1994. Clin Microbiol Infect 2016;22:889.e1-7. [PMID: 27451939 DOI: 10.1016/j.cmi.2016.07.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
476 Parker S, Gil E, Hewitt P, Ward K, Reyal Y, Wilson S, Manson J. Case report: passive transfer of hepatitis B antibodies from intravenous immunoglobulin. BMC Infect Dis 2014;14:99. [PMID: 24559411 DOI: 10.1186/1471-2334-14-99] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
477 Lim YS, Byun KS, Yoo BC, Kwon SY, Kim YJ, An J, Lee HC, Lee YS. Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial. Gut. 2016;65:852-860. [PMID: 25596179 DOI: 10.1136/gutjnl-2014-308353] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 9.2] [Reference Citation Analysis]
478 Invernizzi F, Viganò M, Grossi G, Lampertico P. The prognosis and management of inactive HBV carriers. Liver Int. 2016;36 Suppl 1:100-104. [PMID: 26725905 DOI: 10.1111/liv.13006] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 6.2] [Reference Citation Analysis]
479 Vallet-Pichard A, Pol S. Hepatitis B virus treatment beyond the guidelines: special populations and consideration of treatment withdrawal. Therap Adv Gastroenterol. 2014;7:148-155. [PMID: 25057295 DOI: 10.1177/1756283x14524614] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
480 Wang XX, Pan XB, Han JC, Cong X, Jin Q, Kong XS, Wei L, Feng B. HBsAg stimulates NKG2D receptor expression on natural killer cells and inhibits hepatitis C virus replication. Hepatobiliary Pancreat Dis Int 2018;17:233-40. [PMID: 29625837 DOI: 10.1016/j.hbpd.2018.03.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
481 Ridruejo E, Marciano S, Galdame O, Reggiardo MV, Muñoz AE, Adrover R, Cocozzella D, Fernandez N, Estepo C, Mendizábal M, Romero GA, Levi D, Schroder T, Paz S, Fainboim H, Mandó OG, Gadano AC, Silva MO. Relapse rates in chronic hepatitis B naïve patients after discontinuation of antiviral therapy with entecavir. J Viral Hepat 2014;21:590-6. [DOI: 10.1111/jvh.12200] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
482 Venkatesh SK, Xu S, Tai D, Yu H, Wee A. Correlation of MR elastography with morphometric quantification of liver fibrosis (Fibro-C-Index) in chronic hepatitis B. Magn Reson Med. 2014;72:1123-1129. [PMID: 24166665 DOI: 10.1002/mrm.25002] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
483 Tan Z, Yin Y, Zhou J, Wu L, Xu C, Hou H. Telbivudine treatment of hepatitis B virus-infected pregnant women at different gestational stages for the prevention of mother-to-child transmission: Outcomes of telbivudine treatment during pregnancy. Medicine (Baltimore) 2016;95:e4847. [PMID: 27749537 DOI: 10.1097/MD.0000000000004847] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 4.3] [Reference Citation Analysis]
484 Zeng Y, Li Y, Xu Z, Gan W, Lu L, Huang X, Lin C. Myeloid-derived suppressor cells expansion is closely associated with disease severity and progression in HBV-related acute-on-chronic liver failure. J Med Virol. 2019;91:1510-1518. [PMID: 30905084 DOI: 10.1002/jmv.25466] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
485 Fukuda W, Hanyu T, Katayama M, Mizuki S, Okada A, Miyata M, Handa Y, Hayashi M, Koyama Y, Arii K, Kitaori T, Hagiyama H, Urushidani Y, Yamasaki T, Ikeno Y, Suzuki T, Omoto A, Sugitani T, Morita S, Inokuma S. Incidence of hepatitis B virus reactivation in patients with resolved infection on immunosuppressive therapy for rheumatic disease: a multicentre, prospective, observational study in Japan. Ann Rheum Dis 2017;76:1051-6. [PMID: 27934678 DOI: 10.1136/annrheumdis-2016-209973] [Cited by in Crossref: 48] [Cited by in F6Publishing: 35] [Article Influence: 9.6] [Reference Citation Analysis]
486 Ravindran S, Hancox SH, Howlett DC. Liver biopsy: past, present and future. British Journal of Hospital Medicine 2016;77:90-5. [DOI: 10.12968/hmed.2016.77.2.90] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
487 Yu K, Du Z, Li Q, Cheng Q, Huang C, Shi G, Li N. Comparison of non-invasive models for predicting liver damage in chronic hepatitis B patients. Gastroenterol Hepatol 2019;42:281-8. [PMID: 30772087 DOI: 10.1016/j.gastrohep.2018.12.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
488 Tang H, Griffin J, Innaimo S, Lehman-Mckeeman L, Llamoso C. The Discovery and Development of a Potent Antiviral Drug, Entecavir, for the Treatment of Chronic Hepatitis B. J Clin Transl Hepatol 2013;1:51-8. [PMID: 26357607 DOI: 10.14218/JCTH.2013.00006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
489 Gao F, Zhang WT, Lin YY, Wang WM, Xu N, Bai GQ. Early Start Of Tenofovir Treatment Achieves Better Viral Suppression In Pregnant Women With A High HBV Viral Load: A Real-World Prospective Study. Infect Drug Resist 2019;12:3475-84. [PMID: 31807036 DOI: 10.2147/IDR.S228982] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
490 Liu J, Lee MH, Batrla-Utermann R, Jen CL, Iloeje UH, Lu SN, Wang LY, You SL, Hsiao CK, Yang HI. A predictive scoring system for the seroclearance of HBsAg in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection. J Hepatol. 2013;58:853-860. [PMID: 23246508 DOI: 10.1016/j.jhep.2012.12.006] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 6.9] [Reference Citation Analysis]
491 Gentile G, Andreoni M, Antonelli G, Sarmati L. Screening, monitoring, prevention, prophylaxis and therapy for hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation: a systematic review. Clin Microbiol Infect 2017;23:916-23. [PMID: 28668465 DOI: 10.1016/j.cmi.2017.06.024] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
492 Kemp W, Levy M, Weltman M, Lubel J. Australian Liver Association (ALA) expert consensus recommendations for the use of transient elastography in chronic viral hepatitis. J Gastroenterol Hepatol. 2015;30:453-462. [PMID: 25532416 DOI: 10.1111/jgh.12865] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
493 Lim YS, Yoo BC, Byun KS, Kwon SY, Kim YJ, An J, Lee HC, Lee YS. Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial. Gut. 2016;65:1042-1051. [PMID: 25800784 DOI: 10.1136/gutjnl-2014-308435] [Cited by in Crossref: 62] [Cited by in F6Publishing: 54] [Article Influence: 10.3] [Reference Citation Analysis]
494 Sellier P, Maylin S, Amarsy R, Mazeron MC, Larrouy L, Haïm-Boukobza S, Lopes A, Moreno MD, Ricbourg A, Simoneau G, Magnier JD, Mercier-Delarue S, Delcey V, Evans J, Cambau E, Barranger E, Simon F, Bergmann JF. Untreated highly viraemic pregnant women from Asia or sub-Saharan Africa often transmit hepatitis B virus despite serovaccination to newborns. Liver Int 2015;35:409-16. [PMID: 24698736 DOI: 10.1111/liv.12561] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
495 Yurdaydin C, Idilman R. Therapy of Delta Hepatitis. Cold Spring Harb Perspect Med 2015;5:a021543. [PMID: 26253093 DOI: 10.1101/cshperspect.a021543] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
496 Lee YB, Lee JH, Lee DH, Cho H, Ahn H, Choi WM, Cho YY, Lee M, Yoo JJ, Cho Y. Efficacy of entecavir-tenofovir combination therapy for chronic hepatitis B patients with multidrug-resistant strains. Antimicrob Agents Chemother. 2014;58:6710-6716. [PMID: 25155601 DOI: 10.1128/aac.03845-14aac.03845-14] [Reference Citation Analysis]
497 Asan A, Sayan M, Akhan S, Tekin Koruk S, Aygen B, Sirmatel F, Eraksoy H, Tuna N, Köse S, Kaya A, Eren Tulek N, Aktug Demir N, Mistik R, Ormen B, Korkmaz F, Yildirmak T, Ural O, Aydin M, Turgut H, Gunal O, Demirturk N. Molecular Characterization of Drug Resistance in Hepatitis B Viruses Isolated from Patients with Chronical Infection in Turkey. Hepat Mon 2018;18. [DOI: 10.5812/hepatmon.12472] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
498 Islami F, Dikshit R, Mallath MK, Jemal A. Primary liver cancer deaths and related years of life lost attributable to hepatitis B and C viruses in India. Cancer Epidemiol 2016;40:79-86. [PMID: 26683034 DOI: 10.1016/j.canep.2015.11.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
499 Perrillo RP. Hepatitis B reactivation from immunosuppressive drug therapy: A global menace: Editor’s comment for february issue of clinical liver disease. Clinical Liver Disease. 2015;5:39-42. [PMID: 31040946 DOI: 10.1002/cld.448] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
500 Zeng J, Zheng J, Jin JY, Mao YJ, Guo HY, Lu MD, Zheng HR, Zheng RQ. Shear wave elastography for liver fibrosis in chronic hepatitis B: Adapting the cut-offs to alanine aminotransferase levels improves accuracy. Eur Radiol. 2019;29:857-865. [PMID: 30039224 DOI: 10.1007/s00330-018-5621-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
501 Soriano V, de Mendoza C, Peña JM, Barreiro P. Advances in treating drug-resistant hepatitis B virus in HIV-infected patients. Expert Opin Pharmacother 2015;16:179-86. [PMID: 25529507 DOI: 10.1517/14656566.2015.973852] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
502 Liu TW, Yeh ML, Huang CF, Lin IL, Huang JF, Dai CY, Chen YL, Chuang WL, Yu ML. Clinical performance of a new hepatitis B surface antigen quantitative assay with automatic dilution. Kaohsiung J Med Sci. 2015;31:26-33. [PMID: 25600917 DOI: 10.1016/j.kjms.2014.10.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
503 Lun-Gen L. Antiviral Therapy of Liver Cirrhosis Related to Hepatitis B Virus Infection. J Clin Transl Hepatol 2014;2:197-201. [PMID: 26355652 DOI: 10.14218/JCTH.2014.00022] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
504 Gitto S, Vitale G, Villa E, Andreone P. Update on Alcohol and Viral Hepatitis. J Clin Transl Hepatol 2014;2:228-33. [PMID: 26356547 DOI: 10.14218/JCTH.2014.00030] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
505 Gao YH, Meng QH, Zhang ZQ, Zhao P, Shang QH, Yuan Q, Li Y, Deng J, Li T, Liu XE, Zhuang H. On-treatment quantitative hepatitis B e antigen predicted response to nucleos(t)ide analogues in chronic hepatitis B. World J Hepatol 2016;8:1511-20. [PMID: 28008342 DOI: 10.4254/wjh.v8.i34.1511] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
506 Ji L, Gao Q, Guo R, Zhang X, Zhou Z, Yu Z, Zhu X, Gao Y, Sun X, Gao Y, Li M. Immunomodulatory Effects of Combination Therapy with Bushen Formula plus Entecavir for Chronic Hepatitis B Patients. Journal of Immunology Research 2019;2019:1-10. [DOI: 10.1155/2019/8983903] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
507 Basnayake SK, Easterbrook PJ. Wide variation in estimates of global prevalence and burden of chronic hepatitis B and C infection cited in published literature. J Viral Hepat 2016;23:545-59. [PMID: 27028545 DOI: 10.1111/jvh.12519] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
508 Chen CH, Hu TH, Hung CH, Wang JH, Lu SN, Lee CM. Antiviral effect of entecavir in nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients without virological response at week 24 or 48 of therapy. J Viral Hepat 2014;21:e55-64. [PMID: 24766327 DOI: 10.1111/jvh.12239] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
509 Kim HY, Yoo JJ, Oh S, Yu SJ, Kim YJ, Yoon JH, Kim W, Jung YJ, Kim BH, Kim CM, Park JW, Lee JH. Scoring system for risk stratification of viral reactivation during prophylactic antiviral treatment in Korean patients with hepatitis B undergoing anticancer chemotherapy: A multicenter study. J Med Virol. 2018;90:1593-1603. [PMID: 29900560 DOI: 10.1002/jmv.25241] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
510 Sculier J, Botta I, Bucalau A, Compagnie M, Eskenazi A, Fischler R, Gorham J, Mans L, Rozen L, Speybrouck S, Wang X, Meert A, Berghmans T. Medical anticancer treatment of lung cancer associated with comorbidities: A review. Lung Cancer 2015;87:241-8. [DOI: 10.1016/j.lungcan.2015.01.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
511 Masarone M, De Renzo A, La Mura V, Sasso FC, Romano M, Signoriello G, Rosato V, Perna F, Pane F, Persico M. Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma. BMC Gastroenterol 2014;14:31. [PMID: 24533834 DOI: 10.1186/1471-230X-14-31] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
512 Fan L, Owusu-Edusei K Jr, Schillie SF, Murphy TV. Antiviral treatment among pregnant women with chronic hepatitis B. Infect Dis Obstet Gynecol 2014;2014:546165. [PMID: 25548510 DOI: 10.1155/2014/546165] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
513 He D, Guo S, Chen W, Chen X, Yan G, Wang J, Li M, Zhu P, Huang H, Wang Y. Long-term outcomes after nucleos(t)ide analogues discontinuation in chronic hepatitis B patients with HBeAg-negative. BMC Infect Dis. 2013;13:458. [PMID: 24090287 DOI: 10.1186/1471-2334-13-458] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
514 Fognani E, Giannini C, Piluso A, Gragnani L, Monti M, Caini P, Ranieri J, Urraro T, Triboli E, Laffi G. Role of microRNA profile modifications in hepatitis C virus-related mixed cryoglobulinemia. PLoS One. 2013;8:e62965. [PMID: 23650540 DOI: 10.1371/journal.pone.0062965] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
515 Berg T, Zoulim F, Moeller B, Trinh H, Marcellin P, Chan S, Kitrinos KM, Dinh P, Flaherty JF Jr, McHutchison JG, Manns M. Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients. J Hepatol. 2014;60:715-722. [PMID: 24295873 DOI: 10.1016/j.jhep.2013.11.024] [Cited by in Crossref: 64] [Cited by in F6Publishing: 58] [Article Influence: 8.0] [Reference Citation Analysis]
516 Liang N, Kong Z, Ma SS, Lu CL, Yang M, Feng LD, Shen C, Diao RH, Cui LJ, Lu XY, Nikolova D, Jakobsen JC, Gluud C, Liu JP. Radix Sophorae flavescentis versus no intervention or placebo for chronic hepatitis B. Cochrane Database Syst Rev 2019;4:CD013089. [PMID: 30941748 DOI: 10.1002/14651858.CD013089.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
517 Rong X, Ailing F, Xiaodong L, Jie H, Min L. Monitoring hepatitis B by using point-of-care testing: biomarkers, current technologies, and perspectives. Expert Rev Mol Diagn 2021;21:195-211. [PMID: 33467927 DOI: 10.1080/14737159.2021.1876565] [Reference Citation Analysis]
518 Van Damme P, Ward JW, Shouval D, Zanetti A. Hepatitis B Vaccines. Plotkin's Vaccines. Elsevier; 2018. pp. 342-374.e17. [DOI: 10.1016/b978-0-323-35761-6.00025-0] [Cited by in Crossref: 6] [Article Influence: 2.0] [Reference Citation Analysis]
519 Fong TL, Tien A, Jo KJ, Chu D, Cheung E, Mena EA, Phan QQ, Yu AS, Mohammed W, Velasco A. Durability of Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir. Dig Dis Sci. 2015;60:3465-3472. [PMID: 26138653 DOI: 10.1007/s10620-015-3775-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
520 Sohn W, Kang TW, Choi SK, Jung SH, Lee MW, Lim HK, Cho JY, Shim SG, Sinn DH, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Rhim H, Paik YH. Effect of oral antiviral treatment on long-term outcomes of radiofrequency ablation therapy for hepatitis B virus-related hepatocellular carcinoma. Oncotarget 2016;7:47794-807. [PMID: 27329596 DOI: 10.18632/oncotarget.10026] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
521 Mulabecirovic A, Mjelle AB, Gilja OH, Vesterhus M, Havre RF. Repeatability of shear wave elastography in liver fibrosis phantoms-Evaluation of five different systems. PLoS One 2018;13:e0189671. [PMID: 29293527 DOI: 10.1371/journal.pone.0189671] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
522 Thiele M, Gluud LL, Dahl EK, Krag A. Antiviral therapy for prevention of hepatocellular carcinoma and mortality in chronic hepatitis B: systematic review and meta-analysis. BMJ Open 2013;3:e003265. [PMID: 23945731 DOI: 10.1136/bmjopen-2013-003265] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
523 Chang JW, Lee JS, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Seo YS, Lee HA, Kim MN, Lee YR, Hwang SG, Rim KS, Um SH, Tak WY, Kweon YO, Park SY, Kim SU. Validation of risk prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with entecavir or tenofovir. J Viral Hepat 2021;28:95-104. [DOI: 10.1111/jvh.13411] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
524 Fang J, Li W, Tan M, Peng X, Tan Z, Wang W. Effect of different hepatitis B infection status on the prognosis of active lupus nephritis treated with immunosuppression: a retrospective analysis of 177 patients. Int J Rheum Dis 2018;21:1060-7. [PMID: 29878614 DOI: 10.1111/1756-185X.13313] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
525 Xia B, Wang F, Friedrich-Rust M, Zhou F, Zhu J, Yang H, Ruan W, Zeng Z. Feasibility and Efficacy of Transient Elastography using the XL probe to diagnose liver fibrosis and cirrhosis: A meta-analysis. Medicine (Baltimore) 2018;97:e11816. [PMID: 30278481 DOI: 10.1097/MD.0000000000011816] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 3.7] [Reference Citation Analysis]
526 Sarno G, Montalti R, Giglio MC, Rompianesi G, Tomassini F, Scarpellini E, De Simone G, De Palma GD, Troisi RI. Hepatocellular carcinoma in patients with chronic renal disease: Challenges of interventional treatment. Surg Oncol. 2021;36:42-50. [PMID: 33307490 DOI: 10.1016/j.suronc.2020.11.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
527 Ehrenstein B, Reischl U. [PCR-based detection of pathogens in clinical rheumatology]. Z Rheumatol 2016;75:381-8. [PMID: 26892924 DOI: 10.1007/s00393-016-0058-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
528 Bahcecioglu IH, Sahin A. Treatment of Delta Hepatitis: Today and in the Future - A review. Infectious Diseases 2017;49:241-50. [DOI: 10.1080/23744235.2016.1271998] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
529 Caroleo B, Staltari O, Gallelli L, Perticone F. Reactivation of chronic hepatitis B during treatment with tenofovir disoproxil fumarate: drug interactions or low adherence? BMJ Case Rep 2015;2015:bcr2015209586. [PMID: 26123461 DOI: 10.1136/bcr-2015-209586] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
530 Sporea I, Bota S, Jurchis A, Sirli R, Grădinaru-tascău O, Popescu A, Ratiu I, Szilaski M. Acoustic Radiation Force Impulse and Supersonic Shear Imaging Versus Transient Elastography for Liver Fibrosis Assessment. Ultrasound in Medicine & Biology 2013;39:1933-41. [DOI: 10.1016/j.ultrasmedbio.2013.05.003] [Cited by in Crossref: 65] [Cited by in F6Publishing: 48] [Article Influence: 8.1] [Reference Citation Analysis]
531 Yang J, Yang Y, Xia M, Wang L, Zhou W, Yang Y, Jiang Y, Wang H, Qian J, Jin L, Wang X. A genetic variant of the NTCP gene is associated with HBV infection status in a Chinese population. BMC Cancer 2016;16:211. [PMID: 26968990 DOI: 10.1186/s12885-016-2257-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
532 Patton H, Tran TT. Management of hepatitis B during pregnancy. Nat Rev Gastroenterol Hepatol. 2014;11:402-409. [PMID: 24686270 DOI: 10.1038/nrgastro.2014.30] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 6.7] [Reference Citation Analysis]
533 Liu F, Zou F, Wang X, Hu H, Hu P, Ren H. A model with combined viral and metabolic factors effectively predicts HBeAg status under long term entecavir therapy: a prospective cohort study. Virol J 2015;12:179. [PMID: 26527281 DOI: 10.1186/s12985-015-0409-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
534 Seo YS, Kim MY, Kim SU, Hyun BS, Jang JY, Lee JW, Lee JI, Suh SJ, Park SY, Park H, Jung EU, Kim BS, Kim IH, Lee TH, Um SH, Han KH, Kim SG, Paik SK, Choi JY, Jeong SW, Jin YJ, Lee KS, Yim HJ, Tak WY, Hwang SG, Lee YJ, Lee CH, Kim DG, Kang YW, Kim YS; Korean Transient Elastography Study Group. Accuracy of transient elastography in assessing liver fibrosis in chronic viral hepatitis: A multicentre, retrospective study. Liver Int. 2015;35:2246-2255. [PMID: 25682719 DOI: 10.1111/liv.12808] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 8.2] [Reference Citation Analysis]
535 López-Serrano P, de la Fuente Briongos E, Alonso EC, Pérez-Calle JL, Rodríguez CF. Hepatitis B and immunosuppressive therapies for chronic inflammatory diseases: When and how to apply prophylaxis, with a special focus on corticosteroid therapy. World J Hepatol. 2015;7:539-547. [PMID: 25848477 DOI: 10.4254/wjh.v7.i3.539] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
536 Bao S, Zhao Q, Zheng J, Li N, Huang C, Chen M, Cheng Q, Zhu M, Yu K, Liu C, Shi G. Interleukin-23 mediates the pathogenesis of LPS/GalN-induced liver injury in mice. Int Immunopharmacol 2017;46:97-104. [PMID: 28282579 DOI: 10.1016/j.intimp.2017.03.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
537 Aberra H, Gordien E, Desalegn H, Berhe N, Medhin G, Mekasha B, Gundersen SG, Gerber A, Stene-Johansen K, Øverbø J, Johannessen A. Hepatitis delta virus infection in a large cohort of chronic hepatitis B patients in Ethiopia. Liver Int 2018;38:1000-9. [PMID: 28980394 DOI: 10.1111/liv.13607] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
538 Visram A, Feld JJ. Defining and grading HBV reactivation: Defining and Grading HBV Reactivation. Clinical Liver Disease. 2015;5:35-38. [PMID: 31040945 DOI: 10.1002/cld.426] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
539 Koh C, Canini L, Dahari H, Zhao X, Uprichard SL, Haynes-Williams V, Winters MA, Subramanya G, Cooper SL, Pinto P, Wolff EF, Bishop R, Ai Thanda Han M, Cotler SJ, Kleiner DE, Keskin O, Idilman R, Yurdaydin C, Glenn JS, Heller T. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. Lancet Infect Dis 2015;15:1167-74. [PMID: 26189433 DOI: 10.1016/S1473-3099(15)00074-2] [Cited by in Crossref: 132] [Cited by in F6Publishing: 57] [Article Influence: 22.0] [Reference Citation Analysis]
540 Jindal A, Thadi A, Shailubhai K. Hepatocellular Carcinoma: Etiology and Current and Future Drugs. J Clin Exp Hepatol 2019;9:221-32. [PMID: 31024205 DOI: 10.1016/j.jceh.2019.01.004] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 31.0] [Reference Citation Analysis]
541 Fontaine H, Alric L, Labreuche J, Legendre B, Louvet A, Antoine C, Legendre CM, Hazzan M, Kamar N, Dharancy S, Pol S, Duhamel A, Mathurin P. Control of replication of hepatitis B and C virus improves patient and graft survival in kidney transplantation. J Hepatol 2019;70:831-8. [PMID: 30879789 DOI: 10.1016/j.jhep.2018.12.036] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
542 Kim SB, Kim SU, Kim BK, Park JY, Kim do Y, Ahn SH, Han KH. Outcome of adefovir add-on lamivudine rescue therapy of up to 5 years in patients with lamivudine-resistant chronic hepatitis B. J Gastroenterol Hepatol. 2016;31:241-247. [PMID: 26204913 DOI: 10.1111/jgh.13046] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
543 Trevisan M, Sinigaglia A, Desole G, Berto A, Pacenti M, Palù G, Barzon L. Modeling Viral Infectious Diseases and Development of Antiviral Therapies Using Human Induced Pluripotent Stem Cell-Derived Systems. Viruses 2015;7:3835-56. [PMID: 26184286 DOI: 10.3390/v7072800] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
544 Lieveld FI, Arends JE, Amelung L, Dijk E, Gisolf EH, Vrolijk JM, van Erpecum KJ, Siersema PD, Spanier BWM, Hoepelman AIM, Richter C. Overcoming Outpatient Loss to Follow-up as a Barrier to Efficiently Instituting Hepatitis B Liver-related Care. CLINID 2017;64:233-5. [DOI: 10.1093/cid/ciw746] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
545 Höner zu Siederdissen C, Rinker F, Maasoumy B, Wiegand SB, Filmann N, Falk CS, Deterding K, Port K, Mix C, Manns MP, Herrmann E, Wedemeyer H, Kraft ARM, Cornberg M. Viral and Host Responses After Stopping Long-term Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B. J Infect Dis 2016;214:1492-7. [DOI: 10.1093/infdis/jiw412] [Cited by in Crossref: 68] [Cited by in F6Publishing: 59] [Article Influence: 13.6] [Reference Citation Analysis]
546 Liu Y, Shi C, Fan J, Wang B, Li G. Hepatitis B-related glomerulonephritis and optimization of treatment. Expert Rev Gastroenterol Hepatol 2020;14:113-25. [PMID: 31951758 DOI: 10.1080/17474124.2020.1717948] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
547 Coluccio C, Begini P, Marzano A, Pellicelli A, Imperatrice B, Anania G, Delle Fave G, Marignani M. Hepatitis B in patients with hematological diseases: An update. World J Hepatol. 2017;9:1043-1053. [PMID: 28951776 DOI: 10.4254/wjh.v9.i25.1043] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
548 Liao YP, Jiang JL, Zou WY, Xu DR, Li J. Prophylactic antiviral therapy in allogeneic hematopoietic stem cell transplantation in hepatitis B virus patients. World J Gastroenterol. 2015;21:4284-4292. [PMID: 25892880 DOI: 10.3748/wjg.v21.i14.4284] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
549 Lee YB, Lee JH, Choi WM, Cho YY, Yoo JJ, Lee M, Lee DH, Cho Y, Yu SJ, Kim YJ. Efficacy of adefovir-based combination therapy for patients with Lamivudine- and entecavir-resistant chronic hepatitis B virus infection. Antimicrob Agents Chemother. 2013;57:6325-6332. [PMID: 24100506 DOI: 10.1128/aac.01742-13aac.01742-13] [Reference Citation Analysis]
550 Desalegn H, Aberra H, Berhe N, Medhin G, Mekasha B, Gundersen SG, Johannessen A. Predictors of mortality in patients under treatment for chronic hepatitis B in Ethiopia: a prospective cohort study. BMC Gastroenterol 2019;19:74. [PMID: 31092203 DOI: 10.1186/s12876-019-0993-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
551 Kemp L, Clare KE, Brennan PN, Dillon JF. New horizons in hepatitis B and C in the older adult. Age Ageing 2019;48:32-7. [PMID: 30379991 DOI: 10.1093/ageing/afy170] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
552 Salkic NN, Cickusic E, Jovanovic P, Denjagic MB, Iljazovic-Topcic S, Bevanda M, Ahmetagic S. Online combination algorithm for non-invasive assessment of chronic hepatitis B related liver fibrosis and cirrhosis in resource-limited settings. Eur J Intern Med. 2015;26:628-634. [PMID: 26194460 DOI: 10.1016/j.ejim.2015.07.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
553 Turyadi, Thedja MD, Ie SI, Harahap AR, El-khobar KE, Roni M, Muljono DH. HBsAg, HBeAg and HBV DNA level changes and precore/basal core promoter mutations in the natural history of chronic hepatitis B in Indonesian patients. Hepatol Int 2013;7:969-80. [DOI: 10.1007/s12072-013-9438-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
554 Li MH, Zhang L, Qu XJ, Lu Y, Shen G, Wu SL, Chang M, Liu RY, Hu LP, Li ZZ, Hua WH, Song SJ, Xie Y. Kinetics of Hepatitis B Surface Antigen Level in Chronic Hepatitis B Patients who Achieved Hepatitis B Surface Antigen Loss during Pegylated Interferon Alpha-2a Treatment. Chin Med J (Engl) 2017;130:559-65. [PMID: 28229987 DOI: 10.4103/0366-6999.200554] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
555 Wang YC, Yang SS, Su CW, Wang YJ, Lee KC, Huo TI, Lin HC, Huang YH. Predictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysis. Sci Rep. 2016;6:29605. [PMID: 27405043 DOI: 10.1038/srep29605] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 5.6] [Reference Citation Analysis]
556 Xie Q, Zhou H, Bai X, Wu S, Chen J, Sheng J, Xie Y, Chen C, Chan HL, Zhao M. A Randomized, Open-Label Clinical Study of Combined Pegylated Interferon Alfa-2a (40KD) and Entecavir Treatment for Hepatitis B "e" Antigen-Positive Chronic Hepatitis B. Clinical Infectious Diseases 2014;59:1714-23. [DOI: 10.1093/cid/ciu702] [Cited by in Crossref: 68] [Cited by in F6Publishing: 58] [Article Influence: 9.7] [Reference Citation Analysis]
557 Zlotnick A, Venkatakrishnan B, Tan Z, Lewellyn E, Turner W, Francis S. Core protein: A pleiotropic keystone in the HBV lifecycle. Antiviral Res. 2015;121:82-93. [PMID: 26129969 DOI: 10.1016/j.antiviral.2015.06.020] [Cited by in Crossref: 133] [Cited by in F6Publishing: 115] [Article Influence: 22.2] [Reference Citation Analysis]
558 Brooks J, Gelson W, Rushbrook SM. Therapeutic advances in the management of chronic hepatitis B infection. Ther Adv Chronic Dis 2013;4:157-66. [PMID: 23819019 DOI: 10.1177/2040622313484647] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
559 Zheng Z, Liao W, Liu L, Cai S, Zhu H, Yin S. Effect of nucleos(t)ide analogue on serum HBsAg level in chronic hepatitis B patients: A 3-years study. Biomed Pharmacother 2020;122:109698. [PMID: 31918272 DOI: 10.1016/j.biopha.2019.109698] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
560 Liu Z, Liu F, Wang L, Liu Y, Zhang M, Li T. Clinical characteristics and outcomes of patients with recurrent chronic hepatitis B after nucleos(t)ide analog withdrawal with stringent cessation criteria: A prospective cohort study. Hepatol Res 2017;47:1000-7. [PMID: 27917568 DOI: 10.1111/hepr.12836] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
561 Chen L, Gan QR, Zhang DQ, Yao LF, Lin RS, Li Q, Lin MH, Yu DM, Zhang XX, Pan C. Increased intrahepatic quasispecies heterogeneity correlates with off-treatment sustained response to nucleos(t)ide analogues in e antigen-positive chronic hepatitis B patients. Clin Microbiol Infect 2016;22:201-7. [PMID: 26493847 DOI: 10.1016/j.cmi.2015.10.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
562 Srivastava M, Singh N, Dixit VK, Nath G, Jain AK. Comparative evaluation of long-term monotherapies & combination therapies in patients with chronic hepatitis B: A pilot study. Indian J Med Res 2016;144:424-32. [PMID: 28139541 DOI: 10.4103/0971-5916.198674] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
563 Tran LH, Zupanc ML. Long-Term Everolimus Treatment in Individuals With Tuberous Sclerosis Complex: A Review of the Current Literature. Pediatric Neurology 2015;53:23-30. [DOI: 10.1016/j.pediatrneurol.2014.10.024] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
564 Hermans LE, Svicher V, Pas SD, Salpini R, Alvarez M, Ben Ari Z, Boland G, Bruzzone B, Coppola N, Seguin-Devaux C, Dyda T, Garcia F, Kaiser R, Köse S, Krarup H, Lazarevic I, Lunar MM, Maylin S, Micheli V, Mor O, Paraschiv S, Paraskevis D, Poljak M, Puchhammer-Stöckl E, Simon F, Stanojevic M, Stene-Johansen K, Tihic N, Trimoulet P, Verheyen J, Vince A, Weis N, Yalcinkaya T, Lepej SZ, Perno C, Boucher CA, Wensing AM; HEPVIR Working Group of the European Society for Translational Antiviral Research. Combined Analysis of the Prevalence of Drug-Resistant Hepatitis B Virus in Antiviral Therapy-Experienced Patients in Europe (CAPRE). J Infect Dis 2016;213:39-48. [PMID: 26136470 DOI: 10.1093/infdis/jiv363] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
565 Li S, Yang Y, Ding X, Yang M, She S, Peng H, Xu X, Ran X, Li S, Hu P, Hu H, Zhang D, Ren H. LHBs can elevate the expression of MDR1 through HIF-1α in patients with CHB infection: a comparative proteomic study. Oncotarget 2017;8:4549-62. [PMID: 27999186 DOI: 10.18632/oncotarget.13941] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
566 Aghemo A, Lampertico P, Colombo M. Assessing long-term treatment efficacy in chronic hepatitis B and C: Between evidence and common sense. Journal of Hepatology 2012;57:1326-35. [DOI: 10.1016/j.jhep.2012.06.025] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
567 Van Hees S, Bourgeois S, Van Vlierberghe H, Sersté T, Francque S, Michielsen P, Sprengers D, Reynaert H, Henrion J, Negrin Dastis S, Delwaide J, Lasser L, Decaestecker J, Orlent H, Janssens F, Robaeys G, Colle I, Stärkel P, Moreno C, Nevens F, Vanwolleghem T; Belgian NA Stop Study Group. Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBeAg seroconversion is associated with high relapse rates and fatal outcomes. Aliment Pharmacol Ther 2018;47:1170-80. [PMID: 29498078 DOI: 10.1111/apt.14560] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 7.3] [Reference Citation Analysis]
568 Wong GL. Transient elastography: Kill two birds with one stone? World J Hepatol 2013;5:264-74. [PMID: 23717737 DOI: 10.4254/wjh.v5.i5.264] [Cited by in Crossref: 59] [Cited by in F6Publishing: 58] [Article Influence: 7.4] [Reference Citation Analysis]
569 Tan G, Xu F, Song H, Yuan Y, Xiao Q, Ma F, Qin FX, Cheng G. Identification of TRIM14 as a Type I IFN-Stimulated Gene Controlling Hepatitis B Virus Replication by Targeting HBx. Front Immunol 2018;9:1872. [PMID: 30150992 DOI: 10.3389/fimmu.2018.01872] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
570 Huang H, Sun Z, Pan H, Chen M, Tong Y, Zhang J, Chen D, Su X, Li L. Serum metabolomic signatures discriminate early liver inflammation and fibrosis stages in patients with chronic hepatitis B. Sci Rep 2016;6:30853. [PMID: 27498553 DOI: 10.1038/srep30853] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
571 Ou Q, Guo J, Zeng Y, Chen H. Insights for clinical diagnostic indicators of virus and host in chronic hepatitis B infection. J Viral Hepat 2020;27:224-32. [PMID: 31954089 DOI: 10.1111/jvh.13260] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
572 Bottero J, Brouard C, Roudot-Thoraval F, Deuffic-Burban S, Hofliger P, Abergel A, Volant J, Dhumeaux D, Yazdanpanah Y; Viral Hepatitis Testing Experts group. 2014 French guidelines for hepatitis B and C screening: a combined targeted and mass testing strategy of chronic viruses namely HBV, HCV and HIV. Liver Int. 2016;36:1442-1449. [PMID: 27043826 DOI: 10.1111/liv.13135] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
573 Chen D, Chen Y, Liu J, Xie D, Lu C, Huang Z, Zhu R, Gao Z. Durability of efficacy after telbivudine off-treatment in chronic hepatitis B patients. Journal of Clinical Virology 2014;59:50-4. [DOI: 10.1016/j.jcv.2013.11.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
574 Bonder A, Afdhal N. Utilization of FibroScan in clinical practice. Curr Gastroenterol Rep. 2014;16:372. [PMID: 24452634 DOI: 10.1007/s11894-014-0372-6] [Cited by in Crossref: 63] [Cited by in F6Publishing: 53] [Article Influence: 9.0] [Reference Citation Analysis]
575 Arends P, Sonneveld MJ, Janssen HLA. Hepatitis B virus treatment: Which patients should be treated with interferon? Clin Liver Dis (Hoboken) 2013;2:18-20. [PMID: 30992814 DOI: 10.1002/cld.152] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
576 Sokal EM, Paganelli M, Wirth S, Socha P, Vajro P, Lacaille F, Kelly D, Mieli-vergani G. Management of chronic hepatitis B in childhood: ESPGHAN clinical practice guidelines. Journal of Hepatology 2013;59:814-29. [DOI: 10.1016/j.jhep.2013.05.016] [Cited by in Crossref: 121] [Cited by in F6Publishing: 90] [Article Influence: 15.1] [Reference Citation Analysis]
577 Al-Busafi SA. Do we have guidelines for the prevention of Hepatitis B virus perinatal transmission? Aust N Z J Obstet Gynaecol 2013;53:506. [PMID: 24090464 DOI: 10.1111/ajo.12102] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
578 Kusumoto S, Tanaka Y, Mizokami M, Ueda R. Is Antiviral Prophylaxis Necessary to Prevent Hepatitis B Virus (HBV) Reactivation in Patients With HBV-Resolved Infection Receiving Rituximab-Containing Chemotherapy? JCO 2013;31:4480-4480. [DOI: 10.1200/jco.2013.52.1278] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
579 Tan Y, Ye Y, Zhou X, Chen L, Wen D. Age as a predictor of significant fibrosis features in HBeAg-negative chronic hepatitis B virus infection with persistently normal alanine aminotransferase. PLoS One. 2015;10:e0123452. [PMID: 25885705 DOI: 10.1371/journal.pone.0123452] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
580 Chen YP, Peng J, Hou JL. Non-invasive assessment of liver fibrosis in patients with chronic hepatitis B. Hepatol Int 2013;7:356-68. [PMID: 26201770 DOI: 10.1007/s12072-013-9439-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
581 Guardiola-Arévalo A, Gómez Rodríguez R, Romero Gutiérrez M, Gómez Moreno AZ, García Vela A, Sánchez Simón R, Gómez Hernando C, Andrés Esteban EM. Hepatitis B virus e antigen-negative chronic infection. Treatment based on glutamic pyruvic transaminase and hepatitis B virus deoxyribonucleic acid cut-off values. Gastroenterol Hepatol 2018;41:153-62. [PMID: 29279233 DOI: 10.1016/j.gastrohep.2017.11.003] [Reference Citation Analysis]
582 Boyd A, Maylin S, Moh R, Gabillard D, Menan H, Mahjoub N, Danel C, Anglaret X, Eholié SP, Girard PM, Zoulim F, Delaugerre C, Lacombe K; ANRS 12240 VarBVA study. Identifying patients infected with hepatitis B virus in sub-Saharan Africa: potential for misclassification. Diagn Microbiol Infect Dis 2015;83:248-51. [PMID: 26283522 DOI: 10.1016/j.diagmicrobio.2015.07.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
583 Baiguera C, Boschetti A, Raffetti E, Zanini B, Puoti M, Donato F. Phyllanthus niruri versus Placebo for Chronic Hepatitis B Virus Infection: A Randomized Controlled Trial. Complement Med Res 2018;25:376-82. [PMID: 30372693 DOI: 10.1159/000484927] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
584 Parikh P, Ryan JD, Tsochatzis EA. Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection. Ann Transl Med. 2017;5:40. [PMID: 28251119 DOI: 10.21037/atm.2017.01.28] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 9.3] [Reference Citation Analysis]
585 Laiwatthanapaisan R, Sripongpun P, Chamroonkul N, Dechaphunkul A, Sathitruangsak C, Sakdejayont S, Kongkamol C, Piratvisuth T. Hepatitis B screening rates and reactivation in solid organ malignancy patients undergoing chemotherapy in Southern Thailand. Clin Mol Hepatol 2019;25:366-73. [PMID: 31309773 DOI: 10.3350/cmh.2018.0111] [Reference Citation Analysis]
586 He M, Wu Y, Wang M, Chen W, Yuan W, Jiang J. The Clinical Value of Oxymatrine in Preventing Lamivudine Induced YMDD Mutation: A Meta-Analysis. Evid Based Complement Alternat Med 2015;2015:971616. [PMID: 26508988 DOI: 10.1155/2015/971616] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
587 Zuo S, Zuo X, Wang C, Ma Y, Zhang H, Li Z, Song L, Deng Z, Liu S. A meta-analysis comparing the efficacy of entecavir and tenofovir for the treatment of chronic hepatitis B infection. The Journal of Clinical Pharmacology 2015;55:288-97. [DOI: 10.1002/jcph.409] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
588 Lee SK, Kwon JH, Lee SW, Jang JW, Nam H, Baik KW, Yoo SH, Nam SW, Sung PS, Bae SH, Choi JY, Yoon SK. Sustained off therapy response after peglyated interferon favours functional cure and no disease progression in chronic hepatitis B. Liver Int 2021;41:288-94. [PMID: 33043567 DOI: 10.1111/liv.14701] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
589 . EASL Clinical Practice Guidelines: Autoimmune hepatitis. Journal of Hepatology 2015;63:971-1004. [DOI: 10.1016/j.jhep.2015.06.030] [Cited by in Crossref: 489] [Cited by in F6Publishing: 358] [Article Influence: 81.5] [Reference Citation Analysis]
590 Yildiz UH, Inci F, Wang S, Toy M, Tekin HC, Javaid A, Lau DT, Demirci U. Recent advances in micro/nanotechnologies for global control of hepatitis B infection. Biotechnol Adv 2015;33:178-90. [PMID: 25450190 DOI: 10.1016/j.biotechadv.2014.11.003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
591 Cai S, Yu T, Jiang Y, Zhang Y, Lv F, Peng J. Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result. Clin Exp Med 2016;16:429-36. [PMID: 26164128 DOI: 10.1007/s10238-015-0373-2] [Cited by in Crossref: 35] [Cited by in F6Publishing: 44] [Article Influence: 5.8] [Reference Citation Analysis]
592 Russo FP, Rodríguez-Castro K, Scribano L, Gottardo G, Vanin V, Farinati F. Role of antiviral therapy in the natural history of hepatitis B virus-related chronic liver disease. World J Hepatol 2015;7:1097-104. [PMID: 26052398 DOI: 10.4254/wjh.v7.i8.1097] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
593 van Bömmel F, Berg T. Treatment of HBV related cirrhosis. Liver Int. 2013;33 Suppl 1:176-181. [PMID: 23286862 DOI: 10.1111/liv.12074] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
594 Kockaya G, Kose A, Yenilmez FB, Ozdemir O, Kucuksayrac E. Cost-effectiveness analysis of oral anti-viral drugs used for treatment of chronic hepatitis B in Turkey. Cost Eff Resour Alloc 2015;13:21. [PMID: 26664289 DOI: 10.1186/s12962-015-0046-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
595 Zhang Y, Wang X, Hu A, Wu Y, Zhang P, Yang X, Wen Z, Wen M. Duck enteritis virus infection suppresses viability and induces apoptosis and endoplasmic reticulum stress in duck embryo fibroblast cells via the regulation of Ca2. J Vet Med Sci 2021;83:549-57. [PMID: 33116004 DOI: 10.1292/jvms.19-0584] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
596 Kim GA, Lim YS, An J, Lee D, Shim JH, Kim KM, Lee HC, Chung YH, Lee YS, Suh DJ. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. Gut. 2014;63:1325-1332. [PMID: 24162593 DOI: 10.1136/gutjnl-2013-305517] [Cited by in Crossref: 186] [Cited by in F6Publishing: 166] [Article Influence: 23.3] [Reference Citation Analysis]
597 Pol S, Haour G, Fontaine H, Dorival C, Petrov-Sanchez V, Bourliere M, Capeau J, Carrieri P, Larrey D, Larsen C, Marcellin P, Pawlostky JM, Nahon P, Zoulim F, Cacoub P, de Ledinghen V, Mathurin P, Negro F, Pageaux GP, Yazdanpanah Y, Wittkop L, Zarski JP, Carrat F; French Anrs Co22 Hepather Cohort. The negative impact of HBV/HCV coinfection on cirrhosis and its consequences. Aliment Pharmacol Ther 2017;46:1054-60. [PMID: 28994127 DOI: 10.1111/apt.14352] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 7.5] [Reference Citation Analysis]
598 Chao DC, Hu KQ. Update on rescue therapies in patients with lamivudine-resistant chronic hepatitis B. Drug Des Devel Ther. 2013;7:777-788. [PMID: 23990707 DOI: 10.2147/dddt.s33947] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
599 Gadour E. Autoimmune Hepatitis: Treatment Options and Management Review. Cureus 2021;13:e15682. [PMID: 34150417 DOI: 10.7759/cureus.15682] [Reference Citation Analysis]
600 Lee IK, Jeun M, Jang HJ, Cho WJ, Lee KH. A self-amplified transistor immunosensor under dual gate operation: highly sensitive detection of hepatitis B surface antigen. Nanoscale 2015;7:16789-97. [PMID: 26399739 DOI: 10.1039/c5nr03146j] [Cited by in Crossref: 30] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
601 Chew E, Thursky K, Seymour JF. Very late onset hepatitis-B virus reactivation following rituximab despite lamivudine prophylaxis: the need for continued vigilance. Leukemia & Lymphoma 2014;55:938-9. [DOI: 10.3109/10428194.2013.813502] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
602 Sarmati L, Andreoni M, Antonelli G, Arcese W, Bruno R, Coppola N, Gaeta GB, Galli M, Girmenia C, Mikulska M, Pane F, Perno CF, Picardi M, Puoti M, Rambaldi A, Svicher V, Taliani G, Gentile G. Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation-a position paper. Clin Microbiol Infect. 2017;23:935-940. [PMID: 28668466 DOI: 10.1016/j.cmi.2017.06.023] [Cited by in Crossref: 49] [Cited by in F6Publishing: 43] [Article Influence: 12.3] [Reference Citation Analysis]
603 Kim JH, Sinn DH, Kang W, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment. Hepatology. 2017;66:335-343. [PMID: 28012257 DOI: 10.1002/hep.28916] [Cited by in Crossref: 77] [Cited by in F6Publishing: 69] [Article Influence: 15.4] [Reference Citation Analysis]
604 Mallet V, van Bömmel F, Doerig C, Pischke S, Hermine O, Locasciulli A, Cordonnier C, Berg T, Moradpour D, Wedemeyer H, Ljungman P; ECIL-5. Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5). Lancet Infect Dis 2016;16:606-17. [PMID: 27599653 DOI: 10.1016/S1473-3099(16)00118-3] [Cited by in Crossref: 87] [Cited by in F6Publishing: 27] [Article Influence: 17.4] [Reference Citation Analysis]
605 Tsai MC, Yang TW, Wang CC, Wang YT, Sung WW, Tseng MH, Lin CC. Favorable clinical outcome of nonalcoholic liver cirrhosis patients with coronary artery disease: A population-based study. World J Gastroenterol 2018;24:3547-55. [PMID: 30131661 DOI: 10.3748/wjg.v24.i31.3547] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
606 Tian C, Chen Y, Liu Y, Wang S, Li Y, Wang G, Xia J, Zhao XA, Huang R, Lu S, Wu C. Use of ELISpot assay to study HBs-specific B cell responses in vaccinated and HBV infected humans. Emerg Microbes Infect 2018;7:16. [PMID: 29449582 DOI: 10.1038/s41426-018-0034-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
607 Hiramatsu N, Yamada R, Takehara T. The suppressive effect of nucleos(t)ide analogue treatment on the incidence of hepatocellular carcinoma in chronic hepatitis B patients. J Gastroenterol Hepatol. 2016;31:546-552. [PMID: 26574149 DOI: 10.1111/jgh.13229] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
608 Wang JY, Mao RC, Zhang YM, Zhang YJ, Liu HY, Qin YL, Lu MJ, Zhang JM. Serum microRNA-124 is a novel biomarker for liver necroinflammation in patients with chronic hepatitis B virus infection. J Viral Hepat. 2015;22:128-136. [PMID: 25131617 DOI: 10.1111/jvh.12284] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
609 Chien NH, Huang YT, Wu CY, Chang CY, Wu MS, Kao JH, Mo LR, Tai CM, Lin CW, Yang TH, Lin JT, Hsu YC. Time-varying serum gradient of hepatitis B surface antigen predicts risk of relapses after off-NA therapy. BMC Gastroenterol 2017;17:154. [PMID: 29221441 DOI: 10.1186/s12876-017-0697-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
610 Komatsu H, Inui A, Umetsu S, Tsunoda T, Sogo T, Konishi Y, Fujisawa T. Evaluation of the G145R Mutant of the Hepatitis B Virus as a Minor Strain in Mother-to-Child Transmission. PLoS One 2016;11:e0165674. [PMID: 27812178 DOI: 10.1371/journal.pone.0165674] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
611 Boyd A, Canini L, Gozlan J, Lascoux-Combe C, Miailhes P, Fonquernie L, Girard PM, Lacombe K. Development of anti-hepatitis B surface (HBs) antibodies after HBs antigen loss in HIV-hepatitis B virus co-infected patients. J Clin Virol 2017;95:55-60. [PMID: 28869890 DOI: 10.1016/j.jcv.2017.08.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
612 Lee SJ, Yim HJ, Hwang SG, Seo YS, Kim JH, Yoon EL, Lee JM, Kim BH, Park SJ, Park YM, Kim HS, Lee SH, Ahn SH, Lee JI, Lee JW, Kim IH, Kim HS, Hong SP. Treatment of lamivudine-resistant chronic hepatitis B infection: a multicenter retrospective study. Scand J Gastroenterol 2013;48:196-204. [PMID: 23194375 DOI: 10.3109/00365521.2012.722671] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
613 Kader C, Sunbul M, Das YK, Yarim M, Bedir A, Karaca E, Celikbilek M, Ozaras R. Telbivudine attenuates gentamicin-induced kidney injury in rats. Int J Antimicrob Agents 2017;49:595-602. [PMID: 28373116 DOI: 10.1016/j.ijantimicag.2017.01.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
614 Bruguera M. Historia de la hepatología en Cataluña. Gastroenterología y Hepatología 2013;36:484-91. [DOI: 10.1016/j.gastrohep.2013.04.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
615 Serranti D, Indolfi G, Nebbia G, Cananzi M, D'Antiga L, Ricci S, Stagi S, Azzari C, Resti M; Italian Study Group for Treatment of Chronic Hepatitis C in Children. Transient Hypothyroidism and Autoimmune Thyroiditis in Children With Chronic Hepatitis C Treated With Pegylated-interferon-α-2b and Ribavirin. Pediatr Infect Dis J 2018;37:287-91. [PMID: 28953189 DOI: 10.1097/INF.0000000000001791] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
616 Charles P, Bienvenu B, Bonnotte B, Gobert P, Godmer P, Hachulla É, Hamidou M, Harlé JR, Karras A, Lega JC. Rituximab: Recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatments of adult, antineutrophil cytoplasm antibody-associated necrotizing vasculitides. Presse Med. 2013;42:1317-1330. [PMID: 24095054 DOI: 10.1016/j.lpm.2013.08.003] [Cited by in Crossref: 52] [Cited by in F6Publishing: 36] [Article Influence: 6.5] [Reference Citation Analysis]
617 Kozik JH, Trautmann T, Carambia A, Preti M, Lütgehetmann M, Krech T, Wiegard C, Heeren J, Herkel J. Attenuated viral hepatitis in Trem1-/- mice is associated with reduced inflammatory activity of neutrophils. Sci Rep 2016;6:28556. [PMID: 27328755 DOI: 10.1038/srep28556] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
618 Zhao Y, Wu J, Sun L, Liu G, Li B, Zheng Y, Li X, Tao J. Prevalence of mutations in HBV DNA polymerase gene associated with nucleos(t)ide resistance in treatment-naive patients with Chronic Hepatitis B in Central China. Braz J Infect Dis. 2016;20:173-178. [PMID: 26876337 DOI: 10.1016/j.bjid.2015.12.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
619 Calvopina DA, Coleman MA, Lewindon PJ, Ramm GA. Function and Regulation of MicroRNAs and Their Potential as Biomarkers in Paediatric Liver Disease. Int J Mol Sci 2016;17:E1795. [PMID: 27801781 DOI: 10.3390/ijms17111795] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
620 Sellier PO, Schnepf N, Amarsy R, Maylin S, Lopes A, Mazeron MC, Flateau C, Morgand M, Ciraru-Vigneron N, Berthe A, Simoneau G, Evans J, Souak S, Matheron S, Benifla JL, Simon F, Bergmann JF. Short article: Hepatitis B virus status in children born to HIV/HBV coinfected women in a French hospital: a cross-sectional study. Eur J Gastroenterol Hepatol 2016;28:328-32. [PMID: 26709883 DOI: 10.1097/MEG.0000000000000559] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
621 Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, Dokmeci AK, Gane E, Hou JL, Jafri W, Jia J, Kim JH, Lai CL, Lee HC, Lim SG, Liu CJ, Locarnini S, Al Mahtab M, Mohamed R, Omata M, Park J, Piratvisuth T, Sharma BC, Sollano J, Wang FS, Wei L, Yuen MF, Zheng SS, Kao JH. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1-98. [PMID: 26563120 DOI: 10.1007/s12072-015-9675-4] [Cited by in Crossref: 1076] [Cited by in F6Publishing: 950] [Article Influence: 179.3] [Reference Citation Analysis]
622 Tadmor T, Welslau M, Hus I. A review of the infection pathogenesis and prophylaxis recommendations in patients with chronic lymphocytic leukemia. Expert Review of Hematology 2017;11:57-70. [DOI: 10.1080/17474086.2018.1407645] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
623 Zhong JH, Ke Y, Zhu SL, Wang L, Luo CP, Gong WF, You XM, Ma L, Xiang BD, Li LQ. Adefovir dipivoxil is less expensive than lamivudine and associated with similar prognosis in patients with hepatitis B virus-related hepatocellular carcinoma after radical resection. Onco Targets Ther 2016;9:6897-907. [PMID: 27877054 DOI: 10.2147/OTT.S120062] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
624 Lin CL, Kao JH. Hepatitis B virus genotypes and variants. Cold Spring Harb Perspect Med. 2015;5:a021436. [PMID: 25934462 DOI: 10.1101/cshperspect.a021436] [Cited by in Crossref: 110] [Cited by in F6Publishing: 101] [Article Influence: 18.3] [Reference Citation Analysis]
625 Tao Y, Wu D, Zhou L, Chen E, Liu C, Tang X, Jiang W, Han N, Li H, Tang H. Present and Future Therapies for Chronic Hepatitis B. Adv Exp Med Biol. 2020;1179:137-186. [PMID: 31741336 DOI: 10.1007/978-981-13-9151-4_6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 8.5] [Reference Citation Analysis]
626 Liu Y, Cheng LS, Wu SD, Wang SQ, Li L, She WM, Li J, Wang JY, Jiang W. IL-10-producing regulatory B-cells suppressed effector T-cells but enhanced regulatory T-cells in chronic HBV infection. Clin Sci (Lond). 2016;130:907-919. [PMID: 26980345 DOI: 10.1042/cs20160069] [Cited by in Crossref: 45] [Cited by in F6Publishing: 24] [Article Influence: 9.0] [Reference Citation Analysis]
627 Sarkar J, Saha D, Bandyopadhyay B, Saha B, Chakravarty R, Guha SK. Lamivudine plus tenofovir versus lamivudine plus adefovir for the treatment of hepatitis B virus in HIV-coinfected patients, starting antiretroviral therapy. Indian J Med Microbiol 2018;36:217-23. [PMID: 30084414 DOI: 10.4103/ijmm.IJMM_17_37] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
628 Kong LN, Qin B, Ma Q, Li L, Yao Y. Relationship between hepatitis B virus genotype B and C and response to interferon therapy in HBeAg positive chronic hepatitis B patients: A meta-analysis. J Gastroenterol Hepatol. 2014;29:1387-1395. [PMID: 24548048 DOI: 10.1111/jgh.12559] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
629 Murdaca G, Negrini S, Pellecchio M, Greco M, Schiavi C, Giusti F, Puppo F. Update upon the infection risk in patients receiving TNF alpha inhibitors. Expert Opinion on Drug Safety 2019;18:219-29. [DOI: 10.1080/14740338.2019.1577817] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
630 Simonetti G, Gitto S, Golfieri L, Gamal N, Loggi E, Taruschio G, Cursaro C, Nunzella S, Grandi S, Andreone P. Quality of life of hepatitis B virus surface antigen-positive patients with suppressed viral replication: comparison between inactive carriers and nucleot(s)ide analog-treated patients. Eur J Gastroenterol Hepatol 2018;30:14-20. [PMID: 29064847 DOI: 10.1097/MEG.0000000000000999] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
631 Pattullo V. Hepatitis B reactivation in the setting of chemotherapy and immunosuppression - prevention is better than cure. World J Hepatol. 2015;7:954-967. [PMID: 25954478 DOI: 10.4254/wjh.v7.i7.954] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
632 Cho EY, Yim HJ, Jung YK, Suh SJ, Seo YS, Kim JH, Kim HS, Lee SH, Ahn SH, Lee JI, Jeong SH, Kim JW, Lee JW, Kim IH, Kim HS, Park SJ, Lee JM, Hwang SG; Antiviral Resistance Study Group. Management of Clevudine-Resistant Chronic Hepatitis B: A Multicenter Cohort Study. Gut Liver 2017;11:129-35. [PMID: 27538443 DOI: 10.5009/gnl15597] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
633 He D, Li M, Guo S, Zhu P, Huang H, Yan G, Wu Q, Tao S, Tan Z, Wang Y. Expression pattern of serum cytokines in hepatitis B virus infected patients with persistently normal alanine aminotransferase levels. J Clin Immunol 2013;33:1240-9. [PMID: 23954997 DOI: 10.1007/s10875-013-9931-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
634 Galmozzi E, Viganò M, Lampertico P. Systematic review with meta-analysis: do interferon lambda 3 polymorphisms predict the outcome of interferon-therapy in hepatitis B infection? Aliment Pharmacol Ther. 2014;39:569-578. [PMID: 24461198 DOI: 10.1111/apt.12631] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 4.6] [Reference Citation Analysis]
635 Bissinger AL, Berg CP. Is the HDV seroprevalence in patients admitted to a university hospital representative for all HBV carriers in Germany? Infection 2013;41:1031-2. [PMID: 23435721 DOI: 10.1007/s15010-013-0433-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
636 De Clercq E. Current treatment of hepatitis B virus infections: Current treatment of HBV Infections. Rev Med Virol 2015;25:354-65. [DOI: 10.1002/rmv.1849] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
637 Mueller A, Stoetter L, Kalluvya S, Stich A, Majinge C, Weissbrich B, Kasang C. Prevalence of hepatitis B virus infection among health care workers in a tertiary hospital in Tanzania. BMC Infect Dis 2015;15:386. [PMID: 26399765 DOI: 10.1186/s12879-015-1129-z] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 6.3] [Reference Citation Analysis]
638 Duraisamy GS, Bhosale D, Lipenská I, Huvarova I, Růžek D, Windisch MP, Miller AD. Advanced Therapeutics, Vaccinations, and Precision Medicine in the Treatment and Management of Chronic Hepatitis B Viral Infections; Where Are We and Where Are We Going? Viruses 2020;12:E998. [PMID: 32906840 DOI: 10.3390/v12090998] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
639 Krishnamoorthy TL, Mutimer D. Hepatitis B: encouraging the use of interferon. Curr Opin Infect Dis. 2015;28:557-562. [PMID: 26381998 DOI: 10.1097/QCO.0000000000000209] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
640 Yamazhan T, Kurtaran B, Pullukçu H, Yüksel E, Özkaya D, Taşbakan MI, Sipahi OR, Durusoy R, Aksu HSZ. Pegylated interferon in HBeAg-positive and -negative chronic hepatitis B patients: post-treatment 1-year results of three Turkish centres. Journal of Chemotherapy 2013;26:339-41. [DOI: 10.1179/1973947813y.0000000152] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
641 Ségéral O, N'Diaye DS, Prak S, Nouhin J, Chhun S, Khamduang W, Chim K, Roque-Afonso AM, Piola P, Borand L, Ngo-Giang-Huong N, Rouet F; ANRS 12328 12345 Study Group. Usefulness of a serial algorithm of HBsAg and HBeAg rapid diagnosis tests to detect pregnant women at risk of HBV mother-to-child transmission in Cambodia, the ANRS 12328 pilot study. J Clin Virol 2018;109:29-34. [PMID: 30388664 DOI: 10.1016/j.jcv.2018.10.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
642 Su T, Kao J. Improving clinical outcomes of chronic hepatitis B virus infection. Expert Review of Gastroenterology & Hepatology 2014;9:141-54. [DOI: 10.1586/17474124.2015.960398] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
643 Su M, Guo J, Huang J. Meta-analysis of the correlation between the rs17401966 polymorphism in kinesin family member 1B and susceptibility to hepatitis B virus related hepatocellular carcinoma. Clin Mol Hepatol 2017;23:138-46. [PMID: 28427253 DOI: 10.3350/cmh.2016.0083] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
644 Wang XY, Chen HS. Emerging antivirals for the treatment of hepatitis B. World J Gastroenterol 2014;20:7707-17. [PMID: 24976708 DOI: 10.3748/wjg.v20.i24.7707] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
645 Iida-Ueno A, Enomoto M, Tamori A, Kawada N. Hepatitis B virus infection and alcohol consumption. World J Gastroenterol. 2017;23:2651-2659. [PMID: 28487602 DOI: 10.3748/wjg.v23.i15.2651] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 25] [Article Influence: 9.3] [Reference Citation Analysis]
646 Asselah T, Marcellin P. Long-term Results of Treatment with Nucleoside and Nucleotide Analogues (Entecavir and Tenofovir) for Chronic Hepatitis B. Clinics in Liver Disease 2013;17:445-50. [DOI: 10.1016/j.cld.2013.05.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
647 Kim YA, Estevez J, Le A, Israelski D, Baatarkhuu O, Sarantuya T, Narantsetseg S, Nymadawa P, H Le R, Yuen MF, Dusheiko G, Rizzetto M, Nguyen MH. Screening and management of viral hepatitis and hepatocellular carcinoma in Mongolia: results from a survey of Mongolian physicians from all major provinces of Mongolia. BMJ Open Gastroenterol 2016;3:e000119. [PMID: 27933202 DOI: 10.1136/bmjgast-2016-000119] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
648 Liu C. Treatment of patients with dual hepatitis C virus and hepatitis B virus infection: Resolved and unresolved issues: Treatment of dual hepatitis C and B. J Gastroenterol Hepatol 2014;29:26-30. [DOI: 10.1111/jgh.12421] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
649 Sanai FM, Babatin MA, Bzeizi KI, Alsohaibani F, Al-Hamoudi W, Alsaad KO, Al Mana H, Handoo FA, Al-Ashgar H, Alghamdi H. Accuracy of international guidelines for identifying significant fibrosis in hepatitis B e antigen--negative patients with chronic hepatitis. Clin Gastroenterol Hepatol. 2013;11:1493-1499.e2. [PMID: 23811251 DOI: 10.1016/j.cgh.2013.05.038] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
650 Viganò M, Valenti L, Lampertico P, Facchetti F, Motta BM, D'ambrosio R, Romagnoli S, Dongiovanni P, Donati B, Fargion S, Colombo M. Patatin-like phospholipase domain-containing 3 I148M affects liver steatosis in patients with chronic hepatitis B: Hepatology, Vol. 58, No. X, 2013. Hepatology 2013;58:1245-52. [DOI: 10.1002/hep.26445] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 5.8] [Reference Citation Analysis]
651 Su M, Xiang K, Li Y, Li Y, Deng J, Xu X, Yan L, Zhuang H, Li T. Higher detection rates of amino acid substitutions in HBV reverse transcriptase/surface protein overlapping sequence is correlated with lower serum HBV DNA and HBsAg levels in HBeAg-positive chronic hepatitis B patients with subgenotype B2. Infection, Genetics and Evolution 2016;40:275-81. [DOI: 10.1016/j.meegid.2016.03.019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
652 Wu FP, Yang Y, Li M, Liu YX, Li YP, Wang WJ, Shi JJ, Zhang X, Jia XL, Dang SS. Add-on pegylated interferon augments hepatitis B surface antigen clearance vs continuous nucleos(t)ide analog monotherapy in Chinese patients with chronic hepatitis B and hepatitis B surface antigen ≤ 1500 IU/mL: An observational study. World J Gastroenterol 2020;26:1525-39. [PMID: 32308352 DOI: 10.3748/wjg.v26.i13.1525] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
653 Dionne-Odom J, Njei B, Tita ATN. Elimination of Vertical Transmission of Hepatitis B in Africa: A Review of Available Tools and New Opportunities. Clin Ther 2018;40:1255-67. [PMID: 29983265 DOI: 10.1016/j.clinthera.2018.05.016] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
654 Ouzan D, Pénaranda G, Joly H, Khiri H, Pironti A, Halfon P. Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs. J Clin Virol. 2013;58:713-717. [PMID: 24183313 DOI: 10.1016/j.jcv.2013.09.020] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 4.5] [Reference Citation Analysis]
655 Wong D, Littlejohn M, Edwards R, Jackson K, Revill P, Gaggar A, Kitrinos K, Subramanian M, Marcellin P, Buti-Ferret M, Janssen H, Gane E, Locarnini S, Thompson A. ALT flares during nucleotide analogue therapy are associated with HBsAg loss in genotype A HBeAg-positive chronic hepatitis B. Liver Int 2018;38:1760-9. [PMID: 29427368 DOI: 10.1111/liv.13716] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
656 Xiao L, Xian J, Li Y, Geng A, Yang X, Han L, Xu H. Parameters associated with significant liver histological changes in patients with chronic hepatitis B. ISRN Gastroenterol 2014;2014:913890. [PMID: 24616815 DOI: 10.1155/2014/913890] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
657 Wong VW, Janssen HL. Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection? J Hepatol. 2015;63:722-732. [PMID: 26026875 DOI: 10.1016/j.jhep.2015.05.019] [Cited by in Crossref: 59] [Cited by in F6Publishing: 50] [Article Influence: 9.8] [Reference Citation Analysis]
658 Xiong YL, Li H, Liu F, Zhang D, Ren H, Hu P. Efficacy of PEGylated Interferon in Treatment-Experienced Chinese Patients With HBeAg Positive Chronic Hepatitis B. Hepat Mon 2016;16:e35357. [PMID: 27257427 DOI: 10.5812/hepatmon.35357] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
659 Crossan C, Tsochatzis EA, Longworth L, Gurusamy K, Davidson B, Rodríguez-Perálvarez M, Mantzoukis K, O’Brien J, Thalassinos E, Papastergiou V. Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation. Health Technol Assess. 2015;19:1-409, v-vi. [PMID: 25633908 DOI: 10.3310/hta19090] [Cited by in Crossref: 84] [Cited by in F6Publishing: 77] [Article Influence: 14.0] [Reference Citation Analysis]
660 Ikeda M, Yamamoto H, Kaneko M, Oshima H, Takahashi H, Umemoto K, Watanabe K, Hashimoto Y, Ohno I, Mitsunaga S, Okusaka T. Screening rate for hepatitis B virus infection in patients undergoing chemotherapy in Japan. Int J Clin Oncol 2016;21:1162-6. [PMID: 27260010 DOI: 10.1007/s10147-016-0995-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
661 Teh BW, Sasadeusz JJ. Guarding the sleeping giant: hepatitis B screening and management in patients with hematological malignancy. Leukemia & Lymphoma 2014;55:2426-7. [DOI: 10.3109/10428194.2014.918973] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
662 Fong T, Lee BT, Tien A, Chang M, Lim C, Ahn A, Bae HS. Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide. J Viral Hepat 2019;26:561-7. [DOI: 10.1111/jvh.13053] [Cited by in Crossref: 24] [